

**East Carolina University  
Board of Trustees  
November 12, 2021**

**MINUTES**

The ECU Board of Trustees met in open session as part of their regular scheduled meeting series on November 12, 2021. The meeting originated from room 249 in the Main Campus Student Center, on the campus of East Carolina University in Greenville, NC.

Chair, Mr. Scott Shook called the meeting to order.

**PLEDGE OF ALLEGIANCE**

Mr. Shook introduced Cadet Adrian Sanchez from Elizabeth City, NC and Cadet Malia Xavier from Fayetteville, NC to lead the board in the Pledge of Allegiance.

**READING OF ETHICS STATEMENT**

In compliance with the State Government Ethics Act, Mr. Shook called on Mr. Fussell to read the conflict-of-interest statement. No conflicts were identified.

**ROLL CALL**

Mr. Shook called on Mr. Vince Smith, Secretary, to call the roll.

Present

Cassandra Burt  
Leigh Fanning  
Dave Fussell  
Tom Furr  
Van Isley  
Fielding Miller  
Angela Moss

Jason Poole  
Jeffery Roberts  
Jim Segrave  
Scott Shook  
Vince Smith  
Chandler Ward

All board members were present and a quorum was established.

## **CONSENT AGENDA**

Mr. Shook presented the consent agenda to the board and requested members to review and decide if any items on the agenda require additional discussion.

Hearing no concerns, Mr. Shook asked for a motion to approve the consent agenda.

Mr. Poole motioned to approve the consent agenda, the motion was seconded and approved with no negative votes.

A copy of the consent agenda is listed as “Attachment A.”

## **CHANCELLOR’S REPORT**

Mr. Shook called on Chancellor Philip Rogers to present his report to the board.

A copy of the report is listed as “Attachment B.”

## **RESOLUTION PRESENTATION**

Mr. Shook proposed the following resolution to the board:

**Whereas**, East Carolina University welcomed its 12th chancellor, Dr. Philip Rogers, in March;

**Whereas**, East Carolina University comprises more than 28,000 students and nearly 200,000 living alumni, in addition to a network of loyal parents, friends, community members and corporate and foundation partners;

**Whereas**, East Carolina University has seen steadfast philanthropic support across all priorities;

**Whereas**, East Carolina University has a desire to increase scholarships, enhance research initiatives, construct state-of-the-art facilities, and expand its endowment;

**Whereas**, East Carolina University has a bold strategy to enact, through increased brand awareness and philanthropic support, its vision of a model institution that is future-focused and innovation-driven;

**Therefore**, the Board of Trustees of East Carolina University endorses the launch of the public phase of the \$500 million comprehensive campaign to advance and transform this great institution.

Ms. Fanning seconded the resolution and the resolution passed unanimously.

#### **REPORT FROM THE STUDENT GOVERNMENT ASSOCIATION**

Mr. Shook called on Mr. Chandler Ward, president of the Student Government Association, to provide a report on behalf of the student body. The full text version of his remarks is listed as “Attachment C.”

#### **REPORT FROM THE FACULTY**

Mr. Shook called on Dr. Purificacion Martinez, Chair of the Faculty, to provide a report on behalf of the faculty. The full text version of her remarks is listed as “Attachment D.”

#### **REPORT FROM THE STAFF**

Mr. Shook called on Dr. Hector Molina, Chair of the Staff Senate, to provide a report on behalf of the staff. A full text version of his remarks is listed as “Attachment E.”

#### **REPORT FROM THE BOARD OF VISITORS**

Mr. Shook called on Ms. Wanda Montano, Chair of the Board of Visitors, to provide a report on behalf of the Board of Visitors. A full text version of her remarks is listed as “Attachment F.”

## **COMMITTEE REPORTS AND RECOMMENDATIONS**

### **ATHLETICS AND ADVANCEMENT COMMITTEE**

Mr. Shook called on Mr. Miller, Chair of the Athletics and Advancement Committee, to present the committee report. A full text version of the report is listed as “Attachment G.”

### **AUDIT, RISK MANAGEMENT, COMPLIANCE AND ETHICS COMMITTEE**

Mr. Shook called on Mr. Smith, Chair of the Audit, Risk Management, Compliance and Ethics Committee, to present the committee report. A full text version of the report is listed as “Attachment H.”

### **FINANCE AND FACILITIES COMMITTEE**

Mr. Shook called on Mr. Poole, Chair of the Finance and Facilities Committee, to present the committee report. A full text version of the report is listed as “Attachment I.”

There was one action item coming out of committee. Mr. Poole moved that the board approve the fee proposal for Academic Year 2022-23 as presented in board materials. The motion was seconded and approved unanimously. This item is listed as “Attachment J.”

### **UNIVERSITY AFFAIRS COMMITTEE**

Mr. Shook called on Ms. Fanning, Chair of the University Affairs Committee, to present the committee report. A full text version of the report is listed as “Attachment K.”

There were two items coming out of committee that required the board’s attention.

Ms. Fanning moved that the board authorizes the EC Scholars Program within the Honors College the authority to use of North Carolina General Statute 116-143. which provides the full



cost scholarship opportunities for students at constituent institutions as outlined in the statute and as presented in board materials. The motion was seconded and approved with no negative votes.

This item is listed as “Attachment L.”

Mr. Ward moved that the candidates for degrees, as approved by the Chancellor and Faculty Senate, be authorized for conferral at the annual winter commencement on Friday, December 17, 2021. The motion was seconded and approved with no negative votes.

## **HEALTH SCIENCES COMMITTEE**

Mr. Shook called on Mr. Furr, Chair of the Health Sciences Committee, to present the committee report. A full text version of the report is listed as “Attachment M.”

There was one item that needed board attention. Mr. Furr moved that the board approve the Joint Operating Agreement in support of the clinical integration between East Carolina University and Vidant. The motion was seconded and approved unanimously.

## **CLOSED SESSION**

Mr. Shook asked for a motion to move into closed session.

Mr. Isley moved that the board go into closed session to prevent the premature disclosure of an honorary degree, scholarship, prize, or similar award; and to prevent the disclosure of confidential information under N.C. General Statutes §126-22 to §126-30 (personnel information) and the federal Family Educational Rights and Privacy Act; and to consider the qualifications, competence, performance, character, fitness, or appointment of prospective and/or current employees and/or to hear or investigate a complaint or grievance by or against one or more employees; and to prevent the disclosure of confidentiality of competitive health care

information under N.C. General Statute §131E-97.3; and to consult with an attorney to preserve the attorney-client privilege between the attorney and the Committee.

The motion was seconded and approved, and the board moved into closed session.

## **RETURN TO OPEN SESSION**

Once the board returned to open session, there were action items requiring full board consideration.

## **ITEMS FROM CLOSED SESSION**

Mr. Shook called on Mr. Furr, Chair of the Health Sciences committee.

Mr. Furr moved that the board approve the initial appointment with tenure for Dr. James Whiteside in the Department of Obstetrics and Gynecology, Brody School of Medicine as presented in board materials. This motion was seconded and approved with no negative votes. A full text version is listed as “Attachment N.”

Mr. Furr moved that the board approve the initial appointment with tenure for Dr. Raymond Mattingly in the Department of Pharmacology and Toxicology, Brody School of Medicine, as presented in board materials. This motion was approved with no negative votes. A full text version is listed as “Attachment O.”

Mr. Furr moved that the board approve Faculty Practice Incentive Payments to eligible faculty in the School of Dental Medicine as presented in board materials. The motion was approved with no negative votes. This item is listed as “Attachment P.”

Mr. Furr moved that the board approve Incentive Payments for eligible faculty in the College of Allied Health Sciences as presented in board materials. The motion was approved with no negative votes. A full text version is listed as “Attachment Q.”

Mr. Shook called on Mr. Miller, Chair of the Athletics and Advancement Committee.

Mr. Miller moved that the board approve the naming of the first floor student study room in the Speight Building in honor of Larry and Emma Thaxton Ferguson as presented in board materials. The board approved the motion with no negative votes. A full text version is listed as “Attachment R.”

#### **UNFINISHED BUSINESS**

There was no unfinished business for board consideration.

#### **NEW BUSINESS**

There was no new business for board consideration.

#### **ADJOURNMENT**

Hearing no further business to come before the board during this session, Mr. Shook adjourned the meeting.

Respectfully submitted,

Megan Ayers  
Assistant Secretary to the Board of Trustees

###

**CONSENT  
AGENDA**  
November 12, 2021

**I. Consent Agenda**

A. Minutes

1. September 10, 2021
2. October 21-22, 2021
3. November 8, 2021

B. Athletics & Advancement Committee

1. Naming Catalog for Life Sciences and Biotechnology Building
2. Nonsalary Compensation Plan

C. Finance & Facilities Committee

1. Ground Lease to Pacesetter Land Company, LLC
2. Severance of Eight Building on Millennial Campus Property
3. Nonsalary Compensation Plan - Car Allowances

Chancellor's Update to the Board of Trustees  
November 2021

Since my return to ECU, I have emphasized the importance of approaching our work together as ONE ECU. At every campus event, alumni event, tailgate, donor meeting, and engagement with the community, I encounter people proud to be Pirates. As I shared last week with the Faculty Senate, we have dedicated, passionate, smart, kind, and service-minded people who all contribute in meaningful ways to our success. To put it simply, we are better together.

Togetherness is a key theme in my brief remarks today. Let me begin by how together, as one united ECU family, we can deliver on a key institutional priority.

As we've discussed on many occasions before now, ECU and other institutions across the higher education landscape are operating in an environment of constrained resources and at a time where our revenue model requires careful reinvention and reimagination to ensure a sustainable future. We often discuss public private partnerships, alternative revenue generation strategies, and other creative financing approaches like Rick Staisloff shared with us yesterday – and all of those are important and valuable to explore – but I also ask myself what can we control in the immediate future and how can Pirate Nation bind together to advance our mission? I want to bring us back to the core of what ECU does best in a time that expects us to mobilize every member of our university's philanthropic reserves. ECU is a stake in the future and I hope you're going to help us reach our goal. This is the form of the public phase of our comprehensive campaign. This campaign is an inclusive initiative that will align and advance our university fundraising priorities – THIS is a One ECU moment. It is the largest philanthropic endeavor in ECU history and will serve to bolster academics, athletics, research, health care and more.

Donors, alumni and friends have already shown their willingness to support the university, from all-in efforts like Pirate Nation Gives (a hugely successful effort during my first day on the job – what a welcome home, by the way, thank you Pirate Nation), as well as a healthy number of 8-figure gift conversations within University Advancement. We have already raised well over \$300 million of the original \$500 million goal, and we're now ready to build on the momentum of the last few months to sprint towards our goal. I know Pirate Nation will go above and beyond to propel ECU into the future with a solid endowment, state-of-the-art facilities, increased scholarship opportunities for students and new research achievements.

This campaign will allow us to better serve our region and bring innovative solutions to today's most urgent challenges. After all, we are ECU — a model for student success, regional transformation, and public service.

As I reflect on the last 8 months, the announcement about the creation of ECU Health and the appointment of Dr. Mike Waldrum as our first joint CEO-Dean was another pivotal moment of unity and togetherness among the Pirate ranks. Appointing a joint leader (and an executive dean in Dr. Jason Higginson) was an important initial step in clinically, operationally, and financially integrating ECU and Vidant Health to advance our joint mission and deliver on our commitment to provide quality health care to all eastern North Carolinians. Later in this meeting you will review and consider the proposal to enter into a joint operating agreement designed to provide a framework for the next steps in this integration. As we emphasized at the time of announcing Dr. Waldrum's appointment, we are not exchanging assets, nor will this agreement involve the transfer, sale, or acquisition of the assets of either party or the employment status of employees. It will, however, allow us to achieve efficiencies, provide enhanced care, and together drive innovative solutions to serve this region under a unified clinical brand called ECU Health.

There is still much work ahead to fully operationalize ECU Health, but today is another important milestone in realizing this goal.

Yesterday morning we also cut the ribbon on our new Life Sciences and Biotechnology Building. Thanks to the citizens of North Carolina through the NC Connect bond, we now have a new state of the art facility designed for innovation, research, and education. Together faculty and students will assemble in this building for interdisciplinary discovery in a perfectly positioned location to be part of the new gateway to campus. Recently as I looked back from the roof of this new building toward the Intersect East campus and then the connector back toward the medical complex, I reflected on not only our progress, but also our promise in the years ahead.

A capital campaign to invest in our mission, a clinically integrated academic health system to serve the region, and a new facility designed for discovery and innovation. Three examples of how as One ECU we will leverage our assets to be a national model for student success, public service, and regional transformation.

Over the next several weeks many will participate in various personal and family traditions, including a time to reflect on the blessings we enjoy. For me and my family, among our many blessings, this year we give thanks for an opportunity to be together with our ECU family and serve with each of you and alongside Pirate Nation. Everyone has embraced us since returning home and I know to achieve our aspirations we must

put people at the center and move forward as a unified community. Because we are better together.

## **SGA Report to BOT November 2022**

I joked with several of you yesterday that it appeared to be a ghost town as we entered the new Life Science and Biotechnology Building, but upon our exit, we were greeted by State legislatures, Congress men and women, former chancellors, University city partners, the mayor, construction and planning teams, and of course our very own Deans and ECU faculty. I think that scene yesterday with all of those people perfectly encapsulates what advancements at ECU mean for this community and the impacts it has on regional transformation. This new 141 thousand square foot building is also set to serve nearly 17,000 students on an annual basis, and I want to reiterate my thanks to those involved and their dedication to student success.

This past whole month was in fact special as it encapsulated three of Pirates favorite things, homecoming, Halloween, and football.

- Updates at retreat
- Student attendance, energy to attend in person events
- Student attendance record Thursday night football game- rain
- Chancellor Rogers- graduation ceremonies in December

### November Updates

- Begging of the month Pie the President event: Doctors Without Borders of Haiti
- DEI commission co-chaired by our very own Vince Smith
  - o Student success and student access first thing on the agenda
- Earlier this week: opened Indigenous Land Acknowledgement Space

Aleshia Hunt involvement

Ceremonial Songs, Hoop dances, and representative from tribal leaders across the state



Artwork to come

Mental Health presentation- Dr. Kissler Van Reede

Topic not going away

75% On-Campus Students Vaccinated

78% Total Vaccinations rate (employees & students)

Past 7 Days

2,641 tests

4 positives= .15%

Previous Week

2,744 tests

3 positives= .11%

Highest September 4<sup>th</sup> with 84 Students

Last day with double digit student positive cases Oct. 1<sup>st</sup> (11)

Last cumulative week with double digit positive cases Oct 16- almost a month ago

Date by Week	# of Student + Cases per Week	# of Student Tests per Week
Oct 3-9	26	3,454 (.753%)
Oct 10-16	13	1,856 (.700%)
Oct 17-23	7	2,790 (.250%)
Oct 24-30	3	2,838 (.106%)
Oct 31-Nov 6	5	
Nov 7-Nov 11	2	

Summer planning Covid Planning Committee

“Return of Pirate Nation” and managing the curve and influx of cases

Continue to make up new curves and new spikes

ECU Fall Break Monday and Tuesday Oct 11-12

ECU Halloween weekend Oct 28-31 (7 positives in the last 2 weeks)

Out of compliance students- after losing login to their canvas, 80% of those students were reported in compliance and reinstated as of November 8<sup>th</sup>

Winter Break Discussion

My action item for all of you today is to start the discussion. Not to end all of the implications and mandates that students must abide by, but to start the discussion.

Too comfortable right now

“sense of normalcy”

What is normal

Again, I'm not here to protest these mandates but we need to open the discussion on some of the variables soon as I feel many students are reaching their breaking points. These students truly want to feel like a part of Pirate Nation, and as a University, we must deliver on that promise.

Thank you

Faculty Update to the BOT  
November 2022

Dear Members of the Board of Trustees,

It is my privilege to bring you greetings on behalf of the faculty at ECU. Since I will not have an opportunity to address you before the holidays begin, I would like to extend to all of you and your loved ones the faculty's warm wishes for a season filled with health, relaxation and joy. Next time we see each other it will be 2022. By then, two of my favorite things in life will have taken place: I will have celebrated Thanksgiving with my friends, and I will have spent Christmas with my mom and my family in Madrid. This year, with all those I call dear fully vaccinated, I am grateful to be able to return to a more normal way of celebrating the holidays. I look forward to my husband's always perfectly cooked turkey and my friend Andrew's delicious pecan and pumpkin pies. I know Dale, my husband, cannot wait for my mom's traditional roasted baby goat. The anticipation of joyful days to come has had me in great spirits for the past 10 days or so. And when I look at us, at ECU, I see reasons for cautious optimism. A glass can be half empty or half full. Today, I see it half full, and I am thankful for it.

I am thankful that ECU has been healthy this semester. As the weeks progressed, we kept seeing lower numbers of infections in our dashboard and higher vaccination rates. As of right now, our overall vaccination rate is 78%. For on campus students the rate is 75%. For residential students 73%. For employees 85%. The percentages, which started if I am not mistaken, around 49% at the beginning of the semester, demonstrate that this community, through social

media, conversations in class, appropriate disciplinary measures, has embraced safety and health over dissension and separation.

We stayed in the classroom, as students, administrators and faculty wanted. I consider this a perfect example of how Senior Administrators and Faculty Officers can effectively work together. During the first few weeks of the semester, we remained joined at the hip, with constant communication about what was happening on campus. The administration listened and acted on our concerns and recommendations. Honesty and transparency were the key elements of our collaboration. Happy with this semester's result, but aware that we must remain vigilant, all of us have agreed to meet later this month to finalize plans for Spring 2022. We have the foundations to ensure yet another successful semester: vaccines, testing, masks. I know we all want to put this nightmare behind, however we are not there yet. The faculty has an unequivocal position about next semester: masks for all, mandatory weekly testing for those who choose not to be vaccinated, appropriate disciplinary measures for people who refuse to see that this is not about themselves but the common good.

Another example of collaboration that I am thankful for, just took place in the past 10 days. I talked to you in April about revisions the Faculty Senate was doing to certain parts of the Faculty Manual to offer appropriate professional advancement and more job security to our non-tenure track faculty, those who are not tenure eligible. Chancellor Rogers suggested substantial edits to the Faculty Senate recommendation over the summer. The need to have a fruitful dialogue about the edits and the reasons behind them let the Vice Chancellors and the Faculty Officers to a new way of interacting with Faculty Senate

recommendations. I am happy to report to you that just this Wednesday an agreement was reached, and a final recommendation was sent to the Chancellor. This is yet another testimony of how mutual respect and dialogue are the tools to advance common goals.

The most ambitious common initiative that ECU has right now has one of you as co-chair at the helm, Trustee Smith. The Diversity, Equity and Inclusion Commission started its work on October 1st. We already have a rather large stack of literature to review and tentative drafts of possible members for the Student Success Subcommittee making the rounds. I am excited about what the data and our collective wisdom will bring in terms of concrete DEI measures for this campus.

It is quite likely that none of you remembers that the University of South Carolina used to be one of our aspirational peers. I am glad that they are not anymore. I am grateful that this Board of Trustees selected a Chancellor the faculty can trust, contrary to what happened with the 2019 appointment of a president in South Carolina. I am hopeful that the results of our DEI Commission will not become a "[name-change charade](#)" as happened there, according to reports from the Chronicle of Higher Education. I know Trustee Smith will not let that happen. None of us can let that happen, because recruiting and retaining a diverse group of students, faculty and staff are key to the sustainability that the RBK Group consultants talked about yesterday.

It is true that in September we were not able to win the football game against South Carolina. Despite that, I am thankful for the football games this Fall. It is not because I love football, or soccer or sports in general. I don't care about them at

all. I am grateful because they have given me the opportunity to get to know many of you as people, not as inhabitants of Olympus. You might be surprised to hear this: faculty view Trustees as all powerful and distant gods and goddesses. But now, I see all of you differently. Trustee Burt 's husband took me to the appropriate tailgating spot during my first football game. I have seen Vice Chair Poole and Trustee Furr celebrate each play. Chair Shook has taken me to see the game from his favorite spot in the stadium. I have met Trustee Flanning's beautiful family. I can attest to the fact that Trustee Isey knows his way around little kids. Before all that, Trustee Moss and I chatted about our busy and rewarding summer, filled with family activities. And all the way, we have talked about ECU, and we have gotten to know each other as people, beyond titles, degrees, political affiliations or accomplishments. We have shared our common objective: ECU's future.

I am thankful but not stupid. None of us are. All of us present in this room know that we must confront formidable challenges in the not too distant future. In the past ECU always counted on enrollment growth to finance projects. Vidant and Brody used to think that being frenemies was OK. At some point it was decided that ECU needed to be a player in national collegial sports. Many continue to think that divisions between sides of campus are the way to go. We used to be leaders in distance education. We are taking steps toward a more realistic approach to our reality. I am certain that I represent the faculty in my next remarks: we can't map all the steps, but as pirates, we know where the map is hidden and know how to read it. The first clue is quite clear: hire the right Provost. The Chancellor knows exactly who the faculty wants. Trust us.

Staff Senate remarks to BOT

November 2022

Good morning, Chairman Shook, Members of the Board, and Chancellor Rogers.

On behalf of the Staff Senate – I would like to first acknowledge all our Veterans on campus - staff, faculty, students, and BOT members. We want to express our sincere gratitude to those who have or are currently serving.

The staff across campus continue to be extremely committed and motivated in supporting the University's mission and the Chancellor's vision for a "One ECU", amid staff concerns of mental health and general well-being, feelings of burnout, seeing increased numbers of their peers or colleagues leaving the university, or uncertainty of compensation increases looming from a future state budget.

The staff senate remains devoted to promoting initiatives that encourage health and well-being amongst staff, for example - we concluded our Annual Wellness Walk at Lake Laupus on October 13<sup>th</sup>, where we saw 125 staff and faculty come out and enjoy the lake, get some fresh air and exercise, and connect with 15 local Greenville businesses who focus on wellness.

We also continue to look for ways to ensure diversity, equity, and inclusion continue to be at the forefront – we've worked in partnership with the Women

and Gender Office to host a Women's Roundtable on November 18<sup>th</sup> at 1pm, to spotlight some of our extremely talented women leaders on campus. With over 70% of our staff being women, we felt it was important to create a venue where leaders such as Ms. Stephanie Coleman, Dr. Virginia Hardy, and Dr. Gwen Tyson, who will be our panelist for that event, can share their journeys and stories with faculty, staff, and students.

In addition, we have finalized our date for our Annual B.A.L.L. (Ballard's Annual Lessons in Leadership) event, that is scheduled for April 19<sup>th</sup> from 2-4pm here within the Student Center in Ballroom C. Once we complete the final details with our guest speaker, we'll be sure to share those with campus.

I'd also like to share that we're excited to have begun taking nominations for our annual Staff Emeritus Award, which will be presented this Winter/Spring, while are also actively raising scholarship dollars through various activities, for both our Gail Jordan Memorial and SHRA Children Scholarships.

In closing, as a Staff Senate body we are continuously exploring and strategizing ways to celebrate and demonstrate our appreciation for our amazing staff here at ECU and look forward to our upcoming Staff Appreciation events this Spring.

The staff would also like to thank Chancellor Rogers (including his Executive Cabinet), and the Trustees for your unwavering support of ECU Staff.



Thank You!

## ECU Board of Visitors Report to the ECU Board of Trustees

November 12, 2021  
Wanda Montano, Chair

Good morning! Purple! {Gold!}

It's always a pleasure to see each of you and, on behalf of our entire membership, to share updates from the Board of Visitors.

During the last 2 months, the BoV has conducted its work through its three standing committees as well as through individual efforts.

Our Student Recruitment Committee, co-chaired by Toby Thomas and Terrence Powell, participated in all but one of the Pirates in Your Town events. Assistant Vice Chancellor Stephanie Whaley and her admissions team have been welcoming and supportive of our efforts.

We've hit the road in support of Student Recruitment. Toby spoke at the Charlotte, Raleigh, Greensboro and Fayetteville events and I spoke at the Coastal Studies event in Manteo.

We also attended the Fall Open House providing support to parents and students as these 820 students and more than 2500 attendees navigated the very busy space of the Campus Rec Center.

At the upcoming Pirates Aboard event on March 26<sup>th</sup>, the BoV will sponsor a Parents Welcome station.

BoV members will also participate as Greeters, providing parents with an opportunity for engagement with an alum.

The BoV will also provide 3-5 alumni for a Parents' Session panel.

In January, we will send out handwritten postcards to 1,000 under-represented minority students who have been accepted. The goal is to encourage and support their decision to join Pirate Nation, and offer an opportunity to contact the BoV member for further engagement.

Assistant Vice Chancellor Whaley continues to utilize the Board, and we are open to additional opportunities to engage and support our student recruitment efforts.

Our Nominating Committee has kicked off its work program. The Committee selected Ryan Beeson as its Chair. In addition to recommending the slate of officers to you for appointment, the Committee also recommends to this Board a new class of members.

Last year, the Board of Trustees was actively engaged in recommending new members.

I hope that you will begin thinking about who you might nominate this year. Nominations will be accepted beginning in January.

Our third committee focuses on our Access Scholars. As you know, the Board has as its core philanthropy the underwriting of four Access Scholars.

If you'd like to meet our Scholars for this year, I invite you to check out the BoV website.

In addition to the annual contributions, our members also provide gift cards to local establishments such as Starbucks and Panera, and these are sent to our scholars on special occasions – like exams – to give them a fun boost.

Our members also participate in quarterly calls with the Scholars, providing an opportunity for members to connect and support. One of our new members, Rachelle Chapman, connected with one of the scholars during our most recent call, allowing the student and Ms. Chapman to develop a mentoring relationship.

Our Scholars will join us in person at our January meeting.

Our Committee Chairs, Duane Holder & Johna Faulconer, along with ECU staff person, Melonie Bryan, lead this work.

Speaking of our January meeting, I know we were all excited to visit our new Life Sciences Building during yesterday's ribbon-cutting ceremony. We plan to host our January meeting in the facility, allowing our Members to experience this newest campus resource.

We will be in Manteo at the Coastal Studies Institute for our April session.

As you know, ex-officio membership on the Board of Visitors is extended to the Chairs of other campus-wide Boards.

One of my personal goals for this year was to develop reciprocity with those Boards so that a BoV representative could attend their meetings. This attendance supports cross-Board engagement.

That initiative has borne fruit, and I attended the recent Foundation Board meeting.

Further, the BoV was invited to have a member participate in the Foundation Board's Strategic Planning Retreat in March. Major General Dutch Holland will be the BoV representative.

We look forward to working with this Board, the Chancellor and Vice Chancellor Dyba on the Comprehensive Campaign.

I continue to look for ways to engage the Board membership in support of our University and our mission. We do have bandwidth for more. As always, I look for your input and guidance on our advocacy efforts.

Thank you for the opportunity to spend a few minutes with you, and for the honor of serving East Carolina.

Unlike Dr. Martinez, my father was successful in inculcating his love of sports in me. I am the son he never had. So, onward to victory tomorrow in Memphis!

Go Pirates!

**Minutes**  
**Athletics & Advancement Committee**  
**November 11, 2021**

Advancement

Mr. Chris Dyba reported that east campus is trending well and they are \$718K ahead of schedule. West campus had a great October and is lagging a little behind schedule; however, he feels there is no question that they will meet their goal.

The Life Sciences & Biotechnology Building has great space to entice donors. He reminded the committee that the building was built with bond money but money is needed to outfit the facility and for academic programs. A slate of spaces and a schematic of spaces were presented to the committee for preapproval. The committee approved the naming catalog and this item was included on this morning's consent agenda.

Mr. Dyba shared that he and/or his team met with all the deans and unit directors to discuss their priorities and goals for the upcoming Comprehensive Campaign. Buy in was received from all. Mr. Dyba also shared that there are a few 8-figure gift discussions going on which will be transformative for ECU and ECU's first 8-figure gift. A motion was made endorsing the public phase of the campaign and unanimously approved for presentation to the full board tomorrow.

Athletics

Mr. Jon Gilbert reviewed the metrics for Athletics. He reported that the Pirate Club has done an exceptional job with premium seating and the Student Pirate Club is growing. He shared that Athletics fundraising without Pirate Club is trending in the right direction and a recent \$100,000 gift was received for a new endowment. The new EC Letterwinners Club already has 200 members. He shared that next football season we will host 7 games with the first one being against NC State. Current basketball season ticket sales are less than expected. Athletics continues to monitor athletic expenses compared to budget and is in the green due to the counting of season football ticket sales; however, single game sales lag which is attributed to not selling as many tickets to the South Carolina contest. The upcoming contest against Cincinnati brings the highest ranked team to ever play at ECU.

Mr. Gilbert reported that six institutions were added to the American Athletic Conference. The start date is not finalized as we must wait to see when the three teams exiting leave. He also reminded the committee that each team leaving has a \$10M exit fee that goes into a conference reserve.

He announced that the APR is 993 which is the highest ever at ECU. Much growth has been made over the past three years.

Student game day attendance for the South Florida game was 10,216.

He shared that the Pirate Club brought back the Pirates Supporting Pirates program where businesses can join at a minimum of \$500. Currently there are 173 local businesses. Signing day for fall sports was yesterday, November 10. December 15 is football signing day and the second one is the first Wednesday in February.

Higher education is pushing for a policy on NIL. The newly formed constitution committee will vote in January and it is anticipated that change is coming with a large desegregation to conference level or individual schools.

Mr. Gilbert shared the success of Treasure Island, a place where student clubs from campus can gather during a football game. He believes this new venture has increased student attendance at the football games.

A question was raised asking why we don't compete with our more traditional rivals. Mr. Gilbert responded by saying a lot has to do with funding and revenue.

Our committee approved the non-salary compensation plan relative to academic bonuses which covers the gamut of all sports and competitive bonuses for conference championships and above were presented to the committee. Approval of this plan eliminates the need to come before the committee/board on sport specific as each occurrence arises. This item was included on this morning's consent agenda.

I will have a motion coming out of closed session, but for now, that concludes my report.



## **Report of the Audit, Risk Management, Compliance, and Ethics Committee for November 11, 2021**

### **Operational Metrics Review**

The committee reviewed the operational metrics related to Internal Audit, Healthcare Compliance, Research Compliance, and Athletics Compliance.

Through October, Internal Audit is on track to hit the targets for audit plan completion and auditor productivity. Mr. Poole reported that 92% of the audits on the plan are directly related to a University top risk, emerging risk, or strategic goal. Management has completed or made satisfactory progress towards resolving 95.8% of the audit recommendations that Internal Audit has followed up on during the current fiscal year.

Athletics Compliance and Healthcare Compliance are exceeding their targets for the number of education and consultation sessions they've provided for the year to date. For the year to date, 93.7% of the healthcare providers have passed their documentation reviews, exceeding the target of 90%.

### **Action Items**

The committee approved changes to the fiscal year 2022 annual audit plan, as presented by Chief Audit Officer Wayne Poole. One audit was added to the plan and one audit was postponed. This does not require any action by the full Board.

### **Informational Items**

#### **Enterprise Risk Management – Ms. Stephanie Coleman**

Ms. Coleman presented the University's top enterprise risks matrix, which includes the responsible senior management official for each risk. The matrix includes communications and steps that have been taken on each risk. The matrix also includes information on secondary risks and emerging risks.

Ms. Coleman advised that the University Affairs Committee would be receiving an update on student mental health and well-being, one of ECU's top risks, from Vice Chancellor Virginia Hardy and the Student Affairs team.

#### **Office of Internal Audit – Mr. Wayne Poole**

Mr. Poole provided information on Internal Audit resources as requested by the committee.

Mr. Poole briefed the committee on the University's annual financial audit which has been completed by the Office of the State Auditor. The State Auditor found the financial statements for the 2021 fiscal year to be fairly stated and reported no internal control weaknesses that would impact the accuracy of the financial statements. The financial audit report will be published in the next two weeks.

Mr. Poole advised the committee that this year ECU was selected by the State Auditor as part of the statewide audit of federal student financial aid funds. The State Auditor found no reportable findings related to ECU on this audit.

Mr. Poole also briefed the committee on several recently completed internal audits.

-----  
Mr. Chairman, that concludes my report.



## East Carolina University | Finance & Facilities | November 12, 2021 Highlights

- I. **Minutes** - Approved
- II. **Review of Operational Metrics** - State expenses are on track and the change in unrestricted fund balance is overall better than plan. AF Auxiliary is close to plan while SA auxiliary is a little off plan but anticipate improvement. Tuition compared to prior year is slightly up. DE rates are slightly higher while tuition to budget is better than plan. A lower FTE than normal projection was used in Mandatory Fees. Athletics is showing a significant gain with the football season ticket revenue. ECUP isn't doing as well as plan projection due to unbudgeted electronic health record cost and upper limit payments
- III. **Fee Proposals for Academic Year 2022-2023** - This year's guidelines did not allow any increase in resident tuition. Housing, Dining, Parking and 1card proposed fee increases. Additionally, several Dental fees were proposed. Two of the dental increases will need BOG approval. All other fee increases only require BOT approval. - I'll have a motion at the end of my report.
- IV. **Ground Lease to Pacesetter Land, Company, LLC** - ECU has a developer agreement with Elliott Sidewalk Communities (ESC) for 19.2 acres. Thus far, we have sold them 3 acres which were the historical buildings and have approval to lease 2 acres from BOT and BOG. That leaves 13.7 acres that needs approval by this Board and BOG for us to lease to Pacesetter Land Company which is a part of ESC enterprise . This item was included in this morning's consent agenda.
- V. **Sever Eight Buildings on Millennial Campus-Warehouse District** - We are requesting approval to demolish 8 buildings in the Warehouse District. Most likely not all 8 will be severed, however, the desire is for us to get approval from everyone including Council of State and therefore the project will not be delayed waiting on approvals. This item was included in this morning's consent agenda.
- VI. **Non-salary compensation policy-Car Allowances** - We are requesting an update to include Athletics staff in this benefit if their job requires them to routinely travel for their job. This item was included in this morning's consent agenda.
- VII. **Capital Projects Update** - Information was provided on the Life Sciences and Biotechnology Center, Mendenhall Renovation Phase I, Isley Innovation Hub, Main Campus Steam Plant Fuel Tank Farm, Multi-Sports Strength Training Facility. The Major Capital Projects Schedule was also provided.
- VIII. **Informational Items**
  - A. Stephanie Coleman, VC for Administration & Finance, provided the Comprehensive Budget Report.
  - B. Stephanie Coleman, VC for Administration & Finance, provided the Report of Approved EHRA Employee Salary Adjustments.
  - C. Stephanie Coleman, VC for Administration & Finance, provided the Pension Report.
  - D. Bill Bagnell, Associate VC for Campus Operations, provided information on the Designer Selection. Informal Projects included: Pharma Center Fit-Up in Life Sciences and Biotechnology Building and ESRC Court Lighting Replacement.
  - E. Bill Bagnell, Associate VC for Campus Operations, updated the Committee on Capital Projects. Information was provided on the Chilled water Infrastructure - McGinnis to Wright and Rawl Buildings.
  - F. Stephanie Coleman, VC for Administration & Finance, provided the Statement of Bonded Indebtedness as of June 30, 2021.

Mr. Chairman, I have one motion for the board's consideration this morning:

I move that the board approve the fee proposal for Academic Year 2022-23 as presented in board materials.





**Finance and Facilities Committee**

November 11, 2021

Agenda Item:	III. Fee Proposals for Academic Year 2022-2023
Responsible Person:	Stephanie Coleman, VC Admin & Finance
Requested:	Approval
Notes:	N/A

Attachment J

# 2022-2023 Fee Proposals

## ECU Board of Trustees

### November 2021




**ECU**<sup>®</sup>



# Tuition and Fee Increase Process

- System Office provides guidelines
- Campus Committee comprised of Students, Faculty, and Staff
- Student feedback
- Recommendation from:



# System Office Tuition & Fee Guidance

- No resident tuition increases for undergraduate, graduate or professional students allowed
- Nonresident tuition increase requests allowed
  - ECU is not requesting any tuition increases
- Mandatory fees must remain flat except for limited situations
  - A mandatory fee increase offset by a decrease=no net increase
  - Campus Security Fee catch up from FY21-22 (ECU will be \$8)
  - Exceptional situation (all three of the following must be met)
    1. Fee was not increased in the last two years
    2. Fee does not support an increase in scope of services or activities (increase will cover specific, identifiable inflationary cost increases)
    3. Without the fee increase, ending fund balance is projected to be less than 4 months of recurring expenses.



# Tuition & Fee Approvals

<b>Tuition &amp; Fees</b>	<b>BOT Recommendation or Approval</b>	<b>BOG Approval</b>	<b>BOG Information</b>	<b>Student Involvement Required</b>
Tuition	X	X		X
Tuition Differentials	X	X		X
Mandatory Fees	X	X		X
Application Fees	X	X		X
Special Fees	X	X		X
Misc. Fees *	X		X	
Housing	X		X	
Dining	X		X	
Parking	X		X	

\* Misc fees include graduation, cap & gown, transcripts, transit, and some dental fees

# Tuition History

Tuition				
	2019-20	2020-21	2021-22	3 yr % increase
<b>On Campus</b>			Changed to Credit hour	
<b>Undergraduate Tuition</b>				
Resident	\$ 4,452	\$ 4,452	\$ 185.50	0%
Nonresident	\$ 20,729	\$ 20,729	\$ 863.71	0%
<b>Graduate Tuition</b>				
Resident	\$ 4,749	\$ 4,749	\$ 263.83	0%
Nonresident	\$ 17,898	\$ 17,898	\$ 994.33	0%
<b>DE (Per Credit Hour)</b>				
<b>Undergraduate Tuition</b>				
Resident	\$ 150.41	\$ 150.41	\$ 185.50	23% *
Nonresident	\$ 700.30	\$ 700.30	\$ 863.71	23% *
<b>Graduate Tuition</b>				
Resident	\$ 232.79	\$ 232.79	\$ 263.83	13% *
Nonresident	\$ 877.35	\$ 877.35	\$ 994.33	13% *

Last increase in tuition was from 2016-17 to 2017-18

Tuition was converted to per credit hour in FY 21-22 for everyone

\*DE increased in FY 21-22 due to change in denominator for calculating DE rates (UNC System)

# Mandatory Fees History

## East Carolina University Fees Paid by All Students

	Approved Annual Rates for 2019-20	Approved Annual Rates for 2020-21	Approved Annual Rates for 2021-22	3 year % increase
<b>General Fees</b>				
SGA	\$ 27.50	\$ 27.50	\$ 27.50	0.00%
Media	30.00	30.00	30.00	0.00%
Fine Arts	8.00	8.00	8.00	0.00%
Campus Recreation and Wellness	271.00	271.00	271.00	0.00%
Minges Operations	6.00	6.00	6.00	0.00%
Student Activity Programs	71.50	71.50	71.50	0.00%
Student Centers Operations	288.00	288.00	288.00	0.00%
Athletics Fee	773.00	773.00	773.00	0.00%
Student Health Fee	263.00	263.00	319.00	21.29%
Education and Technology Fee	403.00	403.00	403.00	0.00%
<b>Total General Fees</b>	<b>\$ 2,141.00</b>	<b>\$ 2,141.00</b>	<b>\$ 2,197.00</b>	<b>2.62%</b>
<b>Debt Service</b>				
Athletic Facility Debt	70.00	70.00	70.00	0.00%
Student Union Center	375.00	375.00	375.00	0.00%
<b>Total Debt Service</b>	<b>\$ 445.00</b>	<b>\$ 445.00</b>	<b>\$ 445.00</b>	<b>0.00%</b>
<b>Special Fees</b>				
Campus Safety	\$ 30.00	\$ 30.00	\$ 52.00	73.33%
<b>TOTAL GENERAL STUDENT FEES &amp; DEBT SERVICE</b>	<b>\$ 2,616.00</b>	<b>\$ 2,616.00</b>	<b>\$ 2,694.00</b>	<b>2.98%</b>
<b>Miscellaneous Charges</b>				
Transit	\$ 158.00	\$ 158.00	\$ 158.00	0.00%
Graduation	12.00	12.00	12.00	0.00%
Association of Student Governments	1.00	1.00	1.00	0.00%
<b>Total Miscellaneous Charges paid by all studen</b>	<b>\$ 171.00</b>	<b>\$ 171.00</b>	<b>\$ 171.00</b>	<b>0.00%</b>
<b>Total Fees Paid by Each Student</b>	<b>\$ 2,787.00</b>	<b>\$ 2,787.00</b>	<b>\$ 2,865.00</b>	<b>2.80%</b>

# Cost of Attendance On Campus UG Residents

<b>Costs</b>	<b>2019-2020</b>	<b>2020-2021</b>	<b>2021-2022</b>
Tuition & Fees	\$ 7,239	\$ 7,239	\$ 7,317
Room & Board	10,030	10,136	10,450
Books & Supplies	1,490	1,524	1,546
Personal	1,430	1,462	1,724
Transportation	2,120	2,168	2,198
Loan Fee	80	80	80
<b>Total</b>	<b>\$ 22,389</b>	<b>\$ 22,609</b>	<b>\$ 23,315</b>



# System Comparison

## Academic Year 21-22

Attachment J

Academic Year 2021-22

University	Student Activity Fee	Rank	Athletic Fee	Rank	Student Health Fee	Rank	Ed & Tech Fee	Rank	Safety Fee	Rank	Total General Fees	Rank	Debt Service Fee	Rank	Total General Fees and Debt Service	Rank	Transit Fee	Rank
UNC - Charlotte	650	10	824	5	335	9	622	2	34		2,465	3	720	1	3,185	1	155	5
North Carolina A & T State University	714	4	870	2	370	6	469	8	60		2,483	2	588	4	3,071	2	96	12
Appalachian State University	659	9	783	6	335	9	576	3	60		2,413	5	634	3	3,047	3	160	3
UNC - Asheville	792	1	855	3	403	4	527	7	60		2,637	1	394	10	3,031	4	100	11
UNC - Greensboro	577	12	780	9	372	5	461	9	54		2,244	11	707	2	2,951	5	106	8
Western Carolina University	642	11	782	7	350	7	544	4	60		2,378	6	523	7	2,901	6	123	6
North Carolina Central University	501	15	847	4	313	13	428	12	60		2,149	12	570	5	2,719	7	106	8
<b>East Carolina University</b>	<b>702</b>	<b>5</b>	<b>773</b>	<b>12</b>	<b>319</b>	<b>12</b>	<b>403</b>	<b>14</b>	<b>52</b>		<b>2,249</b>	<b>10</b>	<b>445</b>	<b>8</b>	<b>2,694</b>	<b>8</b>	<b>158</b>	<b>4</b>
UNC - Wilmington	699	6	775	11	246	15	535	5	60		2,315	8	376	11	2,691	9	104	10
Winston Salem State University	546	14	780	9	340	8	416	13	31		2,113	13	423	9	2,536	10	55	13
UNC - Pembroke	698	7	782	8	215	16	534	6	60		2,289	9	240	13	2,529	11		
UNC School of the Arts	748	2	-	16	882	1	754	1	60		2,444	4			2,444	12	121	7
Fayetteville State University	565	13	768	13	287	14	382	15	60		2,062	14	335	12	2,397	13		
North Carolina State University	679	8	232	15	445	2	439	11	60		1,856	15	534	6	2,390	14	205	2
Elizabeth City State University	738	3	899	1	333	11	326	16	30		2,326	7			2,326	15		
UNC - Chapel Hill	394	16	279	14	410	3	442	10	60		1,586	16	186	14	1,771	16	205	1

# Dental Special Fees

- **Dental Housing**

- SoDM contracts with AHEC across the state for D4 housing at CSLC's; rates increasing
- Current annual fee \$1,200; Proposed increase by \$195 to \$1,395

- **Preclinical Materials Fee**

- Practice teeth and typodonts
- Additional cost are being incurred due to change in licensure exam- change from patient to manikins
- Current annual fee for the D1's is \$225, \$300 for the D2's and \$360 for the D3's;
- Propose increases to everyone and have across the board \$450 fee

- Requires approval by BOG



# Dental Miscellaneous Charges Attachment J

- **Dental Risk Management Fee**
  - Liability insurance for student, rate increased
  - Current fee \$50; Proposed increase by \$4 to \$54
  
- **Electronic Textbook Fee**
  - Current annual fee \$888; Proposed increase \$117 to \$1,005
  
- **American Student Dental Association Fee**
  - Professional association for all US dentists, anticipate fee increase
  - Current annual fee \$110; Proposed increase by \$10 to \$120
  
- BOT is final approval



# Housing & Dining

## Housing and Dining

	Approved Rates 2019-20	Approved Rates 2020-21	Approved Rates 2021-22	3 yr % Increase
<b>HOUSING (double occupancy)</b>				
Standard Rate	\$ 5,520	\$ 5,520	\$ 5,630	2%
College Hill Suites (CHS)	\$ 6,390	\$ 6,390	\$ 6,520	2%
Scott Hall	\$ 6,160	\$ 6,160	\$ 6,285	2%
Newly Renovated Residence Halls	\$ 5,980	\$ 5,980	\$ 6,100	2%
<b>FOOD SERVICES</b>				
Pirate 20 with \$450 in Pirate Bucks	\$ 3,950	\$ 3,950	\$ 4,060	3%
Pirate 40 with \$350 in Pirate Bucks	\$ 3,950	\$ 3,950	\$ 4,060	3%
Pirate 60 with \$250 in Pirate Bucks	\$ 3,950	\$ 3,950	\$ 4,060	3%
40 commuter meal plan *	\$ 1,300	\$ 1,300	\$ 1,440	11%
80 commuter meal plan *	\$ 1,670	\$ 1,670	\$ 1,840	10%
120 commuter meal plan *	\$ 2,050	\$ 2,050	\$ 2,240	9%

\* Annualized

# Housing

Cost Comparison Chart of Select Competitors		
	Most Expensive	Least Expensive
ECU	\$ 8,520	\$ 5,630
UNC-C	\$ 11,030	\$ 7,430
UNC-G	\$ 8,928	\$ 5,766
UNC-W	\$ 9,000	\$ 6,112
App State	\$ 7,000	\$ 4,713

## Assumptions:

- Freshman class will be 4100, with a yield of 95%.
- Campus Living will receive transfer for Slay/Umstead.
- Campus Living will reopen College Hill Suites, while retaining 24 spaces offline to be used for Q/I.
- Campus Living is planning to reduce \$100K within its budget through salary savings.

## Justification:

- The increase will be used to offset inflation in materials, services, contracts, and utilities.
- The increase will be used to offset inflationary adjustments to salaries and benefits.
- The remaining increase will be used to invest into the residence halls, making improvements and addressing the disparities between renovated and non-renovated facilities.
  - Short Term examples – Duct cleaning, carpet, furniture, sinks and dormers.
  - Long Term examples – Renovation of bathrooms, heating and air-conditioning replacements, replacing roofs and elevators.
- Housing will develop First-Generation initiatives to promote student success.



# Housing Request

<b>HOUSING</b>					
<b>Doubles &amp; Singles</b>					
	<b>Current Annual Rate (21-22)</b>	<b>Proposed Annual Rate (22-23)</b>	<b>Proposed Increase for 22-23 (\$)</b>	<b>Proposed Increase for 22-23 (%)</b>	
College Hill Suites	\$ 6,520.00	\$ 6,710.00	\$ 190.00	2.91%	
College Hill Suites Single (4 person)	\$ 8,120.00	\$ 8,310.00	\$ 190.00		
College Hill Suites Double (2 person)	\$ 6,920.00	\$ 7,110.00	\$ 190.00		
College Hill Suites Single (2 person)	\$ 8,520.00	\$ 8,710.00	\$ 190.00		
Scott Hall/Ballard Suites	\$ 6,285.00	\$ 6,470.00	\$ 185.00	2.94%	
Scott/Ballard Suites Double (Private Bath)	\$ 6,685.00	\$ 6,870.00	\$ 185.00		
Scott/Ballard Suites Single	\$ 7,885.00	\$ 8,070.00	\$ 185.00		
Scott/Ballard Suites Single (Private Bath)	\$ 8,285.00	\$ 8,470.00	\$ 185.00		
Scott/Ballard Suites Designated Singles	\$ 7,485.00	\$ 7,670.00	\$ 185.00		
Renovated Residence Halls*	\$ 6,100.00	\$ 6,280.00	\$ 180.00	2.95%	
Renovated Residence Hall Single	\$ 7,700.00	\$ 7,880.00	\$ 180.00		
Gateway Residence Hall 5th Floor	\$ 6,174.00	\$ 6,354.00	\$ 180.00		
Standard Residence Halls**	\$ 5,630.00	\$ 5,800.00	\$ 170.00	3.02%	
Standard Residence Hall - Single	\$ 7,230.00	\$ 7,400.00	\$ 170.00		<b>Avg Increase %</b>
CFJ Designated Singles	\$ 6,830.00	\$ 7,000.00	\$ 170.00		<b>2.96%</b>

\*Renovated Residence Halls include Fletcher, Tyler, Ballard (Traditional Rooms), White, Clement, Cotten & Greene

\*\*Standard Residence Halls include Legacy, Jones, Fleming, Jarvis, Umstead & Garrett

# Dining Background

- Food Costs
  - To date in FY22, Aramark has seen an increase in food cost of approximately 5.5% due to inflation, global procurement issues, and substitutions. This does not take in account future inflationary impacts based on supply chain challenges.
  - August 2021 CPI Food Away From Home Index: 4.7%
  - Anticipated increase is \$425,000 for the estimated \$8.85M in annual food costs.



# Labor Costs

## Competitive Labor Rates

Locations	Server/Cashier	Cook	Dish
Parker's BBQ	\$15.00	\$20.00	\$17.00
Villa Verde	\$10.00	\$15.00	
Muscle Maker Grill	\$10.00	\$10.00	\$10.00
Sup Dogs	\$12.50	\$12.50	\$12.50
Panda Express	\$11.00	\$11.00	\$11.00
Chick-Fil-A	\$10.00	\$12.00	
McDonald's	\$9.00 - \$13.00		
<b>Retail</b>			
Target	\$15.00		
Big Lots	\$9.50		
David's Bridal	\$8.00		
Lowe's	\$10.00/\$11.00		

## Current Aramark Salary Structure

Catering Service Worker	\$	8.75
Food Service Worker	\$	8.25
General Utility Worker	\$	8.25
Cashier	\$	8.50
Barista	\$	8.50
Supervisor	\$	13.00
Office Worker	\$	12.00
Cook	\$	11.00
Grill Cook	\$	10.50
Driver	\$	10.00
Stand Worker	\$	8.25
Food Prep Worker	\$	8.25
Baker	\$	10.00

## Cost of New Salary Structure

	Total Wages
<b>Current Annual Labor Spend</b>	\$ 9,685,408
<b>Proposed \$11</b>	\$ 10,921,468
<b>Increase in Labor Cost Over Average</b>	\$ 1,236,061





# Dining Request

	Current Annual Rate (21-22)	Proposed Annual Rate (22-23)	Proposed Increase for 22-23 (\$)	Proposed Increase for 22-23 (%)	
Pirate 20 with \$450 in Pirate Bucks	\$ 4,060	\$ 4,380	\$ 320	7.88%	
Pirate 40 with \$350 in Pirate Bucks	\$ 4,060	\$ 4,380	\$ 320	7.88%	
Pirate 60 with \$250 in Pirate Bucks	\$ 4,060	\$ 4,380	\$ 320	7.88%	
Purple Flex (\$550 in Pirate Bucks)	\$ 4,060	\$ 4,380	\$ 320	7.88%	
40 commuter meal plan	\$ 1,440	\$ 1,480	\$ 40	2.78%	
80 commuter meal plan	\$ 1,840	\$ 1,890	\$ 50	2.72%	<b>Avg Increase %</b>
120 commuter meal plan	\$ 2,240	\$ 2,300	\$ 60	2.68%	<b>5.67%</b>

# Current Comparative Meal Plan Prices of Select Competitors

Attachment J

ECU	Meals Per Semester	Meal Exchange Per Semester	DB Per Semester	Guest Meals	Meal Plan Cost per semester	Meal Plan Cost per year
All Access 60	Unlimited	60	\$ 250.00	5	\$ 2,030.00	\$4,060.00
All Access 40	Unlimited	40	\$ 320.00	5	\$ 2,030.00	\$4,060.00
All Access 20	Unlimited	20	\$ 450.00	5	\$ 2,030.00	\$4,060.00
All Access Flex	Unlimited	0	\$ 550.00	5	\$ 2,030.00	\$4,060.00
Gold 120	120		\$ 200.00	0	\$ 1,120.00	\$2,240.00
Gold 80	80		\$ 280.00	0	\$ 920.00	\$1,840.00
Gold 40	40		\$ 380.00	0	\$ 720.00	\$1,440.00
Gold 450	0		\$ 450.00	0	\$ 450.00	\$900.00

UNCW	Residential Meals Weekly	Meal Exchange Weekly	DB Per Semester	Guest Meals	Meal Plan Cost per semester	Meal Plan Cost per year
Hawk Gold	Unlimited	6	\$300	5	\$ 2,460.82	\$4,921.64
Hawk Silver	Unlimited	3	\$200	5	\$ 2,225.67	\$4,451.34
Hawk Bronze	Unlimited	0	\$100	5	\$ 1,972.50	\$3,945.00
Block 125	125		\$250	5	\$ 1,496.55	\$2,993.10
Block 85	85		\$150	5	\$ 1,006.00	\$2,012.00
Block 50	50		\$50	0	\$ 558.25	\$1,116.50

UNCG	Residential Meals Weekly	Meal Exchange Weekly	DB Per Semester	Guest Meals	Meal Plan Cost per semester	Meal Plan Cost per year
Spartan Unlimited	Unlimited	5	\$100	5	\$ 1,965.99	\$3,931.98
Spartan 19	19	5	\$225	5	\$ 1,957.55	\$3,915.10
Spiro 15	15	3	\$250	0	\$ 1,955.87	\$3,911.74
Charlie's 10	10	1	\$400	0	\$ 1,763.20	\$3,526.40
The Gold Pack	117	1	\$600	0	\$ 1,749.70	\$3,499.40
The Blue Pack	117	1	\$850	0	\$ 1,604.72	\$3,209.44
Rawkin Pack	24 Per Semester		\$200	0	\$ 479.69	\$959.38

App State - All DB Plans	All DB Plan	Meal Plan Cost per semester	Meal Plan Cost per year
Low	\$1,124	\$1,124	\$2,248
Standard	\$1,446	\$1,446	\$2,892
High	\$1,680	\$1,680	\$3,360
Super	\$2,043	\$2,043	\$4,086



# Parking

- 2% increase for all permits, except garage fees and reserved
- Increased reserved permits to same price as garage permits (\$560 to \$720) – Deans, AVCs, VCs, Chancellor
- No change to garage permit

## **Justification**

- Additional revenue generated will be used to cover legislative salary and benefit increases, inflationary expense increases, technology, and expansion.



# 1Card Proposal

- \$5 increase for card replacement fee; From \$15 to \$20
- Similar to other UNC System 1Card Programs

Card Type	ECU	UNC	UNC	UNC	UNC	NC
		Chapel Hill	Charlotte	Wilmington	Greensboro	State
Replacement	\$15.00	\$10.00 + semester fee*	\$20.00	\$25.00	20.00	\$20.00

- Generates approximately \$10,000 per year in revenue to support:
  - Option to link card to bank account
  - Identification card for voter ID
  - Expansion of Bounty Bucks to off campus merchants
  - Upgraded card reader technology



# Feedback

- Two members of the Tuition and Fee Committee did not support the following increases
  - Dental Electronic Textbooks
  - Housing and Dining
- Fee increases (non-Dental) were presented to SGA Assembly. Resolution was passed in support of all increases.
- Dental Administration met with Dental students and discussed increases.



# Next Steps

- Dental Special Fees recommendation to BOG for consideration in February/March 2022
- BOT is final approval for Housing, Dining, Parking, 1Card, and Dental miscellaneous. Information will be shared with BOG.



# Action Items

## 1. Dental Fees

- **Dental Housing Fee** Increase by \$195
- **Preclinical Materials Fee** Increase to \$450 per student
- **Dental Risk Management Fee** Increase by \$4
- **Electronic Textbook Fee** Increase by \$117
- **American Student Dental Association Fee** Increase by \$10

## 2. Housing – 2.96% average increase

## 3. Dining – 5.67% average increase

## 4. Parking- average 2% increase, except Reserved and Garage; Reserved increase from \$560 to \$720

## 5. 1Card Replacement Fee - \$5 increase





**JENNIFER HAYGOOD**

**SENIOR VICE PRESIDENT FOR FINANCE & ADMINISTRATION AND CHIEF FINANCIAL OFFICER**

Post Office Box 2688, Chapel Hill, NC 27515

910 Raleigh Road, Chapel Hill, NC 27514


(919) 962-4600 office

jhhaygood@northcarolina.edu

September 17, 2021

**MEMORANDUM**

TO: Chancellors  
Chiefs of Staff  
Chief Academic Officers  
Chief Financial Officers

FROM: Jennifer Haygood 

SUBJECT: Proposals for 2022-23 Campus-Initiated Tuition and Fee Adjustments

President Hans and the Board of Governors are committed to promoting accessibility and affordability of higher education for all North Carolinians. In light of this commitment and the financial strain the COVID-19 pandemic continues to place on many students and families, the Board will only consider 2022-23 campus-initiated tuition and fee increases in the limited situations outlined below.

Attached are guidelines for your use in submitting requests for changes in tuition and fee rates, effective for the Fall Term 2022. After campus proposals are reviewed by the president and his staff, they will be presented to the Board in January and will be considered for approval at the Board's February meeting. The guidance outlined in this memo is based on recommendations of the president and the Board, the UNC policies 1000.1.1 and 1000.1.2 – *Policy on Tuition Rates* (Attachment 1) and *Policy on Student Fees* (Attachment 2).

***Undergraduate Tuition***

- **No tuition increases are allowed for resident students.** Combined tuition and fee rates for undergraduate residents shall continue to remain in the bottom quartile of an institution's public peers.
- **Increases are allowed for nonresident students.** Campuses should continue to follow the traditional process for recommending campus-initiated tuition increases for nonresident undergraduate students. Combined tuition and fee rates for these students should be market driven and reflect the full cost of providing a quality education. In addition, a goal of each campus should be setting nonresident rates at or above the third quartile of each institution's public peers.



MEMO: 2022-23 Tuition and Fee Adjustments

September 17, 2021

Page 2 of 4

### ***Graduate and Professional School Tuition***

The Board will **not** consider increases for **resident** graduate and professional students; however, campuses can request to establish tuition rates for any new graduate program that will enroll students (residents and nonresidents) for the first time in Fall 2022. The Board will consider school-based and campus-initiated increases for **nonresident** tuition for graduate and professional programs that have been approved by the Board of Governors. Institutions must use the Board's tuition and fee policy as a guideline in developing recommendations for establishing nonresident graduate and professional school tuition rates.

The tuition and fee policy states, "Graduate and professional schools should establish rates consistent with each program's unique market and academic requirements." Tuition for nonresident graduate and professional students will be set with an emphasis on maintaining and increasing the excellence of the institution's graduate and professional programs, as well as ensuring access. Please do not submit requests for tuition increases for graduate programs that have not been previously approved by the Board of Governors.

### ***NC Promise Institutions (ECSU, UNCP, and WCU)***

The 2016 General Assembly set up a tuition buy-down program for ECSU, UNCP, and WCU that began with the 2018-19 academic year. The 2022-23 tuition for undergraduate residents will be \$500 per semester and \$2,500 per semester for undergraduate nonresidents. The cost of the foregone tuition receipts will be offset by an appropriation to increase the UNC budget, subject to funding availability. Changes to the buy-down rate will be considered during the budget allocation process.

**ALL TUITION INCREASE PROPOSALS MUST BE ACCOMPANIED BY A DETAILED JUSTIFICATION ON THE USE OF THE INCREASED FUNDS.**

### ***Mandatory Fees (including debt service fees)***

In accordance with UNC Board policy, the Board of Governors is responsible for establishing fees at the constituent institutions of the UNC System consistent with the philosophy set forth in the North Carolina Constitution. Fees will be charged only for limited, dedicated purposes and shall not be used to defray the cost of general academic and administrative operations of campuses, including academic programs and faculty and administrative salaries and benefits.

For 2022-23, mandatory fees are to remain flat except for certain limited situations:

- A campus may propose a mandatory fee increase if it is offset by a commensurate decrease to another fee, resulting in no net increase. This flexibility does not extend to debt service fees that would otherwise be scheduled to sunset because the associated debt service has been paid in full.
- Last year the Board of Governors approved a \$60 campus security fee at all institutions, except those that resulted in a total mandatory fee increase over three percent. The campus security fee at these institutions will automatically increase to \$60 in 2022-23.

## MEMO: 2022-23 Tuition and Fee Adjustments

September 17, 2021

Page 3 of 4

- The Board of Governors will consider exceptional situations where all three of the following criteria apply to the specific mandatory fee proposed for an increase:
  - The fee was not increased in the last two years.
  - The fee increase will not support an increase in scope of services or activities (i.e., the increase will cover specific, identifiable inflationary cost increases).
  - Without the fee increase, the ending fund balance is projected to be less than four months of recurring expenses.

All increase proposals must be accompanied by an expenditure plan showing how the additional revenues are critically important for the fee-supported activity, including a description of why alternative sources or expenditure reductions are insufficient for addressing the needs of the fee-supported activity. Off-setting decrease proposals must describe the impacts of the reduced revenues. Campuses whose campus security fee will increase to \$60 effective Fall 2022 do not need to submit a justification for the increase.

In approving proposed fee increases submitted by the institutions, the Board will make every effort to keep fees for students as low as possible while providing revenues needed to support the purposes for which the fees are charged. Given that fee increases will only be considered in the exceptional situations described above, we would expect any fee increase proposals to remain far below the overall 3 percent statutory cap on mandatory student fees.

***Special Fees***

Special fees are only applicable to students engaged in particular activities or courses of study. These fees may not be used to supplement general academic revenues that will be provided from campus-initiated tuition increases. Special fee increases may only be proposed for specific, identifiable increases in “pass-through” charges, which are defined as fees charged to cover costs levied by a third party, such (e.g., licensure exam fees, professional memberships, etc.). New special fees will only be considered for new programs of study previously approved by the Board of Governors.

***Application Fees***

Application fees shall remain at the established rates for each institution.

***Student Involvement and Use of Funds***

Tuition and fee proposals must be accompanied by the *Student Involvement in Tuition and Fee Setting Process* form (Attachment 3). Additional information from your institution supporting your student involvement may also be transmitted with your tuition and fee package.

***Attachments***

Please see a list of attachments on the following page needed for completion of the tuition and fee cycle for the 2022-23 academic year.

MEMO: 2022-23 Tuition and Fee Adjustments

September 17, 2021

Page 4 of 4

***Completion Date***

We appreciate your efforts in providing the requested information. Tuition and fee packages are due by **Friday, December 3, 2021**. In addition to any correspondence sent to the UNC System Office, please contact Aubrey Clark-Brown ([aclarkbrown@northcarolina.edu](mailto:aclarkbrown@northcarolina.edu)) if you have any questions about the process and email him the completed Excel workbook of your tuition and fee package. Campus summary information must also be entered into the NCHED web-based system.

Thank you for your assistance.

Att. 1: BOG Policy on Tuition Rates – UNC Policy Manual 1000.1.1

Att. 2: BOG Policy on Student Fees – UNC Policy Manual 1000.1.2 (approved by the BOG Committee on Budget and Finance on 9/16/21 and will be considered for approval by the full Board on 11/18/21)

Att. 3: Student Involvement in the Tuition and Fee Setting Process

Other Attachments: Excel Workbook Supporting Tuition and Fee Requests

NCHED Tuition and Fees User Manual (for data entry into web-based system)  
*(emailed separately to the Budget Officers)*

cc: President Peter Hans

Chief Operating Officer Jonathan Pruitt

Chief of Staff Norma Houston

Senior Vice President Kim van Noort

Vice President Lindsay McCollum Farling

## **Policy on Tuition Rates**

*The General Assembly shall provide that the benefits of The University of North Carolina and other public institutions of higher education, as far as practicable, be extended to the people of the State free of expense. –North Carolina Constitution, Article IX, Section 9*

I. Purpose. The North Carolina Constitution sets the parameters for establishing resident tuition rates at the constituent institutions of the University of North Carolina (UNC). The constitutional provisions for setting tuition are codified in North Carolina General Statutes (hereinafter G.S.) 116-11(7), which states, in part, "The Board [of Governors] shall set tuition and required fees at the institutions, not inconsistent with actions of the General Assembly." This statute governed the setting of tuition rates for both resident and nonresident students from 1971 through 1999, during which time the Board of Governors recommended no tuition increases except as required by session law. In November 1998, the Board adopted a tuition policy, as directed by the General Assembly, which allowed for the consideration of tuition increases as requested by the constituent institutions. These funds are subsequently appropriated by the General Assembly for use by the institution. This policy outlines the framework to be followed by the Board in establishing tuition levels for constituent institutions.<sup>2</sup> Tuition is charged to students enrolled in academic programs during regular terms, summer sessions, or through off-campus instruction, and is used to partially defray the costs of general academic and administrative operations of campuses, including academic programs and faculty and administrative salaries and benefits.

### II. General Policy

A. Undergraduate Tuition. The appropriate tuition policy at the undergraduate level encourages students to pursue academic and intellectual interests without regard to program costs. Accordingly, no difference in tuition between undergraduate programs will occur within an institution, and there will be only minimal differences in undergraduate tuition among campuses in similar institutional categories as defined by the Board to reflect both varying missions and contrasting costs of education, or at the direction of the General Assembly, such as the NC Promise program. Deviation in undergraduate tuition among campuses in different institutional categories will be based upon institutional offerings and will be reasonable. Combined tuition and fee rates for undergraduate residents shall be in the bottom quartile of each respective institution's Board-approved public peers.

B. Graduate and Professional Tuition. The Board will apply Article IX, Section 9 of the North Carolina Constitution to graduate- and professional-level students but with the realization that the costs, sources of funds, and purposes of graduate and professional education are materially different from undergraduate education. The application of what is "practicable" varies by level of

instruction for a number of reasons, and those differences will be reflected in the tuition policies associated with each level. Tuition for graduate and professional students will be set with an understanding that tuition revenues may be needed to maintain and increase the excellence of the University's graduate and professional programs. In setting tuition rates, the Board will consider the need to provide access to these programs for students irrespective of their financial capacity as well as the desire to attract and retain the best students to serve North Carolina's needs in each field.

C. Nonresident Tuition.

1. Under G.S. 116-144, the Board of Governors is required to set tuition rates for nonresident students at levels "... higher than the rates charged residents of North Carolina and comparable to the rates charged nonresident students by comparable public institutions nationwide. . . ." In complying with the statute, the Board will set tuition for nonresident students after considering the results of a review of rates set by comparable public institutions nationwide. Each constituent institution should set a goal to keep its combined undergraduate nonresident tuition and fee rates at or above the third quartile of its respective Board-approved public peers. Nonresident tuition rates should be market driven and cover the full cost of providing a quality education. The Board will further consider the need for tuition remissions for nonresident graduate students when setting tuition rates and tuition remission policies.

2. Constituent institutions are authorized to award tuition remission to certain nonresident graduate students to reduce the tuition rate for these students to the in-state rate. This tuition remission may be given to nonresident graduate students who are awarded a graduate teaching or research assistantship and who are paid a stipend of at least \$2,000 per academic year. Individual institutions may also establish higher minimum stipend amounts or additional policies relating to eligibility for tuition remission. The following conditions apply:

- a. Each institution shall limit the granting of tuition remissions to conform with established budgetary limitations.
- b. Each institution may supplement this appropriation from other non-state sources.
- c. Institutions may not provide tuition remissions to all graduate students.
- d. The president shall adopt administrative procedures and regulations for the implementation of the tuition remission.

D. Tuition Rates for Part-time Students. Effective with the fall term of 2021, part-time resident students and part-time nonresident students taking courses within North Carolina are charged the regular-term tuition rates established by the Board and the tuition rates for these students are implemented on a per-credit-hour basis to be calculated as follows:

1. Part-time undergraduate students shall be charged tuition per credit hour, at a rate equal to the annual undergraduate tuition rate at their institution divided by 24. The per-

credit rate shall be capped at 12 credits per semester for fall and spring semesters, meaning undergraduate students shall not be charged for additional credits beyond 12 in a fall or spring semester.

2. Part-time graduate students shall be charged tuition per credit hour, at a rate equal to the annual graduate tuition rate divided by 18. The per-credit rate shall be capped at nine credits for fall and spring semesters, meaning graduate students shall not be charged for additional credits beyond nine per semester in a fall or spring semester.

E. Other Tuition Rates

1. The authority to set tuition rates for nonresident students taking courses outside North Carolina and to approve tuition rates for self-supported summer enrollment is delegated to the president. The president may also grant exceptions to the method by which the tuition rate is implemented on a per-credit-hour basis, provided that the relevant course or program is receipt-supported.

2. Student Exchange Programs. The constituent institutions are authorized to enter into and extend or modify agreements with institutions in other countries to provide for a balanced exchange of students. A UNC student participating in such an exchange shall be charged tuition by the home UNC institution at a rate consistent with the residency status the student would otherwise have at the home institution and shall be counted in the official FTE of the home institution in that residency status. A foreign student participating in such an exchange agreement shall not be charged tuition by the host UNC institution and shall not be counted in the official FTE of the host UNC institution.

III. Process for Setting Tuition Rates

A. Undergraduate Rates. The Board recognizes that campuses may experience circumstances that suggest an across-the-board change in undergraduate tuition may be needed at one or more institutions. In the event that circumstances lead a campus or campuses to the conclusion that a change in undergraduate tuition rates is needed, campuses are permitted to bring proposals for undergraduate tuition changes to the Board for its consideration. Campuses wishing to submit requests for undergraduate tuition changes will conduct a process that includes meaningful participation by and input from students. A student involvement form signed by the student body president, or designee, should be included with any campus-initiated tuition increase request. A campus will consider the following factors when creating an undergraduate tuition proposal:

1. Availability of state general fund revenue to maintain quality and access within the campuses of the University of North Carolina System;

2. Evidence of institutional efforts to manage costs through increases in productivity, budget flexibility, and/or efficiency improvements;

3. Analysis of the impact of tuition and fee charges on student access to the constituent institutions of the University of North Carolina System as measured by the college-going rate and other metrics so as not to limit access to the University;

4. Changes in various price and income indices (e.g., North Carolina per capita personal income, Consumer Price Index, Higher Education Price Index, Median Household Income);
5. The current level of student charges (tuition, fees, room and board) at UNC System institutions and whether campuses have proposed campus or program tuition differentials for the budget period that would be in addition to general increases in tuition;
6. Analysis of student indebtedness levels within the University, viewed in the context of student attrition rates;
7. Availability of financial aid and amount of unmet need. Financial aid should be reviewed in the context of the different missions of the institutions, the diverse capacities of the institutions to provide financial assistance and the contrasting needs of students attending the institutions.

B. Graduate and Professional Tuition Rates. The Board of Governors will permit individual campuses to initiate requests for Board approval of different base or program tuition rates at the graduate and professional level. If a campus explores the possibility of developing such a request, it will present evidence to ensure that students in the affected graduate and/or professional programs have been consulted. Graduate and professional schools should establish rates consistent with each program's unique market and academic requirements. Tuition for graduate and professional students will be set with an emphasis on maintaining and increasing the excellence of the institution's graduate and professional programs as well as ensuring access. To the extent possible, there should be full tuition remission for graduate assistants to improve an institution's competitiveness in recruiting and retaining highly qualified nonresident graduate students.

In reviewing potential criteria to recommend as a basis for deciding when specific graduate or professional tuition differentials may be appropriate at a particular institution, a flexible policy framework that allows judgments to be reached based on a number of factors is preferable either to cost-based formulas or to discipline or program typologies that treat all academic or professional programs the same. In particular, a flexible approach based on the unique factors associated with specific programs is desirable because of the potential mix of graduate and professional programs that one may find within any given school or college, e.g., a professional school may offer a Ph.D. program in addition to one or more professional degree programs. Therefore, the campuses will consider the following factors in developing graduate and professional school tuition proposals:

1. The anticipated impact of a proposed change on program quality;
2. The projected impact of a proposed change in tuition on access for North Carolina residents;
3. The availability of student financial aid for students with economic need and of tuition remission;
4. The extent to which current and prospective students can afford possible increases in tuition;
5. The relationship of projected tuition revenue to institutional and/or program costs;

6. Tuition and fees, net of remissions and waivers, charged by peer institutions or programs, as compared to tuition and fees, net of remissions, at the UNC institution or program (the public subsidy received by students at public institutions or programs in the peer set, including the UNC institution or program in question, will also be identified as part of the comparison);

7. A plan for the intended use of additional tuition receipts (e.g., needed improvements to the educational program, funding for competitive salary increases, financial aid, etc.);

8. Assistantships or grant support for graduate students; and

9. Analysis of student indebtedness levels within the University.

C. **Timing of Board Action.** The Board will act by March of each year, or as soon as possible thereafter, to establish the University's campus-initiated tuition rates for the next academic year. Setting campus-initiated tuition rates by March will permit students and their families to know in early spring what their tuition charges for the fall semester will be, assuming consistency between the actions of the Board of Governors and the General Assembly.

D. **Individual Consideration of a Campus Request.** The Board will review each campus-based tuition request on an individual basis, within the context of the UNC System's strategic plan, the need for tuition increases, the state's economic environment, and the financial impact on students. The Board is obligated to exercise its discretion in granting, modifying, or denying a campus request. Revenue generated from a campus-initiated change in tuition rates will be accounted for in the budget of the originating campus and transferred within the institution by the chancellor in accordance with the priorities identified in the approved campus proposal.

E. In the event that circumstances require that an increase in tuition be made outside of the process described above, the president may recommend proposed increases in general tuition rates for consideration by the Board. The president will seek counsel from the chancellors and a committee of campus representatives, appointed by the president in consultation with the chancellors, before making the recommendations for tuition changes. The committee of campus representatives appointed by the president shall include students.

The president, the chancellors, and the committee of campus representatives will consider a number of factors in deciding whether to recommend changes to general tuition rates in any given year. After the president recommends any action to the Board of Governors, the Board will also consider the factors in sections III.A and III.B., above.

#### IV. NC Promise Tuition Plan

A. Pursuant to G.S. 116-143.11, beginning with the 2018 fall academic semester, the Board of Governors shall set the rate of in-state undergraduate tuition at Elizabeth City State University, the University of North Carolina at Pembroke, and Western Carolina University at \$500 per academic semester, and the tuition rate for nonresident undergraduate students at \$2,500 per academic semester. The Board of Governors shall give due consideration to maintaining the unique historical



character of each institution, including service to students who are first generation, college-going, economically disadvantaged, or minority.

B. By October 1 of each year, the Board of Governors and the chancellors of the institutions named in this subsection, respectively, shall submit a report to the Joint Legislative Education Oversight Committee, the House Appropriations Committee on Education, the Senate Appropriations Committee on Education/Higher Education, and the Fiscal Research Division on the amount of any financial obligation resulting from the established tuition rate incurred at each constituent institution and at least the following information for the fiscal year:

1. The amount required to offset the forgone tuition receipts at each of the three constituent institutions as a result of the tuition rate established by this section and how those funds were allocated to each institution.
2. The number of enrolled resident students at each institution.
3. The number of enrolled nonresident students at each institution.

V. Fixed Tuition

A. Fixed Tuition Program. Pursuant to G.S. 116-143.9, the Board of Governors of the University of North Carolina shall ensure that policies and procedures are established for a fixed tuition program beginning with the fall 2016 academic year and all subsequent years. The rate of tuition of any eligible first year, continuing or transfer undergraduate student who is admitted to any constituent institution of the University of North Carolina and deemed to be a North Carolina resident for purposes of tuition shall be guaranteed for a designated time period based on program length and classification. The tuition period shall be eight consecutive academic semesters for a first-time student seeking a baccalaureate degree in a four-year program or 10 consecutive academic semesters for a first-time student seeking a baccalaureate degree in a program officially designated by the Board of Governors as a five-year program, not including any summer sessions. Transfer students shall receive fixed tuition for a period determined based on the balance of a designated program length after making the proper adjustments for a student who transfers to the constituent institution. Current undergraduates shall receive fixed tuition for a period determined based on the balance of their designated program length after making the proper adjustments for semesters already completed. The calculation to determine the balance of a designated program length will be determined by the UNC System Office.

B. Guarantee Rate of Tuition. The fixed tuition program is a guarantee that the rate of tuition approved by the Board of Governors will remain constant or decrease during the tuition period. Students must remain continuously enrolled at the constituent institution during the designated time period to receive this benefit. At the end of the tuition period, the cost of tuition for any additional academic semesters reverts to the amount of the current tuition for that constituent institution.

C. Students Subject to Fixed Tuition. Fixed tuition will be for all eligible students deemed to be a North Carolina resident for tuition purposes for the following three categories of degree-seeking undergraduates in four or five-year baccalaureate degree programs.

1. Baccalaureate degree-seeking students entering into an undergraduate four or five-year degree program as a first-time student.
2. New degree-seeking transfer students entering into an undergraduate four or five-year degree program.
3. Currently enrolled resident continuing students who are enrolled in an undergraduate four or five-year degree program.

Any program authorized by the Board of Governors to require 135 semester credit hours or more shall be officially designated as a five-year baccalaureate program. Fixed tuition applies to students enrolled in distance education and traditional on-campus programs.

D. Fixed Tuition Time Period. First-time degree-seeking students are eligible for fixed tuition for a maximum of eight consecutive semesters for a four-year program and 10 consecutive semesters for a five-year program as long as they are continuously enrolled. Continuous enrollment is defined as a student being consecutively enrolled at the same higher education institution in fall and spring semesters in courses creditable toward a baccalaureate degree. A break in continuous enrollment occurs when a student is not enrolled in consecutive semesters at the same constituent institution. Summer terms are not considered part of the fixed tuition time period.

E. Transfer and Currently Enrolled Students. New transfers and currently enrolled continuing students shall receive fixed tuition for a prorated time period calculated based on the number of enrolled semesters accumulated at the transferring or home institution(s).

F. Break in Enrollment. Once a student breaks continuous enrollment at a UNC constituent institution he/she is no longer eligible for the current rate of fixed tuition at the home institution. If the student transfers to another UNC institution they will be treated as a new transfer student, as described above, and will be eligible for fixed tuition at that institution's current rate for the remaining balance of his or her fixed tuition eligibility period.

G. Withdrawal from Home Institution. Students who withdraw from all classes at their home institution before the date of census, will have broken continuous enrollment and will no longer be eligible for fixed tuition at the current rate at their home institution. Students who withdraw from their home institution after the date of census and then subsequently enroll at the same institution in the next semester will not have broken continuous enrollment and will receive the benefit of fixed tuition at the rate they paid in the prior semester of enrollment.

H. Exhaustion of Eligibility Period. Tuition will convert to the amount of the current tuition for that constituent institution for students who exhaust their eligibility period, are not continuously enrolled, or become ineligible as designated in section I., below. Upon application by a student, the reversion to current tuition may be waived if the student demonstrates that any of the following have substantially disrupted or interrupted their continuous enrollment: (1) a military service obligation, (2) serious medical debilitation, (3) short-term or long-term disability, or (4) other extraordinary hardship.

I. Students Exempt from Fixed Tuition. The fixed tuition shall not be implemented for the following students: continuing education, cooperative innovative high school/early college students

while enrolled in high school, consortium, dual-enrollment program, second degree seeking, transient, nonresident students, non-degree seeking and graduate and professional students.

J. Nonresident Students. Students who are originally classified as nonresident for tuition purposes and subsequently are reclassified as a resident for tuition purposes will be eligible for fixed tuition at the institution's current rate for the balance of his or her remaining eligibility period.

K. Fixed Tuition for Part-Time Students. Campuses shall establish fixed tuition rates for part-time enrollment for students eligible for fixed tuition pursuant to this policy.

L. Cost of Attendance Calculation. Financial aid offices shall establish cost of attendance budgets that are realistic and reasonable.

---

<sup>1</sup>Supersedes Section 1000.1.1 originally entitled, *Establishing Tuition and Fees*.

<sup>2</sup>Consistent with G.S. 116-143, no tuition or fees may be charged to students in the high school program at the North Carolina School of Science and Mathematics (NCSSM).

**Policy on Student Fees**

*This policy was approved by the BOG Committee on Budget and Finance on 9/16/21 and will be considered for approval at the full Board meeting on November 18, 2021.*

I. Purpose. The Board of Governors is responsible for establishing fees at the constituent institutions<sup>2</sup> of the UNC System consistent with the philosophy set forth in the North Carolina constitution.

II. General Policy. Fees will be charged only for limited, dedicated purposes and shall not be used to defray the costs of general academic and administrative operations of campuses, including academic programs and faculty and administrative salaries and benefits. The Board will make every effort to keep fees for students as low as possible while providing the revenues needed to support the purposes for which the fees are charged. The 2016 General Assembly enacted a special provision (G.S. 116-143.10) that caps mandatory student fee increases (including debt service fees) to three percent per year.

Each year, the Board establishes the fees listed below. All fees established shall be based upon the recommendation of the chancellor, the institutional board of trustees, and following his or her review, the president. Excluding the application fee charged to prospective students, all fees set by the Board are annual fees. Once an annual fee has been established, semester rates and summer school fees shall be established by the president and part-time rates shall be reported to the president. It is the policy of the Board to act no later than March of each year to establish fees for the following fall semester.

Although the General Assembly provides for most of the instructional costs of institutions through state appropriations, institutions traditionally rely entirely on student fees to finance a number of activities, services, and facilities. Institutional boards of trustees are required to weigh the benefits of the activity, facility, or service against the fee required to provide financial support. Orientation sessions for the boards of trustees will regularly include discussions of the process followed when establishing student fees.

A. Application Fee. An application fee shall be established for each institution. Specific programs within an institution may require an application fee different from the fee charged for most students and the Board may set different fees according to program needs.

B. General Fees. Fees generally applicable to all students shall be established by the Board of Governors. Six general fees are authorized: athletics, association of student government, health services, student activities, educational and technology, and campus security.

C. Fees Related to the Retirement of Debt Incurred for Capital Projects. Fees generally applicable to all students that provide revenues for the retirement of debt shall be fixed by the Board of Governors at the time of the borrowing. Indebtedness fees may not include components for operations and maintenance but shall reflect the cost of servicing the debt at the coverage levels required in Board resolutions and other documents authorizing the debt. Any subsequent changes in fees require Board approval. Indebtedness fees expire when the related debt is retired unless otherwise authorized by the Board of Governors.

D. Special Fees. Fees applicable only to students engaged in particular activities or courses of study shall be established by the Board of Governors when needed. These fees will not be used to provide general academic revenues that are provided from campus-initiated tuition increases.

Each chancellor is authorized to establish miscellaneous service charges for items such as transcripts, diplomas, caps and gowns, special examinations, late registrations, and replacement of I.D. cards. A schedule of such charges shall be filed with the president prior to the beginning of each school year.

III. Process for Establishing Fees. The process shall be initiated at the beginning of the fall semester and contain the following steps:

A. Instructions Issued. The senior vice president for finance and administration shall issue instructions to the chancellors calling for them to initiate a review of fees.

B. Fee Committee Review and Recommendations. Each chancellor shall establish a fee review committee with representatives of all aspects of campus life, including, but not limited to, representatives from business affairs, student affairs, the financial aid office, and the student body. The committee shall conduct a complete review of student fees from a zero-based budgeting perspective and shall make recommendations to the chancellor for establishing fees effective with the upcoming fall semester. The review will include an examination of alternative resources, including available institutional reserves, to determine if other funding is available to provide the services in lieu of establishing the fee. The review will include a reassessment of the existing operating methods to ensure that operations are performed in a cost-effective manner. If the committee determines that an increase in a fee is needed, the committee shall attempt to decrease another fee so that the total cost of education for students does not increase. In order to ensure that all students are able to meet the increased cost of education, the university's financial aid officer, working with the committee, shall determine that sufficient financial aid is available, from whatever sources are possible.

C. Chancellor Recommendations. The chancellor shall review the recommendations of the committee and present recommendations to the board of trustees for review and approval. Before a chancellor makes recommendations to the board of trustees, the recommendations of the fee review committee will be shared with student government leaders so that students may inform the chancellor of their perspectives on the proposed changes.

D. Board of Trustee Recommendations. The recommendations, as approved by the board of trustees, will be forwarded to the president for review.

E. President Recommendations. When the review is completed, the president will present fee recommendations to the Committee on Budget and Finance for consideration by the Board of Governors.

Each step in the process shall be an iterative and comprehensive review of the previous step, resulting in changes to the fee recommendations as deemed appropriate.

IV. Distance Education Fees. Section 400.1.1[R](II)(b) of the UNC Policy Manual defines distance education and off-campus programs.

A. For fee-charging purposes, a distance education program is one designed to deliver 80 percent or more of the direct instruction through distance education or off-campus, as defined in Section 400.1.1[R](II)(b). There may be a requirement for the student to attend the main campus for a portion of the program, but that requirement is minimal.

B. Effective fall 2022, students enrolled in distance education programs as defined above will be assessed certain mandatory fees, including the campus security, educational and technology, and association of student government fees, and will not have access to other services and activities supported by the other Board-approved mandatory fees unless they pay the appropriate additional mandatory fee.

C. Students not enrolled in distance education programs will be assessed all mandatory fees regardless of how their courses are delivered in a given semester.

V. Other Matters

A. Effective Date. The requirements of this policy shall be effective on the date of adoption by the Board of Governors.

B. Relation to State Laws. The foregoing policies as adopted by the Board of Governors are meant to supplement, and do not purport to supplant or modify, those statutory enactments which may govern the activities of public officials.

C. Regulations and Guidelines. These policies shall be implemented and applied in accordance with such regulations and guidelines as may be adopted from time to time by the president.

---

<sup>1</sup>This new policy adopted by the Board of Governors replaces the original Section 1000.1.2, *Policy on Tuition with Respect to Student Exchange Programs with Institutional Abroad*, which was repealed in its entirety by the Board of Governors on September 16, 2021.

<sup>2</sup>Consistent with G.S. 116-143, no tuition or fees may be charged to students in the high school program at the North Carolina School of Science and Mathematics. However, the Board of Governors may approve, upon the recommendation of the Board of Trustees of NCSSM, the imposition of fees, not inconsistent with actions of the General Assembly for distance education services provided by NCSSM to nonresidents and for students participating in extracurricular enrichment programs sponsored by the School.

## **Student Involvement in Tuition and Fee Setting Process**

**Campus Name:** \_\_\_\_\_

**Date:** \_\_\_\_\_

**Campus Administrator Name:** \_\_\_\_\_

**Campus Administrator Title:** \_\_\_\_\_

**Campus Administrator Signature:** \_\_\_\_\_

**Student Body President Name:** \_\_\_\_\_

**Student Body President Signature:** \_\_\_\_\_

### **Collaboration**

- Tuition and fee committee(s) established.
- Students were represented on the committee(s).
- Student representatives were appointed by the Chancellor in consultation with the Student Body President.
- Committees were co-chaired by the Chief Academic Officer and/or Chief Student Affairs Officer or their designee along with the Student Body President and/or Student Senate President.

### **Inclusiveness**

- Students on the tuition and fee committees were representative of student constituencies: (for example, in-state, out-of-state, undergraduate, graduate, professional school, distance education, etc.).
- Student involvement throughout the entire tuition and fee setting process.
- Student forums were conducted (at least two, one mid-day and one in the evening).

### **Transparency**

- Utilization of social media to reach out to students.
- Utilization of university listserv(s) and website.

### **Timeliness**

- Process initiated and completed consistent with the UNC Policy. (September 1<sup>st</sup> through December 1<sup>st</sup>)

### **Accountability**

- Inclusion of student involvement form in the institution's tuition and fee request packet submitted to the UNC System Office.

**Additional Information:**

## University Affairs Meeting - November 11, 2021- Talking Points

**BOT Members Attending:** Fanning, Ward, Furr, Roberts, and Smith.

- **Metrics**
  - **Academic Affairs – Grant Hayes**
    - New freshman applications are slightly behind last year’s pace – largely because the free app days reduced from 12 to 5 from last year to this.
    - NC resident applicants went down, but out of state applicants went up 500-600 apps.
    - Enrollment deposits are trending slightly behind last year, but it’s still early
    - Transfer applications are similar to last year even though it’s still early.
  - **Student Affairs – Virginia Hardy**
    - Housing –Contracts go live this month – earlier than in the past – this is a good thing. We are going to market to transfers for more space designated for them.
    - College Hill Suites will still have Q&I space but the rest of the building will go back to a residence hall as normal.
    - Counseling – YTD comparison – we are serving students more this fall and that is up even compared to pre-COVID years.
  - **Research – Mike Van Scott**
    - After a slow start in July, many of our metrics are tracking back toward our five-year goal – this is a good sign.
- **Action Items – our committee had two action items that we’ll have at the end of my report.**
  - **Honors College (HC) Spotlight**
    - Dean David White explained the history of the Honors College – We are at close to 800 students, and they all receive scholarships. The highest level is called the EC Scholars and typically we have 80 EC Scholars at any given time (20 per year).
    - The graduation rate for HC is around 95% and the retention rate is around 98%.
    - Most HC students come from North Carolina, but we have an international student as well as students across the country. Again, the out of state tuition can be a barrier to these high-level students coming to ECU.
    - We have started admitting transfer students from the NC Community Colleges to the Honors College (new this year).
    - The breakdown for HC students each year is: 20 EC Scholars – 80 Chancellor Scholars and 100 Centennial Scholars.
    - Associate Dean Todd Fraley explained the request from the Honors College to allow out of state students trying to become EC Scholars to be treated as in-state students and only pay in-state rates. This practice does happen at other schools and the statute exists for ECU to follow.



- **Informational Items**

- **Student Mental Health**

- Dr. Valerie Kisler-van Reede and Steven Trotter discussed the holistic approach to mental health and well-being. The mental health crisis isn't a college campus issue, it's not an ECU issue either – this is a young person's issue and the pandemic hasn't helped.
    - Dr. Kisler-van Reede shared data from the First Year Assessment report conducted this summer specific to stress, mental health, and loneliness.
    - There is a direct correlation between those suffering in mental health issues and academic success and engaging with these students can be key to their success.
    - She shared that we are struggling to keep counselors as private practices are recruiting our staff and offering them more money and flexibility by working from home.
    - Students across all classes are having mental health issues. It is no longer a first-year college student problem. She shared a new program called My SSP (Student Support Program) which has provided 24/7 support that helps the influx of caseloads with staff.
    - Steven Trotter discussed the focus is on prevention through the elements of well-being including career, social, financial, physical and community.
    - He explained the philosophy of surviving, striving and thriving and he talked about how our bodies are like a gas tank – recognizing when the tank is low and how to refuel the tank.
    - Steven shared some of the signature prevention strategies programs and workshops and how they connect to the well-being of our students.

- **Career Services and Academic Planning**

- Tom Halasz and Patrick Roberts from Career Services presented on Career Readiness and discussed the Career Advocate Network that is training for faculty and staff to better prepare students for career options.
    - The Career Readiness Continuum demonstrates how Career Services are provided in conjunction with faculty from the first year through to the senior year and also serves graduate/professional students and alumni.
    - Handshake is the software system we use in Career Services including nearly 5,000 appointments and 225 academic unit partnerships.
    - Patrick shared some data specifically from Career Fairs over the last five years. He stated that partnerships with academics have been huge for maintaining student engagement during the pandemic. From the CET Fair, he shared that Amazon attended for the first time ever and student engagement for these events are very high.
    - IPAR also did a demo of the First Destination Dashboard and shared some data specific from the Colleges of Nursing and Engineering and Technology to learn how many graduates have jobs, a map of where the students are working and he showed the ability to drill down to NC and even the county level.

Mr. Chairman, that concludes my report and I have two motions for the board to consider:

**Honors College Motion**

I move the board authorizes the EC Scholars Program within the Honors College the authority to use of North Carolina General Statute 116-143, which provides the full cost scholarship opportunities for students at constituent institutions as outlined in the statute and as presented in board materials.

And I'd like to call on Chandler Ward to make the last motion coming from our committee:

**Conferral of Degrees Motion**

I move the candidates for degrees, as approved by the Chancellor and Faculty Senate, be authorized for conferral at the annual winter commencement on Friday, December 17, 2021.



**University Affairs Committee**

November 11, 2021

Agenda Item: III. B. Honors College Spotlight

Responsible Person: Grant Hayes  
Interim Provost

David White  
Dean, Honors College

Action Requested: Information / Action

Notes:

Proposed Motion:

***Memo: EC Scholar Full Cost Scholarship******Date: 11.11.2021******To: ECU Board of Trustees***

The EC Scholars (ECS) program is the most prestigious merit scholarship award program offered at East Carolina University. It is housed in the ECU Honors College. The ECS scholarship is valued at approximately \$63,000 over four years and it is available to 20 students each year. There are currently 77 EC Scholars. The program includes innovative coursework, networking opportunities with faculty members and community partners, and a required study abroad experience. EC Scholars pursue excellence in every endeavor, collaborate in an effort to cultivate an inclusive and inspiring community, and serve the public while growing as engaged and purposeful citizens. The students we recruit are also being recruited by universities with highly competitive programs and scholarship offers. In response, we must work to position the EC Scholar program as an attractive option for high-achieving students from across the state, region, and nation.

Over the past few years, we have seen a steady increase in the number of ECS applications. During this past application cycle (2020-2021 class), we received nearly 700 applications, a substantial increase over the previous year. With few exceptions, these same students are applying for acceptance to other NC programs for high-achieving students, such as the Park (NCSU), the Morehead-Cain (UNC-CH), and the Levine (UNCC). During this selection process, students compare scholarship amounts, university life, academic programs, funding for summer experiences, research opportunities, alumni successes, and anything else they feel is important to their decision-making process. Students and parents are highly aware of the different levels of financial support for each program. The scholarship amount plays a significant role when a student is selecting a college to attend.

Applicants quickly note that **the ECS Award is the only top merit program among those listed above that does not offer a “full cost” scholarship.** Full Cost scholarships cover tuition, fees, campus housing and meal plan. ECS is currently \$2,922.00 short of “full cost” for North Carolina residents. Also, since the ECS Award for tuition is limited to covering only the NC resident tuition amount, ECS Award recipients from out of state must pay the tuition difference out of pocket. This shortfall is a substantial amount and makes it extremely difficult to attract out-of-state students.

The NC General Assembly provides help to universities in the NC system to attract high-achieving students from out-of-state by allowing those students to be considered in-state students for tuition purposes under certain circumstances. North Carolina General Statutes Section 116-143.6 provides the following full cost scholarship opportunity for students (except athletes) attending constituent institutions. This statute reads,

(a) *Notwithstanding any other provision of law, if the Board of Trustees of a constituent institution of The University of North Carolina elects to do so, it may by resolution adopted consider as residents of North Carolina all persons who receive full scholarships, unless the scholarship is for athletics, to the institution from entities recognized by the institution and attend the institution as*

*undergraduate students. The aforesaid persons shall be considered residents of North Carolina for all purposes by The University of North Carolina.*

*(b) The following definitions apply in this section:*

*(1) "Full cost" means an amount calculated by the constituent institution that is no less than the sum of tuition, required fees, and on-campus room and board.*

*(2) "Full scholarship" means a grant that meets the full cost for a student to attend the constituent institution for an academic year.*

*(c) This section shall not be applied in any manner that violates federal law.*

*(d) This section shall be administered by the electing constituent institution so as to have no fiscal impact.*

*(e) In administering this section, the electing constituent institution shall maintain at least the current number of North Carolina residents admitted to that constituent institution. (2005-276, s. 9.27(a); 2010-31, s. 9.25.)*

This statute will positively impact the future of the EC Scholars program and the entire ECU community in the following ways:

1. By providing a financial incentive to the ESC program to offer all EC Scholars a "full cost" scholarship which increases our current competitive advantage and further alleviates the financial burden our scholars face.
2. By raising the overall academic profile of the University by helping the ECS program to attract and enroll highly competitive applicants from across the state and nation.
3. By allowing the University to direct university wide scholarship resources towards high achieving students in NC (EC Scholars have, at times, used these awards to help reduce the tuition shortfall).

**The ECS program is asking the Board of Trustees to approve the use of this statute.**

If approved, we will continue our fundraising campaign to increase the EC Scholar award from its current level of funding to the value of a "full cost" scholarship. The current annual per-student shortfall amount to be covered by our fundraising efforts is outlined in the chart below.

**Current Annual Value of EC Scholar Award (exclusive of the study abroad stipend amount which is not counted toward meeting the “full cost” of attendance):**

HC Tuition Scholarship – \$4452.00

EC Scholars Award – \$10,000

**Total Value – \$14,452.00**

**ECU “Full Cost” of Attendance:**

Tuition (NC Resident) - \$4452.00

Fees - \$2786.00

Room/Board – \$ 10,136.00 (This difference may vary based on room selection and meal plan, but calculation of “full cost” is based on this cost level.)

**Total Cost - \$17,374**

**Annual Per-Student Difference: ECS Award vs. “Full Cost” of Attendance**

**\$2922.00**

**Health Sciences Committee  
November 11, 2021**

- Minutes from the September 9, 2021 meeting were approved.
- Dr. Ron Mitchelson discussed the newly adopted metrics that include the number of applications to health sciences division undergraduate, graduate and professional programs. Additional metrics include sponsored awards, Laupus Library Resource Utilization, and patient visits.

Mr. Chairman, I will have several motions coming out of closed session, but I do have one motion I'd like the board to consider now:

*I move that the board approve the Joint Operating Agreement in support of the clinical integration between East Carolina University and Vidant, as presented in board materials.*

**MOTIONS FOLLOWING CLOSED SESSION:**

- I move the Board approve the initial appointment with tenure for Dr. James Leigh Whiteside in the Brody School of Medicine as presented in the board materials.
- I move the Board approve the initial appointment with tenure for Dr. Raymond Mattingly in the Brody School of Medicine as presented in the board materials.
- I move the Board approve the College of Allied Health Sciences incentive payments as presented in board materials.
- I move the Board approve the School of Dental Medicine incentive payments as presented in board materials.



**Office of the Vice Chancellor  
Dean, Brody School of Medicine  
Health Sciences Division**

AD-48 Brody Medical Sciences Building | 600 Moye Boulevard | Mail Stop 600  
East Carolina University\* | Greenville, NC 27834-4354  
252-744-2984 office | 252-744-1612 fax

October 19, 2021

Philip Rogers, EdD  
East Carolina University  
Greenville, NC 27858

Dear Chancellor Rogers:

I would appreciate your consideration of the enclosed recommendation for the initial appointment of Professor with permanent tenure for James Leigh Whiteside MD, MA, MHA, FACOG, FACS.

Dr. James Leigh Whiteside is scheduled to join East Carolina University February 1, 2022, as Chair and Professor with a recommendation for permanent tenure in the Department Obstetrics and Gynecology, Brody School of Medicine.

Dr. Whiteside obtained his Medical Degree from The Medical College of Georgia, Augusta, Georgia in 1997. He completed his residency in Obstetrics and Gynecology at Brown University, Women and Infants Hospital of Rhode Island, Providence, Rhode Island in 2001 and continued his education and training with a fellowship in Female Pelvic Medicine and Reconstructive Surgery at the Cleveland Clinic Foundation, Cleveland, Ohio in 2004. He has also completed his Master of Health Administration degree from the University of Cincinnati, Cincinnati, Ohio in 2017.

Currently, he serves as Director Clinical Business Intelligence, Director Female Pelvic Medicine & Reconstructive Surgery, and Professor at the University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology.

Dr. Whiteside's scholarly activity includes 34 articles in peer-reviewed scientific journals, author of eleven book chapters, and has been invited to present at 46 conferences and seminars around the world. He is also the recipient of 21 honors and awards.

For your convenience, attached are the following documents:

- Dr. James Leigh Whiteside's curriculum vitae
- ECU Personnel Action Summary Form for the Board of Trustees

If you approve, we will make arrangements for this recommendation to be placed on the agenda for the November 11, 2021 ECU Board of Trustees meeting.

Sincerely,

DocuSigned by:

*Ron Mitchelson, EdD*  
Ron Mitchelson, PhD

Interim Vice Chancellor, Division of Health Sciences

Enclosures

Approve

Do Not Approve

*Philip Rogers*

Philip Rogers, EdD  
Chancellor

10-27-21  
Date



**ECU FACULTY MANUAL, PART X, SECTION I, Attachment 2.**

**EAST CAROLINA UNIVERSITY PERSONNEL ACTION SUMMARY FORM**  
(Administrator completes Section I. and faculty member (appointee) completes Section II.)

Section I. To be completed by the appropriate administrator(s).

Name of Appointee: James Whiteside, MD, MA, MHA, FACOG, FACS

Department: OBGYN School/College: Brody School of Medicine

Current Rank or Title: (if applicable) Chair and Professor Proposed Rank or Title: Chair and Professor with Tenure

Indicate Type of Action: (select all that apply)

Administrative Appointment:

New Faculty Appointment:

Promotion:

Conferral of Tenure:

Other:

(describe) \_\_\_\_\_

Distinguished Professorship:

(provide name of professorship) \_\_\_\_\_

Effective Date of Action: 2/1/2022

Contract Period: Administrative Appointment: 9 mo.  12 mo.   
Faculty Appointment: 9 mo.  12 mo.

Salary: \$ 555000 Source(s): State Funds: \$ 305030 \*Non-State Funds: \$ 244970

\*Indicate Sources of non-state funds generically (i.e., grants, receipts, trust funds, endowments, medical faculty practice plan, etc.): \_\_\_\_\_

ECU P

Prior Recommendations/Personnel Actions:  
(please check appropriate responses)

Source	Recommended	Not Recommended	Not Applicable
Appropriate Unit Personnel Committee	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chair/Unit Head	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Director	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Dean	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Provost/Vice Chancellor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chancellor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Board of Trustees	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Section II. To be completed by the faculty member.

1. Education Background: *(indicate degree, date earned and institution, note additional study & training)*

EDUCATION:

2017 University of Cincinnati Master of Health Administration  
 2012 Loyola University Chicago Master of Arts  
 1997 The Medical College of Georgia Medical Doctor  
 1992 The University of Georgia Master of Science  
 1989 The College of William and Mary Bachelor of Science

POSTDOCTORAL TRAINING:

2020 Certified Epic Power User Epic Systems Corporation  
 2020 Certified Physician Builder – Analytics Epic Systems Corporation  
 2019 Certified Physician Builder Epic Systems Corporation  
 2017 Lean Six Sigma Yellow Belt GoLeanSixSigma.com  
 2010 Mini-Fellowship Johns Hopkins University School Geriatrics of Medicine, Baltimore, MD  
 2004 Fellowship The Cleveland Clinic Foundation Female Pelvic Medicine and Cleveland, OH  
 2001 Residency Brown University/Women and Obstetrics and Gynecology Infants Hospital of Rhode Island

2. Teaching and other professional experience: *(Show inclusive dates, rank and/or title, institution or agency, and indicate first appointment at current institution with rank and any changes to date)*

ACADEMIC APPOINTMENTS:

2019 – present Director Clinical Business Intelligence University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology  
 2019 – present Professor University of Cincinnati, College of Medicine  
 8/2016 – present Director Female Pelvic Medicine & Reconstructive Surgery, University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology  
 2017 – 2018 Vice Chair of Education University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology  
 2015 – 2018 Residency Program Director University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology  
 2014 – 2015 Associate Fellowship Program Director The Christ Hospital/University of Cincinnati, Fellowship in Female Pelvic Medicine and Reconstructive Surgery  
 2015 – 2019 Associate Professor University of Cincinnati, College of Medicine  
 2013 – present Adjunct Associate Professor Miami University of Ohio, College of Engineering and Computing  
 2013 – 2015 Co-Director Female Pelvic Medicine and Reconstructive Surgery The Christ Hospital/University of Cincinnati College of Medicine  
 2013 – 2015 Voluntary Professor University of Cincinnati College of Medicine  
 2013 – present Adjunct Associate Professor Geisel School of Medicine at Dartmouth  
 2010 – 2012 Associate Professor Geisel School of Medicine at Dartmouth  
 2004 – 2010 Assistant Professor Geisel School of Medicine at Dartmouth  
 2001 – 2004 Clinical Instructor The Cleveland Clinic Foundation

HOSPITAL APPOINTMENTS:

2015 – present Staff physician West Chester Hospital, West Chester, OH  
 2013 – 2015 Women's Service Line Informatics Physician Champion The Christ Hospital, Cincinnati, OH  
 2013 – 2015 Staff physician The Christ Hospital, Cincinnati, OH  
 2013 – present Staff physician, Department of Obstetrics and Gynecology University of Cincinnati Medical Center, Cincinnati, OH  
 2004 – 2012 Staff physician, Department of Obstetrics and Gynecology Dartmouth-Hitchcock Medical Center, Lebanon, NH  
 2005 – 2012 Staff physician, Department of Obstetrics and Gynecology Elliott Hospital Manchester, NH  
 2009 – 2012 Staff physician, Department of Obstetrics and Gynecology Catholic Medical Center Manchester, NH

OTHER PROFESSIONAL POSITIONS:

2018 – present Oral Board Examiner American Board of Obstetrics and Gynecology  
 2016 – 2020 Editorial Board Obstetrics and Gynecology  
 2015 – present Teaching Faculty American Urogynecologic Society Fellows Hands-On Course  
 2015 – 2018 Community Services Coordinator Boy Scouts of America, Troop 674, Montgomery, OH  
 2014 – present Freelance writer  
 2013 – 2015 Medical Board GynMobileHealth  
 2013 Fellow Doximity professional network service  
 2012 – present Editorial Board International Academy of Pelvic Surgery  
 1992 – 1993 Research Assistant Medical College of Georgia, Department of Surgery, Augusta GA

**3. Scholarly & Creative Activities:**

Type	Number
Book	_____
Edited Book	_____
Chapter	11
Refereed Journal Article	34
Other Journal Article	29
Juried Performance/Show	_____
Non-Juried Performance/Show	_____
Other: Presentations	46
Other: Abstracts	48
Other: Grants	9

**4. Membership in professional organizations:**

1997 – present American College of Obstetricians and Fellow Gynecologists  
 2003 – 2017 American Urogynecologic Society Member  
 2004 – 2012 New Hampshire Medical Society Member  
 2004 – 2012 Grafton County Medical Society Member  
 2009 – 2011 Society of Medical Decision Making Member  
 2012 – present American College of Surgeons Fellow  
 2012 – present Society of Gynecologic Surgeons Member  
 2013 – 2014 American Medical Informatic Society Member  
 2014 – 2015, American Institute of Ultrasound Medicine Member

## 5. Professional service on campus:

2019 – present Hospital Informatics Advisory Committee, Member UC Health  
 2019 – present Ambulatory Provider Efficiency Advisory Council (APEAC), Member UC Health  
 2018 – present Value Analysis Product Committee, Ob/Gyn Physician Champion UC Health  
 2017 – present Clinical Practice and Standards Committee Member University of Cincinnati Physicians  
 2016 – 2017 Medical Student Member University of Cincinnati, College Performance Evaluation Workgroup  
 2016 – present Education Policy Committee of Medicine Member University of Cincinnati, College of Medicine  
 2015 – 2019 (committee retired) Physician Advisory Committee Member UC Health  
 2015 – present Quality and Safety Committee  
 2015 – 2019 Program Evaluation Committee Chair University of Cincinnati, Department of Obstetrics & Gynecology, Residency in Obstetrics and Gynecology  
 2015 – 2019 Clinical Competency Committee Chair University of Cincinnati, Department of Obstetrics & Gynecology, Residency in Obstetrics and Gynecology  
 2014 – 2016 Program Evaluation Committee Chair The Christ Hospital/University of Cincinnati, Fellowship in Female Pelvic Medicine and Reconstructive Surgery  
 2014 – present Clinical Competency Committee Member The Christ Hospital/University of Cincinnati, Fellowship in Female Pelvic Medicine and Reconstructive Surgery  
 2015 – 2016 Gross Anatomy Curriculum Task Force Member University of Cincinnati, College of Medicine  
 2014 – 2015 Clinical Integrated Network Population Health Committee Member The Christ Hospital  
 2013 – 2015 Data Warehouse Committee Member The Christ Hospital  
 2013 – 2015 Best Practices Committee Member The Christ Hospital  
 2013 – 2015 Physician Informatics Committee Member The Christ Hospital  
 2012 Supplies and Equipment Acquisition Committee Member Dartmouth-Hitchcock Medical Center  
 2010 Information Systems Imaging Subcommittee Member Dartmouth-Hitchcock Medical Center  
 2010 – 2012 Ethics Committee Member Dartmouth-Hitchcock Medical Center  
 2010 Board of Governor's Nominating Committee Meeting Member Dartmouth-Hitchcock Medical Center  
 2008 – 2012 Department of Obstetrics and Gynecology, Gynecology Morbidity and Mortality Coordinator Dartmouth-Hitchcock Medical Center  
 2007 – 2012 Department of Obstetrics Member Dartmouth-Hitchcock Medical and Gynecology, Center Innovations and Reflections in Women's Health Care  
 2007 – 2012 Department of Obstetrics Member Dartmouth-Hitchcock Medical and Gynecology, Research Center Committee  
 2004 – 2012 H-Quest Steering Member Dartmouth-Hitchcock Medical Committee Center

5. Professional service on campus (continued if needed):

[Empty box for professional service on campus]

**6. Professional service off campus:****National:**

2020 Obstetrics and Gynecology Awards Committee Member Obstetrics and Gynecology Journal

2020 Gynecology Advisory Board Member Epic Systems Corporation

2014 – 2017 Gynecologic Practice Subcommittee on Urogynecology Member American College of Obstetricians and Gynecologists

2011 – 2014 Committee on Ethics Member American College of Obstetricians and Gynecologists

2011 Informed Consent Task Force Member American Urogynecologic Society

2012 – 2015 Health Policy Committee Member American Urogynecologic Society

**Regional:**

2018 - present Socially Engaged Engineering and Computing External Advisory Council Member Miami University of Ohio, College of Engineering and Computing

2018 Interim Chair Search Committee

2016 – present Executive Member of the College of Engineering and Computing Advisory Council Member Miami University of Ohio, College of Engineering and Computing, Department of Chemical, Paper, Biomedical Engineering

2014 – 2018 Health Collaborative Physician Leadership Group Member The Health Collaborative

2014 – present Advisory Council Member Miami University of Ohio, Member Miami University of Ohio, College of Engineering and Computing, Department of Chemical, Paper, Biomedical Engineering

2008 – 2010 Market research Consultant The Advisory Board Company, Washington District of Columbia

1999 – 2000 Rhode Island Fellows Advisory Council Member American College of Obstetricians and Gynecologists

**6. Professional service off campus (continued if needed):**

A large, empty rectangular box with a thin black border, occupying most of the page. It is intended for the user to provide details about professional service performed off campus.

## CURRICULUM VITAE

**Date Prepared: 10/11/2020**

**NAME: James Leigh Whiteside MD, MA, MHA, FACOG, FACS**

**ADDRESS:** Office: University of Cincinnati College of Medicine  
231 Albert Sabin Way  
Cincinnati, OH 45267-0526  
Phone: (513) 558-8448

Home: 11135 Grandstone Lane  
Cincinnati, OH 45249

### EDUCATION:

2017	University of Cincinnati	Master of Health Administration
2012	Loyola University Chicago	Master of Arts
1997	The Medical College of Georgia	Medical Doctor
1992	The University of Georgia	Master of Science
1989	The College of William and Mary	Bachelor of Science

### POSTDOCTORAL TRAINING:

2020	Certified Epic Power User	Epic Systems Corporation
2020	Certified Physician Builder – Analytics	Epic Systems Corporation
2019	Certified Physician Builder	Epic Systems Corporation
2017	Lean Six Sigma Yellow Belt	GoLeanSixSigma.com
2010	Mini-Fellowship Geriatrics	Johns Hopkins University School of Medicine, Baltimore, MD
2004	Fellowship Female Pelvic Medicine and Reconstructive Surgery	The Cleveland Clinic Foundation Cleveland, OH
2001	Residency Obstetrics and Gynecology	Brown University/Women and Infants Hospital of Rhode Island Providence, RI

### LICENSURE AND CERTIFICATION:

6/2013	American Board of Obstetrics and Gynecology Sub-Specialty Certification Female Pelvic Medicine and Reconstructive Surgery
12/2006	American Board of Obstetrics and Gynecology Certification
2001 – 2005,	Ohio
2012 – present	
2004 – 2014	New Hampshire
2012 – present	Kentucky

### ACADEMIC APPOINTMENTS:

2019 – present	Director Clinical Business Intelligence	University of Cincinnati, College of Medicine,
----------------	---	---



James L. Whiteside M.D.

Page 2

2019 – present	Professor	Department of Obstetrics and Gynecology University of Cincinnati, College of Medicine
8/2016 – present	Director Female Pelvic Medicine & Reconstructive Surgery	University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology
2017 – 2018	Vice Chair of Education	University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology
2015 – 2018	Residency Program Director	University of Cincinnati, College of Medicine, Department of Obstetrics and Gynecology
2014 – 2015	Associate Fellowship Program Director	The Christ Hospital/University of Cincinnati, Fellowship in Female Pelvic Medicine and Reconstructive Surgery
2015 – 2019	Associate Professor	University of Cincinnati, College of Medicine
2013 – present	Adjunct Associate Professor	Miami University of Ohio, College of Engineering and Computing
2013 – 2015	Co-Director Female Pelvic Medicine and Reconstructive Surgery	The Christ Hospital/University of Cincinnati College of Medicine
2013 – 2015	Voluntary Professor	University of Cincinnati College of Medicine
2013 – present	Adjunct Associate Professor	Geisel School of Medicine at Dartmouth
2010 – 2012	Associate Professor	Geisel School of Medicine at Dartmouth
2004 – 2010	Assistant Professor	Geisel School of Medicine at Dartmouth
2001 – 2004	Clinical Instructor	The Cleveland Clinic Foundation
<b>HOSPITAL APPOINTMENTS:</b>		
2015 – present	Staff physician	West Chester Hospital, West Chester, OH
2013 – 2015	Women's Service Line Informatics Physician Champion	The Christ Hospital, Cincinnati, OH
2013 – 2015	Staff physician	The Christ Hospital, Cincinnati, OH

Revised 4/14/2020

2013 – present	Staff physician, Department of Obstetrics and Gynecology	University of Cincinnati Medical Center, Cincinnati, OH
2004 – 2012	Staff physician, Department of Obstetrics and Gynecology	Dartmouth-Hitchcock Medical Center, Lebanon, NH
2005 – 2012	Staff physician, Department of Obstetrics and Gynecology	Elliott Hospital Manchester, NH
2009 – 2012	Staff physician, Department of Obstetrics and Gynecology	Catholic Medical Center Manchester, NH

**OTHER PROFESSIONAL POSITIONS:**

2018 – present	Oral Board Examiner	American Board of Obstetrics and Gynecology
2016 – 2020	Editorial Board	Obstetrics and Gynecology
2015 – present	Teaching Faculty	American Urogynecologic Society Fellows Hands-On Course
2015 – 2018	Community Services Coordinator	Boy Scouts of America, Troop 674, Montgomery, OH
2014 – present	Freelance writer	
2013 – 2015	Medical Board	GynMobileHealth
2013	Fellow	Doximity professional network service
2012 – present	Editorial Board	International Academy of Pelvic Surgery
1992 – 1993	Research Assistant	Medical College of Georgia, Department of Surgery, Augusta GA
1994	Research Assistant	Medical College of Georgia, Department of Biochemistry, Augusta, GA

**RESEARCH AFFILIATION:**

2013 – 2015	The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital 7759 University Drive, Suite G West Chester, OH 45069
-------------	---

**MAJOR COMMITTEE ASSIGNMENTS AND CONSULTATIONS:****National:**

2020	Obstetrics and Gynecology Awards Committee	Member	Obstetrics and Gynecology Journal
2020	Gynecology Advisory Board	Member	Epic Systems Corporation
2014 – 2017	Gynecologic Practice Subcommittee on Urogynecology	Member	American College of Obstetricians and Gynecologists

2011 – 2014	Committee on Ethics	Member	American College of Obstetricians and Gynecologists
2011	Informed Consent Task Force	Member	American Urogynecologic Society
2012 – 2015	Health Policy Committee	Member	American Urogynecologic Society
<b><u>Regional:</u></b>			
2018 - present	Socially Engaged Engineering and Computing External Advisory Council	Member	Miami University of Ohio, College of Engineering and Computing
2018	Interim Chair Search Committee	Member	Miami University of Ohio, College of Engineering and Computing, Department of Chemical, Paper, Biomedical Engineering
2016 – present	Executive Member of the College of Engineering and Computing Advisory Council	Member	Miami University of Ohio, College of Engineering and Computing, Department of Chemical, Paper, Biomedical Engineering
2014 – 2018	Health Collaborative Physician Leadership Group	Member	The Health Collaborative
2014 – present	Advisory Council	Member	Miami University of Ohio, College of Engineering and Computing, Department of Chemical, Paper, Biomedical Engineering
2008 – 2010	Market research	Consultant	The Advisory Board Company, Washington District of Columbia
1999 – 2000	Rhode Island Fellows Advisory Council	Member	American College of Obstetricians and Gynecologists
<b><u>Institutional:</u></b>			
2019 – present	Hospital Informatics Advisory Committee	Member	UC Health
2019 – present	Ambulatory Provider Efficiency Advisory Council (APEAC)	Member	UC Health
2018 – present	Value Analysis Product Committee	Ob/Gyn Physician Champion	UC Health
2017 – present	Clinical Practice and Standards Committee	Member	University of Cincinnati Physicians
2016 – 2017	Medical Student	Member	University of Cincinnati, College

	Performance Evaluation Workgroup		of Medicine
2016 – present	Education Policy Committee	Member	University of Cincinnati, College of Medicine
2015 – 2019 (committee retired)	Physician Advisory Committee	Member	UC Health
2015 – present	Quality and Safety Committee	Member	University of Cincinnati, Department of Obstetrics & Gynecology
2015 – 2019	Program Evaluation Committee	Chair	University of Cincinnati, Department of Obstetrics & Gynecology, Residency in Obstetrics and Gynecology
2015 – 2019	Clinical Competency Committee	Chair	University of Cincinnati, Department of Obstetrics & Gynecology, Residency in Obstetrics and Gynecology
2014 – 2016	Program Evaluation Committee	Chair	The Christ Hospital/University of Cincinnati, Fellowship in Female Pelvic Medicine and Reconstructive Surgery
2014 – present	Clinical Competency Committee	Member	The Christ Hospital/University of Cincinnati, Fellowship in Female Pelvic Medicine and Reconstructive Surgery
2015 – 2016	Gross Anatomy Curriculum Task Force	Member	University of Cincinnati, College of Medicine
2014 – 2015	Clinical Integrated Network Population Health Committee	Member	The Christ Hospital
2013 – 2015	Data Warehouse Committee	Member	The Christ Hospital
2013 – 2015	Best Practices Committee	Member	The Christ Hospital
2013 – 2015	Physician Informatics Committee	Member	The Christ Hospital
2012	Supplies and Equipment Acquisition Committee	Member	Dartmouth-Hitchcock Medical Center
2010	Information Systems Imaging Subcommittee	Member	Dartmouth-Hitchcock Medical Center
2010 – 2012	Ethics Committee	Member	Dartmouth-Hitchcock Medical Center
2010	Board of Governor's Nominating Committee Meeting	Member	Dartmouth-Hitchcock Medical Center
2008 – 2012	Department of Obstetrics and Gynecology, Gynecology Morbidity and	Coordinator	Dartmouth-Hitchcock Medical Center

2007 – 2012	Mortality Department of Obstetrics and Gynecology, Innovations and Reflections in Women's Health Care	Member	Dartmouth-Hitchcock Medical Center
2007 – 2012	Department of Obstetrics and Gynecology, Research Committee	Member	Dartmouth-Hitchcock Medical Center
2004 – 2012	H-Quest Steering Committee	Member	Dartmouth-Hitchcock Medical Center

#### **MEMBERSHIP, OFFICE & COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:**

1997 – present	American College of Obstetricians and Gynecologists	Fellow
2003 – 2017	American Urogynecologic Society	Member
2004 – 2012	New Hampshire Medical Society	Member
2004 – 2012	Grafton County Medical Society	Member
2009 – 2011	Society of Medical Decision Making	Member
2012 – present	American College of Surgeons	Fellow
2012 – present	Society of Gynecologic Surgeons	Member
2013 – 2014	American Medical Informatic Society	Member
2014 – 2015, 2019	American Institute of Ultrasound Medicine	Member

#### **AWARDS AND HONORS:**

2001	David H. Nichols Award for Excellence in Pelvic Surgery, Women and Infants Hospital of Rhode Island
2003	Golden Laparoscope Award, Third Prize Video, American Association of Gynecologic Laparoscopists
2003	June Allyson Foundation Research Fellowship Award, American Urogynecologic Society
2004	Editor's Choice Article, American Journal of Obstetrics and Gynecology for Whiteside JL, Weber AM, Meyn L, Walters MD. Risk Factors for Prolapse Recurrence after Vaginal Repair
2004	Best Resident/Fellow Paper, Joint meeting of American Urogynecologic Society/Society of Gynecologic Surgeons for Stepp KJ, Barber MD, Yoo EH, Whiteside JL, Paraiso MF, Walters MD. Incidence of Perioperative Complications of Urogynecologic Surgery in Elderly Women
2005	Berlex Faculty Development Course Attendee
2007, 2008, 2009, 2010, 2011	Top 10% Reviewer for Obstetrics and Gynecology
2008	APGO Excellence in Teaching Award
2008	Best Poster, American Urogynecologic Society Annual Meeting for Regional Variation in Pelvic Floor Surgery in Northern New England

- 2009 Best Poster, American Urogynecologic Society Annual Meeting for Anatomic and Functional Outcomes of sacrocolpopexy with or without concomitant posterior colporrhaphy in women with pelvic organ prolapsed
- 2010 Top 5% Reviewer for American Journal of Obstetrics and Gynecology
- 2015 Top Docs of Northern Kentucky, Northern Kentucky Magazine
- 2017 Top 1% globally reviewers of Medicine. Publons Peer Review Awards
- 2019 Top 1% globally reviewers of Clinical Medicine. Publons Peer Review Awards
- 2020 Top Doc, Ohio Top Docs
- 2020 Excellence in Surgical Teaching Award – Elected by Obstetrics and Gynecology residents
- 2020 2020 Top 10 Reviewer for Female Pelvic Medicine and Reconstructive Surgery Journal

**JOURNAL REFEREE ACTIVITIES:**

- 2001 – 2019 Journal of American Association of Gynecologic Laparoscopists
- 2001 – 2004 The Journal of Reproductive Medicine
- 2001 – 2004 Journal of Gynecologic Surgery
- 2001 – 2020 American Journal of Obstetrics and Gynecology
- 2001 – 2017 International Urogynecology Journal and Pelvic Floor Dysfunction
- 2005 – 2020 Obstetrics and Gynecology
- 2008 – 2015 International Journal of Gynecology and Obstetrics
- 2008 – 2020 Neurourology and Urodynamics
- 2010 Clinical Anatomy
- 2010 – 2014 European Journal of Obstetrics & Gynecology and Reproductive Biology
- 2012 – 2020 Female Pelvic Medicine and Reconstructive Surgery
- 2014 – 2014 British Journal of Obstetrics and Gynecology
- 2014 – 2020 The Journal of Urology

**GRANT REFEREE ACTIVITIES:**

- 2008 ZonMw - the Netherlands organization for health research and development  
Grant application: A randomized controlled trial evaluating the cost-effectiveness of peri-operative pelvic physiotherapy in patients undergoing prolapse surgery. .
- 2008 National Institute for Academic Anesthesia  
Grant application: Lipid Emulsion Resuscitation: Bolus versus Continuous Infusion.
- 2011 ZonMw – the Netherlands organization for health research and development  
Grant application: Extended conservative treatment versus surgery in women with outlet constipation.
- 2009 – 2011,  
2015, 2017 American Urogynecologic Society - Member of grant review committee

**RESEARCH FUNDING:**

**Past:**

1. Long-term Differences in Quality of Life, Pelvic Floor Dysfunction, and Sexual Function between Total Abdominal Hysterectomy and Laparoscopic-Assisted Vaginal Hysterectomy. RPC 6942. Research Programs Council Cleveland Clinic Foundation. \$1680, 2001. Principal Investigator.
2. The Effects of Relaxin on Neuroregeneration and Urinary Incontinence following Pudendal Nerve Crush. American Urogynecologic Society/June Allyson Foundation Research Fellowship Award. \$24,000, 2003. Principal Investigator.
3. Decision-making in Pelvic Floor Disorders: Translating Outcomes to Practice. NIH RO3. \$100,000, 2009-2012. Principal Investigator.
4. A Randomized Placebo-Controlled Parallel-Design Trial of the Effect of Solifenacin Treatment for Overactive Bladder in Women with Anterior Vaginal Wall Prolapse Managed with a Pessary. Astellas Grant. Paul Tulikangas Principal Investigator. James Whiteside Site Principal Investigator.
5. A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence. Cook Myosite Incorporated. Site Investigator.
6. Study for Urge incontinence. Medtronic, Inc. Product Surveillance Registry. Site Investigator.
7. American Medical Systems 522 Elevate study A Prospective, Safety and Efficacy Cohort Study of Elevate® Anterior and Apical Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse Repair. Site Investigator.
8. A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder. Astellas. Site Investigator.
9. Use of Fractional CO<sub>2</sub> Laser in the Management of Vaginal Atrophy and Dyspareunia in Breast Cancer Survivors. University of Cincinnati Cancer Institute Survivorship Grant. \$50,000, 2017. Principal Investigator.

**TEACHING EXPERIENCE/CURRENT TEACHING RESPONSIBILITIES:****Dartmouth College:**

2009 – 2012 Didactic lecturer, Thayer engineering students on bioethics and medical innovation

**Dartmouth Medical School:**

2004 – 2012 Didactic lecturer, 3rd year medical students on topics of pelvic floor anatomy, urinary incontinence, pelvic organ prolapse, and ethics in Obstetrics and Gynecology

- 2004 – 2012 Teaching attending, 4th year medical student clinic rotation in Obstetrics and Gynecology
- 2007 – 2008 Panel discussant, Scientific Basis of Medicine Program in Human Reproduction, 2<sup>nd</sup> year Medical School Core Curriculum

**Dartmouth-Hitchcock Medical Center:**

- 2004 – 2012 Didactic lecturer, resident conferences on topics of general gynecology and Female Pelvic Medicine and Reconstructive Surgery
- 2004 – 2012 Supervise residents in operating room suite and in outpatient clinics
- 2005 – 2012 Mentor to residents for research projects
- 2006 – 2012 Benign Gynecology Attending Physician, Department of Obstetrics and Gynecology. Consultation and supervise residents for in-house patient issues and emergency cases that present during these times.

**University of Cincinnati Medical Center**

- 2015 – present Didactic lecturer, resident conferences on topics of general gynecology and Female Pelvic Medicine and Reconstructive Surgery
- 2015 – present Supervise residents in operating room suite and in outpatient clinics
- 2015 – present Mentor to residents for research projects

**The Christ Hospital Female Pelvic Medicine and Reconstructive Surgery Fellowship:**

- 2013 – 2018 Didactic lecturer, fellow conferences on topics in Female Pelvic Medicine and Reconstructive Surgery
- 2013 – present Supervise fellows in operating room suite and in outpatient clinics
- 2013 – present Mentor to fellows for research projects

**Miami University of Ohio, College of Engineering and Computing, Department of Chemical, Paper and Biomedical Engineering:**

- 2013 – present Didactic lecturer on bioethics and biomedical innovation in engineering

**The International Academy of Pelvic Surgery:**

- 2012 – present Didactic lecturer on bioethics and topics in Female Pelvic Medicine and Reconstructive Surgery
- 2012 – present Prosector for cadaver laboratory teaching in female pelvic anatomy

**The American Urogynecologic Society:**

- 2012 – present Didactic lecturer on topics in Female Pelvic Medicine and Reconstructive Surgery at the annual fellows course
- 2012 – present Prosector for cadaver laboratory teaching in female pelvic anatomy

**INVITED PRESENTATIONS:**

**Regional:**

- |         |   |   |             |
|---------|---|---|-------------|
| 10/2003 | The Evolution and Anatomy of Mid-Urethral Sling Procedures. | Dartmouth-Hitchcock Medical Center, Department of Obstetrics and Gynecology | Lebanon, NH |
|---------|---|---|-------------|



9/2004	Vaginitis: The Jungle of Evidence	Rutland Regional Medical Center	Rutland, VT
1/2005	Laparoscopic Reconstructive Pelvic Surgery: Hopes and Headaches	Maine Medical Center	Portland, ME
1/2005	Update in Stress Urinary Incontinence	Southern New Hampshire Medical Center	Nashua, NH
2/2005	Anatomy of Pelvic Support	Dartmouth-Hitchcock Medical Center, Department of Obstetrics and Gynecology	Lebanon, NH
10/2005	Laparoscopic Reconstructive Pelvic Surgery: Hopes and Headaches	Dartmouth-Hitchcock Medical Center	Manchester, NH
4/2006	Overactive Bladder: What is it when you've got to go?	Central Vermont Medical Center	Berlin, VT
9/2006	Surgical Management of Female Stress Urinary Incontinence	Southern New Hampshire Medical Center	Nashua, NH
11/2006	Overactive Bladder: What is it when you've got to go?	New London Hospital	New London, NH
5/2007	Update in female urinary incontinence	Provocative Issues in Women's Health	Lebanon, NH
9/2007	Update in female urinary incontinence	Catholic Medical Center	Manchester, NH
3/2008	Posterior vaginal wall prolapse repair: Is old new again?	Southern New Hampshire Medical Center	Nashua, NH
4/2008	Voiding dysfunction and sacral nerve stimulation	Dartmouth-Hitchcock Medical Center, Department of Urology	Lebanon, NH
10/2008	Epistemology and the Treatment of Female Urinary Incontinence: What do we know, what can we know?	New Hampshire Medical Society	Kennebunkport, ME
1/2009	Pelvic floor surgery - What do we want Steinway's or Yamaha's?	American College of Obstetrician Gynecologist, District I Maine Section	Carrabassett Valley, ME
2/2009	Update in female urinary incontinence	Androscoggin Valley Hospital	Berlin, NH

3/2009	Pelvic floor surgery – what do we want Steinway’s or Yamaha’s?	Dartmouth-Hitchcock Medical Center, Department of Obstetrics and Gynecology	Lebanon, NH
4/2009	Anatomy of pelvic support.	Dartmouth-Hitchcock Medical Center, Department of Urology	Lebanon, NH
4/2009	Chronic pelvic pain: A gynecologist’s perspective	New London Hospital	New London, NH
3/2010	Slings and things	Dartmouth-Hitchcock Medical Center, Department of Urology	Lebanon, NH
5/2010, 5/2011	Pelvic Inflammatory Disease: A Gynecologist’s Perspective	Dartmouth-Hitchcock Medical Center, Division of Infectious Disease	Lebanon, NH
5/2011	What is Female Pelvic Medicine and Reconstructive Surgery?	Catholic Medical Center	Manchester, NH
9/2013	Surgical Treatment of Pelvic Floor Dysfunction: Do We Want Steinways or Yamaha’s?	University of Kentucky Medical Center, Department of Obstetrics and Gynecology	Lexington, KY
9/2013	Human Rights: What? Why?	Miami University of Ohio, Department of Chemical, Paper and Biomedical Engineering	Oxford, OH
9/2014	Making the Diagnosis: Do Multichannel Urodynamic Studies Really Add Up?	University of Kentucky Medical Center, Department of Obstetrics and Gynecology	Lexington, OH
3/2015	Making the Diagnosis: Do Multichannel Urodynamic Studies Really Add Up?	University of Cincinnati/The Christ Hospital, Department of Obstetrics and Gynecology	Cincinnati, OH
11/2015	Evaluation of Female Pelvic Masses: When to Consult a Gynecologist for an ICU Patient?	University of Cincinnati/The Christ Hospital, Department of Anesthesia	Cincinnati, OH
5/2017	What is Value and How Can We Find More of It with Respect to Hysterectomy?	Good Samaritan Hospital, Department of Obstetrics and Gynecology	Cincinnati, OH
12/2019	Asymptomatic	University of Kentucky	Lexington, KY

	Microscopic Hematuria in Women: What would Thomas Bayes say?	Medical Center, Department of Obstetrics and Gynecology	
<b><u>National:</u></b>			
2/2004	Laparoscopic Reconstructive Pelvic Surgery: Hopes and Headaches	The Cleveland Clinic Foundation	Cleveland, OH
4/2004	Fundamentals of Urodynamic Assessment	Michigan State University	Lansing, MI
4/2004	Chronic Pelvic Pain: Overview and Gynecologic Perspective	Michigan State University	Lansing, MI
9/2007	Epistemology and Treatment of Female Stress Urinary Incontinence	American Urogynecologic Society – 28 <sup>th</sup> Annual Meeting	Ft. Lauderdale, FL
9/2007	Developing an Outcomes Clinical Database for General and Academic Practices	American Urogynecologic Society – 28 <sup>th</sup> Annual Meeting	Ft. Lauderdale, FL
11/2007	Posterior Vaginal Wall Prolapse Repair: Is old new again?	American Association of Gynecologic Laparoscopists – 36 <sup>th</sup> Annual Meeting	Washington, DC
9/2011	Informed Consent: A Bioethicists Perspective	American Urogynecologic Society – 32 <sup>nd</sup> Annual Meeting	Providence, RI
8/2012	Surgical Treatment of Pelvic Floor Dysfunction: Do we Want Steinway's or Yamaha's	The Christ Hospital Department of Obstetrics and Gynecology	Cincinnati, OH
12/2014	Surgical Treatment of Pelvic Floor Dysfunction: Do We Want Steinways or Yamaha's?	Reading Hospital, Department of Obstetrics and Gynecology	Reading, PA
4/2016	Debate: Surgeon as Innovator	Society of Gynecologic Surgeons 42 <sup>nd</sup> Annual Meeting	Palm Springs, CA
11/16/2017	Acute Cystitis in Females	Kroger Little Clinic	Cincinnati, OH

5/2018	What is Value and How Can We Find More of It with Respect to Hysterectomy?	MedStar/Georgetown Medical Center	Washington, DC
3/2/2019	ACOG/AUGS Committee Opinion on AMH: What Were We Thinking?	Society of Urodynamics and Female Urogenital Reconstruction 50 <sup>th</sup> Annual Meeting	Miami, FL
9/2019	Evaluation, decision-making process and surgical approach in cases with complex voiding dysfunction and pelvic floor diseases: an interactive case-based discussion	American Urogynecology Society, Clinical Workshop	Nashville, TN
2/2020	There and Back Again...and Again	ACOG Editorial Board Meeting	Ft. Lauderdale, FL

**International:**

10/2003	Anatomy of the Obturator Region	American Medical Systems	Florence, Italy
5/2019	Sacral Nerve Stimulation: <i>What do we NOT know &amp; how should we try to know it?</i>	14 <sup>th</sup> International Neuromodulation Society Meeting	Sydney, Australia

**BIBLIOGRAPHY:****Journal Articles:****Original Articles:**

1. Whiteside JL, Katz T, Anthes T, Boardman L, Peipert JF. Risks and adverse outcomes of sexually transmitted diseases. Patients' attitudes and beliefs. J Reprod Med 2001;46(1):34-38.
2. Barrett JP, Whiteside JL, Boardman L. Fatal clostridial sepsis after spontaneous abortion. Obstet Gynecol 2002;99(5 PT 2):899-901.
3. Whiteside JL, Walters M, Mekhail N. Spinal cord stimulation for intractable vulvar pain. A case report. J Reprod Med 2003;48(10):821-823.

4. Whiteside JL, Barber M, Walters M, Falcone T. Anatomy of Ilioinguinal and Iliohypogastric Nerves in Relation to Trocar Placement and Low Transverse Incisions. *Am J Obstet Gynecol* 2003;189(6):1574-1578.
5. Whiteside JL, Walters M. Anatomy of the Obturator Region: Relations to a trans-obturator sling. *Int Urogynecol J* 2004;15(4):223-6.
6. Whiteside JL, Barber M, Paraiso M, Hugney C, Walters M. Clinical Evaluation of Anterior Vaginal Wall Support Defects: Interexaminer and Intraexaminer Reliability. *Am J Obstet Gynecol* 2004;191(1):100-4.
7. Whiteside JL, Weber AM, Meyn L, Walters M. Risk Factors for Prolapse Recurrence after Vaginal Repair. *Am J Obstet Gynecol* 2004;191(5):1533-8.
8. Whiteside JL, Weber AM, Meyn L, Walters M. Risk Factors for Prolapse Recurrence after Vaginal Repair. *Obstet Gynecol Surv* 2005;60(3):164-165.
9. Stepp KJ, Barber MD, Yoo EH, Whiteside JL, Paraiso MF, Walters MD. Incidence of Perioperative Complications of Urogynecologic Surgery in Elderly Women. *Am J Obstet Gynecol* 2005;192(5):1630-1639.
10. Whiteside JL, Barber MD, Paraiso MF, Walters MD. Vaginal Rugae: Measurement and Significance. *Climacteric* 2005;8(1):71-75.
11. Whiteside JL, Barber MD. Ilioinguinal/Iliohypogastric Neurectomy for Management of Intractable Right Lower Quadrant Pain following Cesarean Section: a case report. *J Reprod Med* 2005;50(11):857-9.
12. Whiteside JL, Hijaz A, Imrey P, Barber MD, Paraiso MF, Rackley RR, Vasavada S, Walters MD, Daneshgari FD. Reliability and Agreement of Urodynamics Interpretations in a Female Pelvic Medicine Center. *Obstet Gynecol* 2006;108(2):315-23.
13. Whiteside JL, Viazmenski A, Strohbehn K, Hanissian PD. Does Pelvic Organ Prolapse Reduction Affect Abdominal Leak Point Pressures? *J Reprod Med* 2008;53(4):294-8.
14. Grimes CL, Hanissian PD, Strohbehn K, Goldman MB, Whiteside JL. Urodynamic leak point pressures weakly correlate with subjective urinary incontinence severity. *Int J Gynecol Obstet* 2008;102(2):120-3.
15. Algoe K, Chen H, Schned AR, Whiteside JL. Intraperitoneal India Ink Deposits Appearing as Endometriosis in a Patient with Chronic Pelvic Pain. *Obstet Gynecol* 2008;112(2 PT 2):448-50.
16. Kinsler EL, Vande Vusse L, Malone M, Zacharski LR, Whiteside JL. Pelvic Organ Prolapse with Hypermobility Syndrome and Operative Bleeding Managed with Aprotinin. *J Pelvic Med Surg* 2008;14(1):65-68.
17. Whiteside JL, Ensrud-Bowlin KM, Wang G, Watsche B, Roberts KP. Lead Placement and Associated Nerve Distribution of an Implantable Periurethral Electrostimulator. *Int Urogynecol J* 2009;20(3):325-329.

18. Whiteside JL, Asif RB, Novello RJ. Fibrin Sealant for Management of Complicated Obstetrical Lacerations. *Obstet Gynecol* 2010 Feb;115(2 Pt 2):403-4.
19. Vande Vusse LK, Zacharski LR, Dumas MG, McKernan LJ, Cornell CJ, Kinsler EA, Whiteside JL. Pro-hemostatic Therapy: The Rise and Fall of Aprotinin. *Semin Thromb Hemost* 2010; 36(1) 103-112.
20. Paine MA, Harnsberger JR, Whiteside JL. Transrectal Mesh Erosion Remote from Sacrocolpopexy: Management and Comment. *Am J Obstet Gynecol*. 2010 Aug;203(2):e11-3.
21. Whiteside JL, Small TA, Grimes CL, MacKenzie TA, Shore L, Birenbaum D. Interexaminer Agreement of Microscopic Assessment of Saline Prepared Vaginal Fluid. *J Low Genit Tract Dis*. 2011 Apr; 15(2): 120-3.
22. Kaser DJ, Kinsler EL, MacKenzie TA, Hanissian P, Strohbehn K, Whiteside JL. Anatomic and Functional Outcomes of Sacrocolpopexy with and without Posterior Colporrhaphy. *Int Urogynecol J*. 2012 Sep; 23(9):1215-20.
23. Whiteside JL, Johnson JD, Spratt KF. Goals, symptoms, signs, and treatments among women with pelvic floor disorders. *Female Pelvic Med Reconstr Surg*. 2014 Mar-Apr; 20(2):104-10.
24. Quezada Y, Karram M, Whiteside JL. Case Report: Diagnosis and Management of Peritoneovaginal Fistula. *J Minim Invasive Gynecol*. 2015 Jan;22(1):134-6.
25. Kakos AB, Lovejoy DA, Whiteside JL. What is the Quality of Information about Pelvic Organ Prolapse Available on the Internet? *Int Urogynecol J*. 2015 Apr; 26(4):551-5.
26. Zoorob D, South M, Karram M, Sroga J, Maxwell R, Shah A, Whiteside JL. A Pilot Randomized Trial of Levator Injections versus Physical Therapy for the Treatment of Pelvic Floor Myalgia and Sexual Pain. *Int Urogyn J*. 2015 June; 26(6):845-852.
27. Quezada Y, Paquette I, Rafferty J, Karram M, Whiteside JL. Does Preoperative Anal Physiology Testing or Ultrasound Predict Clinical Outcome With Sacral Neuromodulation for Fecal Incontinence? *Int Urogyn J*. 2015 Nov;26(11):1613-7.
28. Zoorob D, Karram MM, Sroga J, Stecher A, Maxwell R, Whiteside JL. Correlation of Litigation and Injury in Mesh Placed Vaginally: Analysis For Surgical Outcomes and Determinants Instigating Lawsuits. *Female Pelvic Med Reconstr Surg*. 2016 Sept.
29. Kakos, AB, Allen V, Whiteside JL. Factors Associated with Hemostatic Agent Use During Laparoscopic Hysterectomy. *J Minim Invasive Gynecol* 2016 Nov - Dec;23(7):1167-1171
30. Sax MR, Whiteside JL. Abdominal Wall Pain: Clinical Conundrums Persistent Abdominal Pain Two-Years Post-Cesarean Delivery. *Obstet Gynecol* 2019 July (134) 102-105.

31. Polen-De C, Lang P, Meganathan K, Hohmann S, Jackson A, Whiteside JL. Nationwide Salpingectomy Rates for an Indication of Sterilization Before and After Published Practice Guidelines. *Contraception*. 2019 Aug;100(2):111-115.
32. Lang P, Quezada Y, Whiteside JL. Indwelling Urinary Catheter Management Approaches Among Women Undergoing Benign Gynecologic Surgery: A Randomized Trial. *Female Pelvic Med Reconstr Surg*. October 28, 2019.
33. Levy D, Casey S, Zemtsov G, Whiteside JL. Salpingectomy versus Tubal Occlusion for Permanent Contraception During Cesarean Delivery: Outcomes and Physician Attitudes. *J Minimal Invasive Gynecol*. 2020. In press.
34. Stachowicz A, Yuen H, Levy D, Farley G, Whiteside JL. The Influence of Hospital Type on 30-day Emergency Department Visits After Benign Gynecologic Surgery. *J Gyn Surg*. 2020. In press.

### Reviews:

1. Whiteside JL, Whiteside JW. Acute Bronchitis: A Review of Diagnosis and Evidence-Based Management. *Primary Care Update for Ob/Gyn's*, 2002;9(3):105-109.
2. Whiteside JL, Walters M. Urinary Incontinence: An Overview and its Relation to Female Genital Tract Tumors. *CME J Gynecol Onc*. 2002;7:91-99.
3. Whiteside JL, Falcone T. Endometriosis-related Pelvic Pain: What is the Evidence? *Clin Obstet Gynecol*. 2003;46(4):824-830.
4. Whiteside JL, Keup H. Laparoscopic Management of the Ovarian Mass: A Practical Approach. *Clin Obstet Gynecol*. 2009;52(3):327-334.
5. Whiteside JL. Informed Consent and the Use of Transvaginal Synthetic Mesh. *Obstet Gynecol*. 2011; 118(6): 1409-16.
6. Whiteside JL. Making Sense of Urodynamic Studies for Women with Urinary Incontinence and Pelvic Organ Prolapse. *Urol Clin N Am*. 2012;39: 257-263.
7. Whiteside JL. Finding the Value of Minimally Invasive Gynecologic Surgery. *Clin Obstet Gynecol*. 2017; 60(2): 223-230.
8. Nager CW, Sung VW, Whiteside JL. Asymptomatic Microscopic Hematuria in Women. *Am College Obstetricians Gynecologists*. *Obstet Gynecol*. 2017; 129(6) 168-172.
9. Lang P, Whiteside JL. Anterior Compartment Prolapse: What's New? Current Opinions in Obstetrics and Gynecology. *Curr Opin Obstet Gynecol*. 2017; 29(5): 337-342.
10. Whiteside JL. What Is New in Hysterectomy: Best Articles from the Past Year. *Obstet Gynecol*. 2017; 129(6): 1131-1132.
11. Whiteside JL. What Is New with Bladder Pain: Best Articles from the Past Year. *Obstet Gynecol*. 2018. 2018;132(5):1296-1299.

12. Whiteside JL, Kaeser C, Ridgeway B. Achieving High-Value in the Surgical Approach to Hysterectomy. *Am J Obstet Gynecol.* 2019; 220(3):242-245.
13. Whiteside JL, Yuen, H. Asymptomatic Microscopic Hematuria in Women. *Clin Obstet Gynecol.* 2019 Dec;31(6):471-476.
14. Whiteside JL. What is New with Surgical Recovery: Best Articles from the Past Year. *Obstet Gynecol.* 2019 Oct;134(4):874-877.
15. Stachowicz, A, Whiteside JL. Topical Hemostats in Benign Gynecologic Surgery. *Obstet Gynecol.* 2020 Feb; 135 (2):463-468.
16. Stachowicz AS, Yuen H, Levy D, Farley GJ, Whiteside JL. The Influence of Hospital Type on 30-day Emergency Department Visits after Benign Gynecologic Surgery. *J Gyn Surg.* ahead of print. <http://doi.org/10.1089/gyn.2020.0128>.

#### **Letters to the Editor:**

1. Theofrastus J, Whiteside JL, Paraiso MF. The Utility of Urodynamic Testing. Editorial in *J Am Assoc Gynecol Laparoscop*, 2003;10(4):548-552.
2. Whiteside JL. The Now and Not Yet of Pelvic Floor Dysfunction. Editorial in *Int Urogynecol J.* 2004;15(6):367-8.
3. Whiteside JL. Is Evidence an Ethic? Editorial in *Int Urogynecol J.* 2008;19:745-746.
4. Whiteside JL. Robotic Gynecologic Surgery: A Brave New World? Editorial in *Obstet Gynecol* 2008;112(6):1198-2000.
5. Whiteside JL. What *is* Female Pelvic Medicine and Reconstructive Surgery? Editorial in *Female Pelvic Medicine and Reconstructive Surgery* 2010; 16(5): 255-256.
6. Whiteside JL. Lessons from Sumo. Editorial in *International Academy of Pelvic Surgery* 2011; 1(10).
7. Whiteside JL. Rings, Caves, Truth and Medicine? Editorial in *Female Pelvic Medicine and Reconstructive Surgery* 2014. Sep-Oct; 20(5): 243-4.
8. Whiteside JL. Externalities. Editorial in *International Academy of Pelvic Surgery* 2015; 3(5).
9. Whiteside JL. Urine Trouble Without Cranberries. Editorial in *Am J Obstet Gynecol.* 2015 Aug;213(2):123-4.

#### **Abstracts:**

##### **Presented at National Meetings :**



1. Attitudes and Beliefs Regarding the Risks of Sexually Transmitted Diseases and Pelvic Inflammatory Disease: A Survey of Women at an Urban Center. American College of Obstetricians/Gynecologists District I Meeting, Burlington, VT, 1999.
2. Whiteside JL, Barber M, Paraiso M, Hugney C, Walters M. Clinical Evaluation of Anterior Vaginal Wall Support Defects. Annual Scientific Meeting, Society of Gynecologic Surgeons, Anaheim, California, 2003.
3. Whiteside JL, Barber M, Walters M, Falcone T. Anatomy of Iliioinguinal and Iliohypogastric Nerves In Relation to Trocar Placement and Low Transverse Incisions. Oral presentation, Annual Scientific Meeting, Society of Gynecologic Surgeons, Anaheim, CA, 2003.
4. Whiteside JL, Barber M, Walters M, Falcone T. Nerves in Relation to Trocar Placement and Low Transverse Incisions. Oral presentation. Annual Meeting, Obstetrical and Gynecological Society, Cleveland, OH, 2003.
5. Anatomy of Iliioinguinal and Iliohypogastric Nerves In Relation to Trocar Placement and Low Transverse Incisions, The Cleveland Clinic, Cleveland, OH, 2003.
6. Whiteside JL, Weber AM, Meyn L, Walters M Risk Factors for Recurrent Pelvic Organ Prolapse, Oral presentation. Annual Scientific Meeting, American Urogynecologic Society, Hollywood, FL, 2003.
7. Whiteside J; Hijaz A; Barber, M; Imrey, P; Vasavada, S; Walters, M; Paraiso, M; Rackley, R; Daneshgari, F. Inter- and Intraobserver Reliability of Urodynamic-Based Diagnosis of Lower Urinary Tract Symptoms (LUTS), J Pelvic Med Surg 11: S23-24, 2005. Oral presentation, Annual Scientific Meeting, American Urogynecologic Society, Atlanta, GA, 2005.
8. Whiteside JL, Viazmenski A, Strohbehn K, Hanissian PD. The Effect of Pelvic Organ Prolapse Reduction on Abdominal Leak Point Pressure. Annual Scientific Meeting, Society of Gynecologic Surgeons. Tucson, AZ, 2006.
9. Whiteside JL, Grimes CL, Strohbehn K, Hanissian PD, Goldman MB. Do Abdominal Leak Point Pressures Correlate with Subjective Incontinence Severity?, Annual Scientific Meeting, Society of Gynecologic Surgeons, Orlando, FL, 2007.
10. Whiteside JL, Singleton SL, Strohbehn K, Gormley EA, Hanissian PD, McDonough C, Goldman MB. Factors Associated with Patients' Acceptance and Perceptions of Computer-based Surveys in Urogynecology, Annual Meeting, Society of Medical Decision Making, Pittsburgh, PA, 2007.
11. Small TA, Grimes CL, MacKenzie TA, Birenbaum D, Whiteside JL. Interexaminer Agreement of Microscopic Assessment of Saline Prepared Vaginal Fluid, Annual Clinical Meeting, American College of Obstetrician Gynecologist, New Orleans, LA, 2008.

12. Whiteside JL, McCutcheon M, Strohbehk K, Hanissian PD, Gormley EA. Regional Variation in Pelvic Floor Surgery in Northern New England. Annual Meeting, American Urogynecologic Society, Chicago, IL, 2008.
13. Kaser D, Kinsler E, Mackenzie T, Hanissian P, Strohbehk K, Whiteside J. Anatomic and Functional Outcomes of sacro colpopexy with or without concomitant posterior colporrhaphy in women with pelvic organ prolapsed, Annual Meeting, International Continence Society, San Francisco, CA, 2009.
14. Hanissian PD, Whiteside JL. A Novel Approach to Dissect the Bladder from the Anterior Vaginal Wall at the Time of Laparoscopic Sacrocolpopexy, Annual Meeting, American Urogynecologic Society, Hollywood, FL, 2009.
15. Kaser D, Kinsler E, Mackenzie T, Hanissian P, Strohbehk K, Whiteside J. Anatomic and Functional Outcomes of sacrocolpopexy with or without concomitant posterior colporrhaphy in women with pelvic organ prolapsed, Annual Scientific Meeting, American Urogynecologic Society, Hollywood, FL, 2009.
16. Kinsler E, Kaser D, Mackenzie T, Hanissian P, Strohbehk K, Whiteside J. Does Urodynamic Testing Alter Subjective Urinary Continence Outcomes following Sacrocolpopexy?, Annual Scientific Meeting, American Urogynecologic Society, Hollywood, FL, 2009.
17. Fitzpatrick DL, Spratt KF, Whiteside JL. Does the Epworth Sleepiness Scale Correlate with Pelvic Floor Dysfunction? Annual Scientific Meeting, American Urogynecologic Society, Long Beach, CA, 2010.
18. Hanissian P, Strohbehk K, [ ], Whiteside JL. Mesh Attachment for Sacrocolpopexy: A Mechanical Study to Determine the Optimal Suture Orientation. Annual Scientific Meeting, American Urogynecologic Society, Long Beach, CA, 2010.
19. Whiteside JL, Spratt KF. Factors Associated with Decision Regret Across Treatment for Pelvic Floor Dysfunction. Annual Scientific Meeting, American Urogynecologic Society, Long Beach, CA, 2010.
20. Asif RB, Strohbehk K, Dann EW, Whiteside JL. Anatomic Distances Between the Sacral Promotory and Vaginal Landmarks. Annual Scientific Meeting, American Urogynecologic Society, Long Beach, CA, 2010.
21. Johnson JD, Spratt KF, Whiteside JL. Goals, symptoms, signs, and treatments among women with pelvic floor disorders. Annual Scientific Meeting Society of Medical Decision Making. Toronto Ontario, Canada, 2010.
22. Lessard L, Pennington P, Whiteside JL. Subjective and Objective Voiding Assessment in Females. Annual Scientific Meeting, Society of Gynecologic Surgeons, Baltimore, MD, 2012.

23. Birenbaum DL, Whiteside JL. Operative Repair of Vaginal Stenosis Secondary to Vaginal Lichen Planus. Annual Scientific Meeting Int Soc Study of Vulvovaginal Disease, Chicago, IL, 2012
24. Whiteside JL, Spratt KF. Use of Analytic Hierarchy Process to Evaluate Physician Decision Coherence in Prioritizing Pelvic Floor Treatment Outcomes. Society of Gynecologic Surgery. Charlestown, SC, 2013.
25. Lee K, Whiteside JL, Prescott L, Kinsler E, Strohbehn K. A Comparison of Perioperative Outcomes in Women with Different Body Mass Indices after Laparoscopic Sacrocolpopexy. Society of Gynecologic Surgery. Scottsdale, AZ, 2014.
26. Zoorob D, Dougher E, Karram MM, Whiteside JL. Attitudes Toward Health Care Reform Among Female Pelvic Medicine and Reconstructive Surgery Fellows. Annual Scientific Meeting, American Urogynecologic Society, Washington DC, 2014.
27. Zoorob D, Dougher E, Karram M, Whiteside JL. Female Pelvic Medicine and Reconstructive Surgery Fellows Perspectives on Personal and Faculty Surgical Skills. Annual Scientific Meeting, American Urogynecologic Society, Washington DC, 2014.
28. Whiteside JL, Spratt KF, Quezada Y. Does Cognitive Dissonance Influence Subjective Urinary Incontinence Treatment Outcome Assessments? Annual Scientific Meeting, American Urogynecologic Society, Washington DC, 2014.
29. Kakos AB, Lovejoy DA, Whiteside JL. What is the Quality of Information about Pelvic Organ Prolapse Available on the Internet? Annual Scientific Meeting, American Urogynecologic Society, Washington DC, 2014.
30. Quezada Y, Karram MM, Whiteside JL, Rafferty JF, Paquette IM. Does Preoperative Anal Physiology Testing or Ultrasound Predict Clinical Outcome With Sacral Neuromodulation for Fecal Incontinence? Annual Scientific Meeting, American Urogynecologic Society, Washington DC, 2014.
31. Quezada Y, Karram MM, Whiteside JL, Rafferty JF, Paquette IM. Peripheral Nerve Evaluation vs. Staged Implant Testing with Sacral Neuromodulation for Fecal Incontinence. Annual Scientific Meeting, American Urogynecologic Society, Washington DC, 2014.
32. Zoorob D, Karram MM, Sroga J, Stecher A, Maxwell R, Whiteside JL. Perioperative Differences in Cohorts Seeking and Not Seeking Litigation Related to Mesh. Annual Scientific Meeting, American Urogynecologic Society, Seattle WA, 2015.
33. Zoorob D, Karram MM, Sroga J, Stecher A, Maxwell R, Whiteside JL. Correlation of Litigation and Injury in Mesh Placed Vaginally: Analysis For Surgical Outcomes

and Determinants Instigating Lawsuits. Annual Scientific Meeting, American Urogynecologic Society, Seattle WA, 2015.

34. Kakos, AB, Allen V, Whiteside JL. Factors Associated with Hemostatic Agent Use During Laparoscopic Hysterectomy. Annual Scientific Meeting, Society of Gynecologic Surgeons, Palm Springs CA, 2016
35. Hussain S, Thida BS, Gupta A, Whiteside JL. Medicare Claims by Region and Physician Practice Type in Obstetrics and Gynecology. Annual Scientific Meeting, Society of Gynecologic Surgeons, Palm Springs, CA, 2016
36. Lang P, Whiteside JL. What do Internet-Based Patient Evaluation of Obstetricians and Gynecologists Mean? Annual Scientific Meeting, Society of Gynecologic Surgeons, San Antonio, TX, 2017
37. Lang P, Quezada Y, Whiteside JL. A Randomized Trial Comparing Conventional and “Fast Track” Indwelling Urinary Catheter Management Among Women Undergoing Benign Gynecologic Surgery. Annual Scientific Meeting, Society of Gynecologic Surgeons, Orlando, FL, 2018.
38. Polen-De C, Lang P, Meganathan K, Hohmann, S, Jackson A, Whiteside JL. A nationwide analysis of salpingectomy rates for sterilization following the 2015 American College of Obstetricians and Gynecologists committee opinion, “Salpingectomy for ovarian cancer prevention.” SGO Annual Meeting on Women’s Cancer. New Orleans, LA, 2018.
39. Westerfield L, Yuen H, Whiteside JL. Management of Endometrial Polyps with and without the Intrauterine Morcellator. Annual Scientific Meeting, Society of Gynecologic Surgeons, Tucson, NM, 2019.
40. Yuen H, Stachowicz A, Lang P, Levy D, Whiteside JL. Factors Associated with Emergency Department Utilization after Benign Gynecologic Surgery. Annual Scientific Meeting, Society of Gynecologic Surgeons, Tucson, NM, 2019
41. Yuen H, Meganathan K, Whiteside JL. Does Cardiac Function Differ with Lower Urinary Tract Symptoms and a History of Sleep Apnea? AUGS/IUGA Joint Scientific Meeting, Nashville, TN, 2019.
42. Murillo A, Yuen H, Hohmann S, Whiteside JL. Nationwide Rates of Cystoscopy with Hydrodistention Before and After Published Practice Guidelines. AUGS/IUGA Joint Scientific Meeting, Nashville, TN, 2019.
43. Kaeser C, Whiteside JL. Pre-emptive Anesthesia with Posterior Repair: A Randomized Trial. AUGS/IUGA Joint Scientific Meeting, Nashville, TN, 2019.

44. Levy D, Casey S, Zemtsov G, Whiteside JL. Salpingectomy vs. Tubal Occlusion for Permanent Contraception During Cesarean Delivery: Outcomes and Physician Attitudes. Society of Gynecologic Surgeons 46<sup>th</sup> Annual Scientific Meeting.
45. Yuen H, Whiteside JL. Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy: A Randomized Controlled Trial. AUGS Scientific Meeting, Virtual Meeting, 2020.
46. Stachowicz A, Lambert J, Hohmann S, Whiteside JL. Hemostatic Agent Use in Outpatient Benign Hysterectomy: A Nationwide Assessment. Society of Gynecologic Surgeons 47<sup>th</sup> Annual Scientific Meeting. (Submitted)

#### **Presented at International Meetings :**

1. Whiteside J, Weber A. Risk Factors for Recurrent Pelvic Organ Prolapse, Annual General Meeting, International Continence Society, Florence, Italy, 2003.
2. Whiteside J, Walters M. Anatomy of the Obturator Region: Relations to a trans-obturator sling, Annual General Meeting, International Continence Society, Florence, Italy, 2003.
3. Roberts KP, Wang G, Ensrud-Bowlin KM, Whiteside JL. Electrode placement and relationships of periurethral nerves of an implantable electrostimulator, Accessa™, in female human cadavers, Oral presentation, Annual Meeting, International Neuromodulation Society, Acapulco, Mexico, 2007.

#### **Book Chapters:**

1. Barber MD, Whiteside JL, and Walters MD. Neurophysiologic Testing of the Pelvic Floor. In: Sciarra J editor. Gynecology and Obstetrics. Lippencott Williams and Wilkins; 2003.
2. Whiteside JW, Ricanati E, Whiteside JL. Evaluation of the Female Patient. In: Sokol E, Sokol A, editors. The Requisites in Obstetrics and Gynecology: General Gynecology. Mosby Elsevier; 2007. p. 99-123.
3. Whiteside JL. Laparoscopic Management of Adnexal Masses. In: Falcone T, Hurd W, editors. Clinical Reproductive Medicine and Surgery. Mosby Elsevier; 2007. p. 747-757.
4. Whiteside JL, Walters, MD. Pathophysiology of Stress Urinary Incontinence. In: Walters MD, Karram M editors. Urogynecology and Reconstructive Pelvic Surgery 3<sup>rd</sup> Edition, Philadelphia: Mosby Elsevier; 2007. p. 157-171.
5. Whiteside JL. The Effects of Gynecologic Cancer and its Treatment on the Lower Urinary Tract. In: Walters MD, Karram M editors. Urogynecology and Reconstructive Pelvic Surgery 3<sup>rd</sup> Edition, Philadelphia: Mosby Elsevier; 2007. p. 425-435.

6. Hanissian P, Whiteside JL. The Transobturator Approach to the Midurethral Sling. In: Graham SD, Glenn JF. editors. Glenn's Urologic Surgery. 7<sup>th</sup> Edition Lippincott Williams and Wilkins; 2010. p. 282-287.
7. Whiteside JL, Uranga, R. Prophylactic Oophorectomy at Hysterectomy. In: Walters MD, Barber M. editors. Hysterectomy for Benign Disease. Saunders; 2010. p. 161-178.
8. Whiteside JL, Muffly T. Overview of Pelvic Floor Disorders: Diagnosis and Treatment. In: Goldman MB, Hatch MC. Editors. Women and Health. Academic Press; 2012.
9. Whiteside JL, Walters, MD. Pathophysiology of Stress Urinary Incontinence. In: Walters MD, Karram M editors. Urogynecology and Reconstructive Pelvic Surgery 4<sup>th</sup> Edition, Philadelphia: Mosby Elsevier; 2015.
10. Whiteside JL. The Effects of Gynecologic Cancer and its Treatment on the Lower Urinary Tract. In: Walters MD, Karram M editors. Urogynecology and Reconstructive Pelvic Surgery 4<sup>th</sup> Edition, Philadelphia: Mosby Elsevier; 2015.-
11. Whiteside JL, Karram M. Native Tissue Suture Repair of Enterocele and Vaginal Vault Prolapse: Abdominal Approach. In: Baggish M, Karram M editors. Atlas of Pelvic Anatomy and Gynecologic Surgery. 4<sup>th</sup> Edition, Philadelphia: Mosby Elsevier; 2016.

**Scholarly Work Published in other media:**

1. Whiteside JL. Physiological Consequences of Resource Allocation in Two Agricultural Species, Capsicum annum and Lycopersicon esculentum. Master of Science Thesis. University of Georgia Press, 1992.
2. Whiteside JL, Falcone T, Paraiso, MF. Laparoscopic management of adnexal masses. Video presentation at Annual Meeting of American Society of Reproductive Medicine, Seattle, WA, October 2002. Video also presented at Annual Global Congress of Gynecologic Endoscopy. American Association of Gynecologic Laparoscopy, Miami Beach, FL, November 2002.
3. Whiteside JL, Sokol A, Falcone, T. Laparoscopic management of the ovarian remnant. Video presentation at the 2003 Annual Global Congress of Gynecologic Endoscopy. American Association of Gynecologic Laparoscopy. Awarded 3<sup>rd</sup> prize for best surgical video in the Golden Laparoscope Competition. Video also presented at Annual Meeting of American Society of Reproductive Medicine, Philadelphia, PA, October 2004.
4. Whiteside JL, Walters MD. Anatomy of the Trans-Obturator Mid-Urethral Sling. Video presentation at the Joint Scientific Meeting of American Urogynecologic Society and Society of Gynecologic Surgeons. San Diego, CA, July 2004.
5. Falcone T, Tulikangas P, Whiteside JL. Audio presentation for American College of Obstetricians and Gynecologists Update. Surgical approach to hysterectomy. Cleveland, OH, September 2005.
6. Barber M, Whiteside JL, Walters M. Neurophysiologic Testing of the Pelvic Floor. Global Library of Women's Medicine. [www.GLOWM.com](http://www.GLOWM.com). March 2008.

7. Braga J, Whiteside JL. Recurrent Prolapse and Transvaginal Mesh Kit Repair: Anatomy and Correction. Video presentation at the Annual Meeting of American Urogynecologic Society. Hollywood, FL, September 2009.
8. Hardy-Fairbanks A, Whiteside JL. Pelvic Floor Surgery Following Kidney Transplantation: Technique and Comment. Video presentation at the Annual Meeting of the American Urogynecologic Society, Long Beach, CA, September 2010.
9. Whiteside JL. Case discussant for International Academy of Pelvic Surgery. December 2010.
10. Whiteside JL. Doc Do I Really Need That? Cincinnati Enquirer. March 2013.
11. Whiteside JL. Save Money, Live Better. Female Health Today. May 2014.
12. Whiteside JL. Ready...Aim...Treat! Female Health Today. September 2014.
13. Whiteside JL. How Would I Know I'm Better? Female Health Today. December 2014.
14. Lang P, Whiteside JL. Supporting the Vaginal Cuff at the Time of Hysterectomy. Follow the Evidence in International Academy of Pelvic Surgery. May 2015.
15. Lang P, Whiteside JL. Endometrial Ablation: Finding the Right Candidate. Follow the Evidence in International Academy of Pelvic Surgery. August 2015.
16. Whiteside JL. Doctor: So much health care not healthy. Cincinnati Enquirer. May 26, 2015.
17. Hussain S, Boschuetz T, Whiteside JL, Role of Cystoscopy During Hysterectomy. Follow the Evidence in International Academy of Pelvic Surgery. April 2016
18. Kakos AB, Whiteside JL, Karram M. Route of Surgery for Primary Pelvic Organ Prolapse. Follow the Evidence in International Academy of Pelvic Surgery. September 2015.
19. Kaeser C, Whiteside JL. Choosing the Ideal Mid-Urethral Sling. Follow the Evidence in International Academy of Pelvic Surgery. September, 2016.
20. Barbour N, Lang P, Whiteside JL. Postpartum Voiding Complications and Effects of Regional Anesthesia on Bladder Function. Follow the Evidence in International Academy of Pelvic Surgery. April 2017.
21. Sax M, Whiteside JL. Defining and Training the Expert Surgeon. Follow the Evidence in International Academy of Pelvic Surgery. May 2018
22. Zemtsov G, Kaeser C, Whiteside JL. Urinary Catheter Clamping for Short-Term Bladder Drainage After Female Pelvic Surgery. Follow the Evidence in International Academy of Pelvic Surgery. August 2018.
23. Patel A, Stachowicz A, Whiteside JL. Urethral Dilation. Follow the Evidence in International Academy of Pelvic Surgery. September 2018.
24. Smith LV, Stachowicz A, Whiteside JL. Botox for Refractory Pelvic Floor Over-activity. Follow the Evidence in International Academy of Pelvic Surgery. December 2018.
25. Yuen HT, Hollingsworth J, Whiteside JL. Hydrodistension for Bladder Pain Syndrome. Follow the Evidence in International Academy of Pelvic Surgery. February 2019.
26. Sax MR, Whiteside JL. Contraception: Choosing the Right Method for You. In Foundation for Female Health Awareness. February 2019.

27. Gelvin BJ, Whiteside JL. ERAS fluid management implementation in gynecologic surgery. Follow the Evidence in International Academy of Pelvic Surgery. December 2019.
28. Cunningham S, Whiteside JL, Postpartum Perineal Wound Complications. Follow the Evidence in International Academy of Pelvic Surgery. March 2020.
29. McKenzie L, Whiteside JL. What is a Urinary Tract Infection? Follow the Evidence in International Academy of Pelvic Surgery. November 2020.

**Featured in other media:**

1. Poor Documentation: Why It Happens and How to Fix It, [www.fortherecordmag.com](http://www.fortherecordmag.com), May 21, 2016.
2. 18 things that'll screw up your vagina, [www.theberry.com](http://www.theberry.com), April 6, 2016.
3. If You like Pee-ña Coladas...This Cocktail Guide Is for You, Food & Wine, February 09, 2016.
4. Women's Health: Can you skip the annual exam?, [www.courier-journal.com](http://www.courier-journal.com), September 2, 2016.
5. Asymptomatic Microscopic Hematuria in Women Obstetrics & Gynecology · June 23, 2017.
6. Research Supports New Criteria for Evaluating Urologic Cancer in Women [www.eurekalert.org](http://www.eurekalert.org) May 02, 2017.
7. Everything You Need to Know About Birth Control and Travel [www.brides.com/story/everything-you-need-to-know-about-birth-control-and-travel](http://www.brides.com/story/everything-you-need-to-know-about-birth-control-and-travel) November 22, 2017.





Office of the Vice Chancellor  
Dean, Brody School of Medicine  
Health Sciences Division

AD-48 Brody Medical Sciences Building | 600 Moye Boulevard | Mail Stop 600  
East Carolina University\* | Greenville, NC 27834-4354  
252-744-2984 office | 252-744-1612 fax

October 19, 2021

Philip Rogers, EdD  
East Carolina University  
Greenville, NC 27858

Dear Chancellor Rogers:

I would appreciate your consideration of the enclosed recommendation for the initial appointment of Professor with permanent tenure for Raymond Mattingly, PhD.

Dr. Raymond Mattingly is scheduled to join East Carolina University December 13, 2021 as Chair and Professor with a recommendation for permanent tenure in the Department of Pharmacology and Toxicology, Brody School of Medicine.

Dr. Mattingly completed his MA in Natural Sciences and Pharmacology at the University of Cambridge, Cambridge, UK in 1991. He then completed his PhD in Pharmacology at the University of Virginia, Charlottesville, VA in 1993.

Currently, he serves as Chair of the Department of Pharmacology at Wayne State University in Detroit, Michigan. Dr. Mattingly was hired as an Assistant Professor with permanent tenure at Wayne State University in 1998, was promoted to Associate Professor in 2003, and promoted to full Professor in 2012. Since 2015, he has also held a secondary appointment as Professor in the Department of Oncology at Wayne State University.

Dr. Mattingly's scholarly activity includes 10 manuscripts in peer-reviewed scientific journals, author of two books and three book chapters, and has presented more than 51 conferences and seminars. He is a gifted researcher, with 50 active and completed projects.

For your convenience, attached are the following documents:

- Dr. Raymond Mattingly's curriculum vitae
- ECU Personnel Action Summary Form for the Board of Trustees

If you approve, we will make arrangements for this recommendation to be placed on the agenda for the November 11, 2021 ECU Board of Trustees meeting.

Sincerely,  
DocuSigned by:

*Ron Mitchelson, Lt*  
Ron Mitchelson, PhD  
Interim Vice Chancellor, Division of Health Sciences

Enclosures

Approve

Do Not Approve

*Philip Rogers*  
Philip Rogers, EdD  
Chancellor

10-27-21  
Date

**ECU FACULTY MANUAL, PART X, SECTION I, Attachment 2.**

**EAST CAROLINA UNIVERSITY PERSONNEL ACTION SUMMARY FORM**  
 (Administrator completes Section I. and faculty member (appointee) completes Section II.)

Section I. To be completed by the appropriate administrator(s).

Name of Appointee: Raymond Mattingly

Department: Pharmacology and Toxicology School/College: Brody School of Medicine

Current Rank or Title: *(if applicable)* Chair and Professor Proposed Rank or Title: Chair and Professor with Tenure

Indicate Type of Action: *(select all that apply)*

Administrative Appointment:

New Faculty Appointment:

Promotion:

Conferral of Tenure:

Other:

*(describe)* \_\_\_\_\_

Distinguished Professorship:

*(provide name of professorship)* \_\_\_\_\_

Effective Date of Action: 12/13/2021

Contract Period: Administrative Appointment: 9 mo.  12 mo.   
 Faculty Appointment: 9 mo.  12 mo.

Salary: \$ 257000 Source(s): State Funds: \$ 231746 \*Non-State Funds: \$ 25254

\*Indicate Sources of non-state funds generically (i.e., grants, receipts, trust funds, endowments, medical faculty practice plan, etc.): \_\_\_\_\_

Grants 216642

Prior Recommendations/Personnel Actions:  
*(please check appropriate responses)*

Source	Recommended	Not Recommended	Not Applicable
Appropriate Unit Personnel Committee	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chair/Unit Head	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Director	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Dean	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Provost/Vice Chancellor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Chancellor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Board of Trustees	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Section II. To be completed by the faculty member.

**1. Education Background:** *(indicate degree, date earned and institution, note additional study & training)*

B.A. (Hons.), Natural Sciences and Pharmacology, University of Cambridge, Cambridge, U.K., 1987  
 M.A., Natural Sciences and Pharmacology, University of Cambridge, Cambridge, U.K., 1991 Ph.D., Pharmacology, University of Virginia, Charlottesville, VA, 1993

**TRAINING**

Technical Assistant. Prize Scholar, Churchill College, University of Cambridge. Adviser: Dr Michael R. Hanley, MRC Molecular Neurobiology Unit, Cambridge, 1987. Phorbol diester binding to neuroblastoma cells.

Graduate Research Assistant. President's Fellow, University of Virginia. Adviser: Dr Joseph Lerner, University of Virginia, 1987 – 1988.

Insulin-dependent regulation of mRNA accumulation.

Ph.D. Student/Candidate. Predoctoral Fellow, Howard Hughes Medical Institute. Adviser: Dr James C. Garrison, University of Virginia, 1989 – 1992. Inositol phosphate production and metabolism in transformed cells.

Research Associate. Adviser: Dr James C. Garrison, University of Virginia, 1992 – 1993.

Tyrosine phosphorylation of the G protein Gq.

Research Fellow. Fellow of the Markey Center for Molecular Genetics. Adviser: Dr Ian G. Macara, University of Vermont, 1993 – 1996. Regulation of Ras by exchange factors and GTPase-activating proteins.

Research Fellow. National Research Service Award (NRSA, F32) Fellow of the National Cancer Institute. Adviser: Dr Ian G. Macara, University of Virginia, 1997 – 1998. Integration of signal transduction through heterotrimeric and Ras-related G proteins.

**2. Teaching and other professional experience:** *(Show inclusive dates, rank and/or title, institution or agency, and indicate first appointment at current institution with rank and any changes to date)*

**FACULTY APPOINTMENTS**

Assistant Professor, Department of Pharmacology, Wayne State University, 1998 – 2003 Associate Professor (with continuing tenure), Department of Pharmacology, Wayne State

University, 2003 – 2012

Professor (with continuing tenure), Department of Pharmacology, Wayne State University, 2012 –

Professor (secondary appointment), Department of Oncology, Wayne State University, 2015 –

Department Chair, Department of Pharmacology, Wayne State University, 2016 – .

**OTHER PROFESSIONAL APPOINTMENTS**

Research Member of the Barbara Ann Karmanos Cancer Institute, 1999 –

Full Member (1999 – 2010) and Associate Leader (2002 – 2010) of the Cell Signaling and Function Research Core, EHS Center for Molecular and Cellular Toxicology with Human Applications, Detroit, Michigan

Research Member, Karmanos Cancer Institute, Program in Molecular Biology & Genetics (1999 – 2012) and Molecular Therapeutics Program (2012 – )

Graduate Officer, Department of Pharmacology, Wayne State University School of Medicine, 2001 – 2007

Faculty Member, Graduate Program in Cancer Biology, Wayne State University, 2001 – Faculty Member, Graduate Program in Molecular & Cellular Toxicology, Wayne State

University, 2001 – 2011

Co-Leader of the Program in Molecular Biology and Genetics of the Barbara Ann Karmanos Cancer Institute, 2003 – 2012

Course Director, Medical Pharmacology and Therapeutics, Wayne State University School of Medicine, 2008 – 2016

Deputy Director, Cancer Biology Training Program, Wayne State University School of Medicine, 2011 – 2016.

**3. Scholarly & Creative Activities:**

Type	Number
Book	2
Edited Book	
Chapter	3
Refereed Journal Article	10
Other Journal Article	51
Juried Performance/Show	
Non-Juried Performance/Show	
Other: Grant Awards	50
Other: Presentation	13
Other: Seminars	38

**4. Membership in professional organizations:**

Member, Graduate Recruitment and Education Committee of the American Society for Pharmacology and Experimental Therapeutics, 2003 – 2006.

American Society for Pharmacology and Experimental Therapeutics American Association for Cancer Research

Association of Medical School Pharmacology Chairs

## 5. Professional service on campus:

## Wayne State University Departmental:

Co-director (1998 – 1999) and Director (1999 – 2000) of the WSU Department of Pharmacology seminar series

Member, Faculty Recruitment Committee, WSU Department of Pharmacology, 1999 – 2007

Member (2000 – 2015) and Chair & Graduate Officer (2001 – 2007), Graduate Affairs Committee, WSU Department of Pharmacology

Elected Member, Faculty Salary/Merit Review Committee, WSU Department of Pharmacology, 2003 – 2007; 2010 – 2013; 2014 – 2015

Elected Member, Promotion & Tenure Committee, WSU Department of Pharmacology, 2004 – 2006; 2008 – 2011; 2011 – 2014; 2015 (Chair)

Member, Curriculum Committee, WSU Department of Pharmacology, 2008 – 2015

Member, Internal Academic Program Review Committees, WSU Department of Pharmacology, 2004 – 2005; 2013 – 2014

Member, Internal Departmental/Chair Review Committee, WSU Department of Pharmacology, 2005.

## School of Medicine:

Member (2000 – 2009) and Chair (2005 – 2009), WSU School of Medicine Faculty Senate Library Committee

Member, WSU School of Medicine Graduate Affairs Council, 2001 – 2007 Member, WSU School of Medicine IBS 7020 curriculum committee, 2001 – 2014

Member, Basic Science Education Course Directors' Committee, WSU School of Medicine, 2008 – 2016

Member, WSU School of Medicine Faculty Senate Curriculum Committee, 2010 – 2013; re- appointed 2013 – 2016. Committee replaced by Curriculum Management Committee

Member, Steering Committee for the Cancer Biology Graduate Program, WSU School of Medicine, 2011 –

Member, Faculty Development Workgroup for Strategic Planning, WSU School of Medicine, 2011 – 2012

Co-chair, Identifying Future Scientists Workgroup for Strategic Planning, WSU School of Medicine, 2013

Member, Biomedical Science Curriculum Workgroup for Strategic Planning, WSU School of Medicine, 2013

Member, Year 2 Operations Committee, WSU School of Medicine, 2013 – 2014

Member, Best Practices Working Group for medical curriculum renewal, WSU School of Medicine, 2015 – 2016

Member, Foundations Content Curriculum Team, WSU School of Medicine, 2015 – 2016 Member, WSU School of Medicine Faculty Senate Curriculum Management Committee, 2016 –

Member (2016 – ) and Chair (2016 – 2019), Basic Science Chairs and Directors Committee, WSU School of Medicine

Member, Combined Chairs Committee, WSU School of Medicine, 2016 –

Participant, Chairs' Coaching Workshop, "Guiding Performance Discussions", WSU School of Medicine, 2016

Representative of AMSPC (Association of Medical School Pharmacology Chairs) at the AAMC/CFAS (Council of Faculty and Academic Societies) Meeting, Orlando, FL 2017

Member, Substance Use Curriculum Task Force, WSU School of Medicine, 2017 – 2019 Member, Longitudinal and Integration Sub-committee, WSU School of Medicine, 2017 –

Member, Curriculum Management Course Review Sub-committee, 2018 – ; peer reviewer of M1 Foundations Course (2019); peer reviewer of M1 Reproductive and Endocrine Systems Course (2019); peer reviewer of M2 Pediatrics Clerkship (2019)

Member, Curriculum Management Continuous Quality Improvement Team, WSU School of Medicine, 2020 – .

## University:

Member, WSU Library Committee, 2001 – 2005 Member, WSU Radiation Safety Committee, 2003 – 2016

Member, Scholarships and Fellowships Review Panel, WSU Graduate School, 2004 & 2009 Internal Auditor, WSU Radiation Safety Program, 2008 & 2009

Member, Search Committee for Dean of the Eugene Applebaum College of Pharmacy and Health Sciences, 2014 – 2015. Successful outcome: recruitment of Dr. Serrine Lau

Member, Review Advisory Panel, for the academic program review of the WSU Biomedical Engineering graduate programs, 2015

Participant, New Chairs & Directors Training, "Problems, Remediation, Joint Work of Administration and Union", 2016

Member, Research Working Group, Project Leapfrog: Wayne State University and Henry Ford Health System, 2018 – 2019

Member, Steering Committee for WSU IBio Faculty Recruitment Initiative, 2018 – 2020.

5. Professional service on campus (continued if needed):

--

## 6. Professional service off campus:

Member, Graduate Admissions Committee, WSU Cancer Biology Program, 2003 – 2006 Member, Microscopy & Imaging Resources Laboratory's Advisory committee, WSU, 2003 –

Member, Program Leadership Committee, EHS Center in Molecular and Cellular Toxicology with Human Applications, WSU, 2004 – 2009

Member, Scientific Leadership Council sub-committee on cores, Karmanos Cancer Institute, 2004

Member, Curriculum Committee of the Institute of Environmental Health Sciences, 2007 – 2011 Member, Proteomics Core Advisory Committee, Karmanos Cancer Institute, 2009 –

Member, Program Leaders' Committee, Karmanos Cancer Institute, 2010 – 2012

Member, Scientific Retreat Committee for Program Reorganization, Karmanos Cancer Institute, 2012

Member, Scientific Leadership Council, Karmanos Cancer Institute, 2012 – 2015

Member, Steering Committee for the Molecular Therapeutics Program, Karmanos Cancer Institute, 2012 – 2015

Scholarly Service

Grant Review Committees NIH:

Ad hoc grant reviewer, Scientific Review Group ZHL1-CCT-B C1 (SBIR contract proposals) for the National Heart, Lung, and Blood Institute, 2003

Ad hoc member, Tumor Cell Biology study section, NIH/Center for Scientific Reviews (three meetings: 2006 – 2007)

Chartered Member, Tumor Cell Biology study section, NIH/Center for Scientific Reviews (full term: 2007 – 2011)

Member, Special Emphasis Panel/Scientific Review Group 2009/10 ZRG1 OBT-H (95) S for ARRA applications, NIH/Center for Scientific Reviews (2009)

Member, Scientific Review Groups: ZCA1 SRLB-C (J1), Cancer Biology-2 (2012); ZCA1 SRLB-C (M1), Cancer Biology-2 (2013); ZCA1 SRLB-C (O1), Cancer Biology-2 (2013); ZCA1 SRLB-C (M1), Cancer Biology-2 (2014); ZCA1 RPRB-0 (M1) P and ZCA1 SRB-C (O1) S (2015); and ZCA1 RPRB-0 (M1) P and ZCA1 SRB-C (O1) S (2015); ZCA1 SRB-C (M1) and ZCA1 SRB-C (A1) (2016) for the National Cancer Institute

Member: Pilot study of relative quality of grant applications for the NIH/Center for Scientific Reviews, 2014

Member, ZRG1 OBT-H (81)A panel for R15 applications for NIH/Center for Scientific Reviews, 2015

Member, ZRG1 F09A-D 2015-10, F09A-D 2016/01, F09A-D(20) 2016/05, F09A-D(20) 2016- 10, F09A-R(20) 2017-01, F09A-R(20) 2017-05, F09A-R(20) 2017-10, F09A-R(20) 2018/01, F09A-R (20) 2018/05, F09A-R (20) 2018/10, F09A-R (20) 2019/01, F09A-R (20) 2019/05, F09A-R (20) 2019/10, ZRG1 F09A-R (20) 2020/01, ZRG1 F09A-R (20) 2020/05, ZRG1 F09A-R (20) 2020/10 Fellowships Oncology review panels for NIH/Center for Scientific Reviews.

Other Federal Government:

Ad hoc grant reviewer by mail, Department of Veterans Affairs, Office of External Reviews, 2002 & 2003

Ad hoc grant reviewer by mail, National Science Foundation, 2004

Regular Member, Panel NF-A, Department of Defense CDMRP Neurofibromatosis Research Program, 2003, 2005, 2009

Regular Member (online reviews), NF-Concept Panel, Department of Defense CDMRP Neurofibromatosis Research Program, 2006 & 2007

Ad hoc grant reviewer by telephone, NF-Ad-hoc Panel, Department of Defense CDMRP Neurofibromatosis Research Program, 2007

Regular Member, Panel for Organotypic Culture Models for Predictive Toxicology Centers, EPA-STAR-G2013-L1 for the Environmental Protection Agency, 2014

Regular Member, Panel CET-2/CT, Department of Defense CDMRP Neurofibromatosis Research Program, 2019

Specialist Member, Panel OCRP Pilot-1 Panel, Department of Defense CDMRP Ovarian Cancer Research Program, 2020.

Other National and International:

Ad hoc grant reviewer for the U.S.–Israel Binational Science Foundation, 1997, 1998, 2000, 2006

Regular Member, Komen for the Cure panel MCBG#1, 2008

Grant reviewer for the National Medical Research Council of Singapore, 2010 & 2012

Grant Reviewer, Bankhead-Coley Cancer Research Program, Florida Department of Health, 2010, 2011, 2012, 2013

Proposal Referee, NIHR (National Institute for Health Research) Evaluation, Trials and Studies Coordinating Centre (NETSCC), Medical Research Council, U.K., 2010

Scientific Panel Member for the Inaugural Newton Fund Call on Non-Communicable Diseases (NCD) for the South African Medical Research Council, 2015

Grant reviewer, National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), U.K., 2016

Grant reviewer, Medical Research Council (MRC), U.K., 2019

Grant Reviewer, Veni Talent Program, The Netherlands Organisation for Health Research and Development, 2020.

Regional/Local:

Grant reviewer for the Barbara Ann Karmanos Cancer Institute: 2002 Prostate Cancer Ethnic Research Competition; 2005, 2009, 2011 Strategic Research Initiatives; Molecular Therapeutics Program grants competition (2014, 2015); American Cancer Society Institutional Research Grants (2012, 2013, 2014, 2015); cancer biology T32 awardee competition (2010 – ); member of pre-submission KCI study sections (2012 – 2014); Co-chair of pre-submission KCI study sections (2014 – 2015)

External reviewer, Henry Ford Health System, 2004, 2005

Reviewer for the Office of Vice-President for Research: pre-competition for applications to the Ralph Wilson Sr and Ralph Wilson Jr Medical Research Foundation, 2005 – 2009; Member, Internal Review Committee for Pre-Review of NSF Major Instrumentation Applications, WSU Office of Research, 2018, 2019, 2020.

**6. Professional service off campus (continued if needed):**

Service for Peer-Reviewed Journals Editorial Board Membership:

Journal of Epithelial Biology and Pharmacology, 2007 – 2014

Breast Cancer Research and Treatment, 2010 – 2014.

Review of Manuscripts:

African Journal of Pharmacy & Pharmacology, Anti-Cancer Drugs, Apoptosis, Autophagy, Biochemical Pharmacology, Biochimica et Biophysica Acta, Biomolecules, Breast Cancer Research and Treatment, Cancer Letters, Cancer Chemotherapy & Pharmacology, Cancer Research, Cancers, Carcinogenesis, Cell Biology International, Cell Death and Disease, Cell Proliferation, Cellular and Molecular Life Sciences, Critical Reviews in Toxicology, European Journal of Surgical Research, Experimental Cell Research, Expert Opinion on Drug Discovery, Hepatology, Immunotherapy, Indian Journal of Medical Research, International Journal of Biochemistry & Cell Biology, International Journal of Cancer, International Journal of Developmental Neuroscience, Journal of Biological Chemistry, Journal of Cellular Biochemistry, Journal of Cellular Physiology, Journal of Clinical Immunology, Journal of Molecular Signaling, Journal of Neurochemistry, Journal of Pathology, Journal of Pharmacology and Experimental Therapeutics, Medical Oncology, Molecular Biology of the Cell, Molecular and Cellular Biology, Molecular Carcinogenesis, Molecular and Cellular Neuroscience, Nature Protocols, Neoplasia, Neuroscience, Oncogene, Oncotarget, PLoS One, Scientific Reports, Trends in Cell Biology.



Prepared: 20<sup>th</sup> November 2020

Signature:



## Raymond R. Mattingly

Office: Department of Pharmacology  
Wayne State University  
540 E. Canfield Ave, Room 6380  
Detroit, MI 48201

Telephone: +1 313-577-1580

Fax: +1 313-577-6739

Email: [r.mattingly@wayne.edu](mailto:r.mattingly@wayne.edu)

Internet: <https://pharmacology.med.wayne.edu/profile/ae8291>

### EDUCATION

B.A. (Hons.), Natural Sciences and Pharmacology, University of Cambridge, Cambridge, U.K., 1987

M.A., Natural Sciences and Pharmacology, University of Cambridge, Cambridge, U.K., 1991

Ph.D., Pharmacology, University of Virginia, Charlottesville, VA, 1993

### TRAINING

Technical Assistant. Prize Scholar, Churchill College, University of Cambridge. Adviser: Dr Michael R. Hanley, MRC Molecular Neurobiology Unit, Cambridge, 1987. Phorbol diester binding to neuroblastoma cells.

Graduate Research Assistant. President's Fellow, University of Virginia. Adviser: Dr Joseph Lerner, University of Virginia, 1987 – 1988. Insulin-dependent regulation of mRNA accumulation.

Ph.D. Student/Candidate. Predoctoral Fellow, Howard Hughes Medical Institute. Adviser: Dr James C. Garrison, University of Virginia, 1989 – 1992. Inositol phosphate production and metabolism in transformed cells.

Research Associate. Adviser: Dr James C. Garrison, University of Virginia, 1992 – 1993. Tyrosine phosphorylation of the G protein Gq.

Research Fellow. Fellow of the Markey Center for Molecular Genetics. Adviser: Dr Ian G. Macara, University of Vermont, 1993 – 1996. Regulation of Ras by exchange factors and GTPase-activating proteins.

Research Fellow. National Research Service Award (NRSA, F32) Fellow of the National Cancer Institute. Adviser: Dr Ian G. Macara, University of Virginia, 1997 – 1998. Integration of signal transduction through heterotrimeric and Ras-related G proteins.

**FACULTY APPOINTMENTS**

Assistant Professor, Department of Pharmacology, Wayne State University, 1998 – 2003

Associate Professor (with continuing tenure), Department of Pharmacology, Wayne State University, 2003 – 2012

Professor (with continuing tenure), Department of Pharmacology, Wayne State University, 2012 –

Professor (secondary appointment), Department of Oncology, Wayne State University, 2015 –

Department Chair, Department of Pharmacology, Wayne State University, 2016 – .

**OTHER PROFESSIONAL APPOINTMENTS**

Research Member of the Barbara Ann Karmanos Cancer Institute, 1999 –

Full Member (1999 – 2010) and Associate Leader (2002 – 2010) of the Cell Signaling and Function Research Core, EHS Center for Molecular and Cellular Toxicology with Human Applications, Detroit, Michigan

Research Member, Karmanos Cancer Institute, Program in Molecular Biology & Genetics (1999 – 2012) and Molecular Therapeutics Program (2012 – )

Graduate Officer, Department of Pharmacology, Wayne State University School of Medicine, 2001 – 2007

Faculty Member, Graduate Program in Cancer Biology, Wayne State University, 2001 –

Faculty Member, Graduate Program in Molecular & Cellular Toxicology, Wayne State University, 2001 – 2011

Co-Leader of the Program in Molecular Biology and Genetics of the Barbara Ann Karmanos Cancer Institute, 2003 – 2012

Course Director, Medical Pharmacology and Therapeutics, Wayne State University School of Medicine, 2008 – 2016

Deputy Director, Cancer Biology Training Program, Wayne State University School of Medicine, 2011 – 2016.

**MAJOR PROFESSIONAL SOCIETIES**

American Society for Pharmacology and Experimental Therapeutics

American Association for Cancer Research

Association of Medical School Pharmacology Chairs

**HONOURS AND AWARDS**

Prize Scholarships, Churchill College, Cambridge, 1985, 1986, and 1987

Double first-class honours degree (Natural Sciences and Pharmacology), University of Cambridge, 1987

Mellon Fellowship, Yale University, 1987 (declined)

President's Fellowship, University of Virginia, 1987 – 1988

Howard Hughes Medical Institute, Doctoral Fellowship, 1988 – 1993

Fellowship of the Markey Center for Molecular Genetics, University of Vermont, 1993 – 1994

National Research Service Award (F32) from the National Cancer Institute, 1994 – 1997

Faculty Development Award from the Pharmaceutical Research and Manufacturers of America Foundation, 2000 – 2002

Faculty Research Excellence Award, Wayne State University School of Medicine, 2002

Wayne State University School of Medicine Faculty Honor Roll, 2003

Scholar of the Ralph Wilson Sr. and Ralph Wilson Jr. Medical Research Foundation, 2004 – 2006

College Teaching Awards, Wayne State University School of Medicine, 2004, 2007, 2011 & 2015

Member of the Academy of Pharmacology Educators, The Division for Pharmacology Education, American Society for Pharmacology and Experimental Therapeutics, 2014 –

Eligibility for continuous submission privileges at National Institutes of Health/Center for Scientific Reviews [NIH/CSR] due to “substantial service to peer review at the National Institutes of Health”, 2016 – 2017; 2017 – 2018.

**SERVICE****Wayne State University****Departmental:**

Co-director (1998 – 1999) and Director (1999 – 2000) of the WSU Department of Pharmacology seminar series

Member, Faculty Recruitment Committee, WSU Department of Pharmacology, 1999 – 2007

Member (2000 – 2015) and Chair & Graduate Officer (2001 – 2007), Graduate Affairs Committee, WSU Department of Pharmacology

Elected Member, Faculty Salary/Merit Review Committee, WSU Department of Pharmacology, 2003 – 2007; 2010 – 2013; 2014 – 2015

Elected Member, Promotion & Tenure Committee, WSU Department of Pharmacology, 2004 – 2006; 2008 – 2011; 2011 – 2014; 2015 (Chair)

Member, Curriculum Committee, WSU Department of Pharmacology, 2008 – 2015

Member, Internal Academic Program Review Committees, WSU Department of Pharmacology, 2004 – 2005; 2013 – 2014

Member, Internal Departmental/Chair Review Committee, WSU Department of Pharmacology, 2005.

**School of Medicine:**

Member (2000 – 2009) and Chair (2005 – 2009), WSU School of Medicine Faculty Senate Library Committee

Member, WSU School of Medicine Graduate Affairs Council, 2001 – 2007

Member, WSU School of Medicine IBS 7020 curriculum committee, 2001 – 2014

Member, Basic Science Education Course Directors' Committee, WSU School of Medicine, 2008 – 2016

Member, WSU School of Medicine Faculty Senate Curriculum Committee, 2010 – 2013; re-appointed 2013 – 2016. Committee replaced by Curriculum Management Committee

Member, Steering Committee for the Cancer Biology Graduate Program, WSU School of Medicine, 2011 –

Member, Faculty Development Workgroup for Strategic Planning, WSU School of Medicine, 2011 – 2012

Co-chair, Identifying Future Scientists Workgroup for Strategic Planning, WSU School of Medicine, 2013

Member, Biomedical Science Curriculum Workgroup for Strategic Planning, WSU School of Medicine, 2013

Member, Year 2 Operations Committee, WSU School of Medicine, 2013 – 2014

Member, Best Practices Working Group for medical curriculum renewal, WSU School of Medicine, 2015 – 2016

Member, Foundations Content Curriculum Team, WSU School of Medicine, 2015 – 2016

Member, WSU School of Medicine Faculty Senate Curriculum Management Committee, 2016 –

Member (2016 – ) and Chair (2016 – 2019), Basic Science Chairs and Directors Committee, WSU School of Medicine

Member, Combined Chairs Committee, WSU School of Medicine, 2016 –

Participant, Chairs' Coaching Workshop, "Guiding Performance Discussions", WSU School of Medicine, 2016

Representative of AMSPC (Association of Medical School Pharmacology Chairs) at the AAMC/CFAS (Council of Faculty and Academic Societies) Meeting, Orlando, FL 2017

Member, Substance Use Curriculum Task Force, WSU School of Medicine, 2017 – 2019

Member, Longitudinal and Integration Sub-committee, WSU School of Medicine, 2017 –

Member, Curriculum Management Course Review Sub-committee, 2018 – ; peer reviewer of M1 Foundations Course (2019); peer reviewer of M1 Reproductive and Endocrine Systems Course (2019); peer reviewer of M2 Pediatrics Clerkship (2019)

Member, Curriculum Management Continuous Quality Improvement Team, WSU School of Medicine, 2020 – .

**University:**

Member, WSU Library Committee, 2001 – 2005

Member, WSU Radiation Safety Committee, 2003 – 2016

Member, Scholarships and Fellowships Review Panel, WSU Graduate School, 2004 & 2009

Internal Auditor, WSU Radiation Safety Program, 2008 & 2009

Member, Search Committee for Dean of the Eugene Applebaum College of Pharmacy and Health Sciences, 2014 – 2015. Successful outcome: recruitment of Dr. Serrine Lau

Member, Review Advisory Panel, for the academic program review of the WSU Biomedical Engineering graduate programs, 2015

Participant, New Chairs & Directors Training, “Problems, Remediation, Joint Work of Administration and Union”, 2016

Member, Research Working Group, Project Leapfrog: Wayne State University and Henry Ford Health System, 2018 – 2019

Member, Steering Committee for WSU IBio Faculty Recruitment Initiative, 2018 – 2020.

**Other:**

Member, Graduate Admissions Committee, WSU Cancer Biology Program, 2003 – 2006

Member, Microscopy & Imaging Resources Laboratory's Advisory committee, WSU, 2003 –

Member, Program Leadership Committee, EHS Center in Molecular and Cellular Toxicology with Human Applications, WSU, 2004 – 2009

Member, Scientific Leadership Council sub-committee on cores, Karmanos Cancer Institute, 2004

Member, Curriculum Committee of the Institute of Environmental Health Sciences, 2007 – 2011

Member, Proteomics Core Advisory Committee, Karmanos Cancer Institute, 2009 –

Member, Program Leaders' Committee, Karmanos Cancer Institute, 2010 – 2012

Member, Scientific Retreat Committee for Program Reorganization, Karmanos Cancer Institute, 2012

Member, Scientific Leadership Council, Karmanos Cancer Institute, 2012 – 2015

Member, Steering Committee for the Molecular Therapeutics Program, Karmanos Cancer Institute, 2012 – 2015

Member, Basic Sciences Faculty Recruitment Committee for the Molecular Therapeutics Program, Karmanos Cancer Institute, 2013 – 2014

Member, Internal Academic Program Review Committee, WSU Program in Cancer Biology, 2014 – 2015.

**Professional service:**

Member, Graduate Recruitment and Education Committee of the American Society for Pharmacology and Experimental Therapeutics, 2003 – 2006.

**Consulting:**

Consultant, Global Research Network (New York, NY), on open access in scholarly journal publishing, 2004

Consultant, Mylan Pharmaceuticals Inc, Morgantown, WV 2004 – 2008.

**Scholarly Service**

**Grant Review Committees**

**NIH:**

Ad hoc grant reviewer, Scientific Review Group ZHL1-CCT-B C1 (SBIR contract proposals) for the National Heart, Lung, and Blood Institute, 2003

Ad hoc member, Tumor Cell Biology study section, NIH/Center for Scientific Reviews (three meetings: 2006 – 2007)

Chartered Member, Tumor Cell Biology study section, NIH/Center for Scientific Reviews (full term: 2007 – 2011)

Member, Special Emphasis Panel/Scientific Review Group 2009/10 ZRG1 OBT-H (95) S for ARRA applications, NIH/Center for Scientific Reviews (2009)

Member, Scientific Review Groups: ZCA1 SRLB-C (J1), Cancer Biology-2 (2012); ZCA1 SRLB-C (M1), Cancer Biology-2 (2013); ZCA1 SRLB-C (O1), Cancer Biology-2 (2013); ZCA1 SRLB-C (M1), Cancer Biology-2 (2014); ZCA1 RPRB-0 (M1) P and ZCA1 SRB-C (O1) S (2015); and ZCA1 RPRB-0 (M1) P and ZCA1 SRB-C (O1) S (2015); ZCA1 SRB-C (M1) and ZCA1 SRB-C (A1) (2016) for the National Cancer Institute

Member: Pilot study of relative quality of grant applications for the NIH/Center for Scientific Reviews, 2014

Member, ZRG1 OBT-H (81)A panel for R15 applications for NIH/Center for Scientific Reviews, 2015

Member, ZRG1 F09A-D 2015-10, F09A-D 2016/01, F09A-D(20) 2016/05, F09A-D(20) 2016-10, F09A-R(20) 2017-01, F09A-R(20) 2017-05, F09A-R(20) 2017-10, F09A-R(20) 2018/01, F09A-R (20) 2018/05, F09A-R (20) 2018/10, F09A-R (20) 2019/01, F09A-R (20) 2019/05, F09A-R (20) 2019/10, ZRG1 F09A-R (20) 2020/01, ZRG1 F09A-R (20) 2020/05, ZRG1 F09A-R (20) 2020/10 Fellowships Oncology review panels for NIH/Center for Scientific Reviews.

**Other Federal Government:**

Ad hoc grant reviewer by mail, Department of Veterans Affairs, Office of External Reviews, 2002 & 2003

Ad hoc grant reviewer by mail, National Science Foundation, 2004

Regular Member, Panel NF-A, Department of Defense CDMRP Neurofibromatosis Research Program, 2003, 2005, 2009

Regular Member (online reviews), NF-Concept Panel, Department of Defense CDMRP Neurofibromatosis Research Program, 2006 & 2007

Ad hoc grant reviewer by telephone, NF-Ad-hoc Panel, Department of Defense CDMRP Neurofibromatosis Research Program, 2007

Regular Member, Panel for Organotypic Culture Models for Predictive Toxicology Centers, EPA-STAR-G2013-L1 for the Environmental Protection Agency, 2014

Regular Member, Panel CET-2/CT, Department of Defense CDMRP Neurofibromatosis Research Program, 2019

Specialist Member, Panel OCRP Pilot-1 Panel, Department of Defense CDMRP Ovarian Cancer Research Program, 2020.

**Other National and International:**

Ad hoc grant reviewer for the U.S.–Israel Binational Science Foundation, 1997, 1998, 2000, 2006

Regular Member, Komen for the Cure panel MCBG#1, 2008

Grant reviewer for the National Medical Research Council of Singapore, 2010 & 2012

Grant Reviewer, Bankhead-Coley Cancer Research Program, Florida Department of Health, 2010, 2011, 2012, 2013

Proposal Referee, NIHR (National Institute for Health Research) Evaluation, Trials and Studies Coordinating Centre (NETSCC), Medical Research Council, U.K., 2010

Scientific Panel Member for the Inaugural Newton Fund Call on Non-Communicable Diseases (NCD) for the South African Medical Research Council, 2015

Grant reviewer, National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), U.K., 2016

Grant reviewer, Medical Research Council (MRC), U.K., 2019

Grant Reviewer, Veni Talent Program, The Netherlands Organisation for Health Research and Development, 2020.

**Regional/Local:**

Grant reviewer for the Barbara Ann Karmanos Cancer Institute: 2002 Prostate Cancer Ethnic Research Competition; 2005, 2009, 2011 Strategic Research Initiatives; Molecular Therapeutics Program grants competition (2014, 2015); American Cancer Society Institutional Research Grants (2012, 2013, 2014, 2015); cancer biology T32 awardee competition (2010 – ); member

of pre-submission KCI study sections (2012 – 2014); Co-chair of pre-submission KCI study sections (2014 – 2015)

External reviewer, Henry Ford Health System, 2004, 2005

Reviewer for the Office of Vice-President for Research: pre-competition for applications to the Ralph Wilson Sr and Ralph Wilson Jr Medical Research Foundation, 2005 – 2009; Member, Internal Review Committee for Pre-Review of NSF Major Instrumentation Applications, WSU Office of Research, 2018, 2019, 2020.

### **Service for Peer-Reviewed Journals**

#### **Editorial Board Membership:**

*Journal of Epithelial Biology and Pharmacology*, 2007 – 2014

*Breast Cancer Research and Treatment*, 2010 – 2014.

#### **Review of Manuscripts:**

*African Journal of Pharmacy & Pharmacology, Anti-Cancer Drugs, Apoptosis, Autophagy, Biochemical Pharmacology, Biochimica et Biophysica Acta, Biomolecules, Breast Cancer Research and Treatment, Cancer Letters, Cancer Chemotherapy & Pharmacology, Cancer Research, Cancers, Carcinogenesis, Cell Biology International, Cell Death and Disease, Cell Proliferation, Cellular and Molecular Life Sciences, Critical Reviews in Toxicology, European Journal of Surgical Research, Experimental Cell Research, Expert Opinion on Drug Discovery, Hepatology, Immunotherapy, Indian Journal of Medical Research, International Journal of Biochemistry & Cell Biology, International Journal of Cancer, International Journal of Developmental Neuroscience, Journal of Biological Chemistry, Journal of Cellular Biochemistry, Journal of Cellular Physiology, Journal of Clinical Immunology, Journal of Molecular Signaling, Journal of Neurochemistry, Journal of Pathology, Journal of Pharmacology and Experimental Therapeutics, Medical Oncology, Molecular Biology of the Cell, Molecular and Cellular Biology, Molecular Carcinogenesis, Molecular and Cellular Neuroscience, Nature Protocols, Neoplasia, Neuroscience, Oncogene, Oncotarget, PLoS One, Scientific Reports, Trends in Cell Biology.*

### **TEACHING**

#### **Faculty Development in Education**

Stanford Faculty Development Program in Medical Education, 20 hours, 2007

Best practices in medical school curriculum visits to Case Western Reserve University and University of California - San Francisco medical schools, 2015

Case Western Reserve University, Center for the Advancement of Medical Learning, faculty workshop on case inquiry teaching, 3 hours, 2015.

#### **Years at Wayne State:**

1998 – present.



**Years at other universities:**

Tutor for autonomic, cardiovascular and renal pharmacology (1990 and 1991) for the Medical School of the University of Virginia

Lectures on the Molecular basis of cancer/Mechanisms of drug action (1997 and 1998) and Protein kinase C as a therapeutic target (1997) for the Graduate School of the University of Virginia.

**Courses taught at Wayne State:****Graduate:**

Director, Recent Developments in Pharmacology (PHC7700), 1 hour/week (Winter 1999)

Discussion Leader, Protein Targeting, 2 hours (Fall 1999), 1 hour (Fall 2018, 2019, 2020), and Transformation and Metastasis, 1 hour p.a. (Fall 2005, 2006, 2007), sections of IBS7015, formerly IBS7020

Lecturer, Signal Transduction and Cancer Therapy section of CB7240, 2 hours p.a. (Winter 2000, 2002, 2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018, 2020)

Mini-Course Director and Lecturer, Signal Transduction Targets for Cancer Therapy, PHC7650F, 13 hours (Fall 2000), 12 hours (Winter 2003), 13 hours (Fall 2005)

Lecturer, Autonomic and Cholinergic Pharmacology sections of PHC7010, 5 hours p.a. (Fall 2000, Winter 2002, 2003), 4 hours p.a. (Winter 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2012), 3 hours p.a. (Winter 2011, 2012, 2017, 2018, 2019, 2020)

Lecturer, Signal Transduction section of Cell Biology (IBS7015, formerly IBS7500, formerly IBS 7020), 5 hours (Fall 2001, 2002, 2003, 2004, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2016, 2017), 4 hours (2015, 2018, 2019, 2020)

Discussion Leader, Signal Transduction section of Cell Biology (IBS7015, formerly IBS 7020), 2 hours (Fall 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014), 1 hour (Fall 2015, 2016, 2017, 2018, 2019, 2020)

Lecturer, Protein Kinases in PHC7010, 1 hour p.a. (Winter 2002, 2003, 2004), 2 hours p.a. (Winter 2005, 2006)

Lecturer, Ras Superfamily GTPases in Cancer section of CB7090, 3 hours p.a. (Winter 2003, 2005, 2007, 2009)

Lecturer, Toxicant Effects on Signal Transduction in PHC7410/BIO7011 (formerly MTX7010), 1.5 hours (Fall 2009, 2010, 2011), 2 hours (Fall 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020)

Mini-Course Co-Director, Novel Therapeutic Approaches Targeting the Tumor Microenvironment, PHC7650B, 12 hours (Winter 2010)

Lecturer and workshop discussion leader, CB7300 F31 grant writing course, 2.5 hours (Summer 2015); discussion leader, 1.5 hours (Summer 2016, 2017, 2018)

Lecturer, Ocular and Pulmonary Pharmacology section of PHC7010, 1 hour each (Winter 2019)

Lecturer, Cardiac Pharmacology section of PHC7010, 3 hours (Winter 2019).

**Medical Students (Years I-IV):**

Lecturer, Cholinergic Pharmacology module of Year II Medical Pharmacology: 6 hours (Summer 2000); 5 hours p.a. (Winter 2000, Fall 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015); 4 hours p.a. (2016, 2017, 2018)

Course Director, Year II Medical Pharmacology (included Introductory Pharmacology in the Fall and Integrative Pharmacology in the Spring of years 2008-2010) team-taught course of ~85 hours p.a., 2008 – 2016

Course introductory lecture, review and mini-exam sessions, post-exam review sessions, Step One preparation sessions of Year II Medical Pharmacology, 8-10 hours p.a. (2008/2009, 2009/2010, 2010/2011, 2011/2012, 2012/2013, 2013/2014, 2014/2015, 2015/2016)

Pharmacovigilance/Drug Interactions module of Year II Medical Pharmacology (some topics moved to M1 year from 2018), 6 hours p.a. (2009/2010, 2010/2011, 2012/2013, 2013/2014, 2014/2015, 2015/2016), 4 hours (2011/2012); also Geriatric and Cardiovascular Pharmacology, 10 hours (2016/2017, 2017/2018, 2018/2019, 2019/2020, 2020/2021)

Moderator, self-study topic on Pharmacology of Osteoporosis (2009/2010, 2010/2011, 2011/2012, 2012/2013, 2013/2014, 2014/2015, 2015/2016, 2016/2017, 2017/2018, 2018/2019)

Content developer, self-study topic on Pharmacology of Glaucoma (2012/2013, 2013/2014, 2014/2015, 2015/2016, 2016/2017, 2017/2018, 2018/2019)

Discussion leader, Step One Preparation course for students on a delayed track, 2 hours p.a., 2012, 2013

Mentor, First Patient Project, two-year longitudinal, self-directed learning activity (2015 – 2016)

Facilitator, Problem-Based Learning for M2 students, topics from Microbiology/Infectious Disease, Musculoskeletal/Skin/Peripheral Nervous System, Gastrointestinal, Renal and Urinary, Endocrine and Reproductive, and Central Nervous System units and Pathophysiology/Cardiopulmonary units, ~9 hours (2016 – 2017, 2017 – 2018, 2018 – 2019, 2019 – 2020)

Facilitator, Problem-Based Learning for M1 students, topics from Musculoskeletal/Skin/Peripheral Nervous System, Gastrointestinal, Renal and Urinary, Endocrine and Reproductive, and Central Nervous System units, ~9 hours (2016 – 2017, 2017 – 2018, 2018 – 2019, 2019 – 2020, 2020 – 2021)

Lecturer, Pharmacology of Joint Inflammation for Musculoskeletal/Skin/Peripheral Nervous System unit of Year I medical curriculum: 2 hours (2018); 1.5 hours (2019, 2020)

Lecturer, Cholinergic Pharmacology for Musculoskeletal/Skin/Peripheral Nervous System unit of Year I medical curriculum: 3 hours (2018, 2019, 2020)

Lecturer, Pulmonary Pharmacology for Cardiovascular/Pulmonary unit of Year I medical curriculum: 1 hour (2018, 2019, 2020).

**Pharmacy Practice (Applebaum College of Pharmacy & Health Sciences):**

Lecturer, Ocular Pharmacology (1 hour, 2018, 2019, 2020) and Pulmonary Pharmacology (1 hour, 2018, 2019, 2020).

**Mentorship & Essays/theses/dissertations directed**

**Adviser for student laboratory rotation projects:**

Mugdha V. Ghole, pharmacology graduate student (1998)  
 Julie Legakis, pharmacology graduate student (1999)  
 Dr. Alina Murariu, Fulbright Awardee (1999)  
 Eric March, high school student (1999), undergraduate summer student (Michigan Technological University; 2000, 2002, 2003), and Summer Fellow of the Karmanos Cancer Institute (2001)  
 Raymond Menard, pharmacology graduate student (1999)  
 Aimee Felczak, undergraduate student (Kalamazoo College) and Summer Fellow of the Karmanos Cancer Institute (1999, 2000)  
 Michelle Milstein, pharmacology graduate student (1999)  
 Chien-Chung Chen, pharmacology graduate student (2000)  
 Desma Cooley, pharmacology graduate student (2001)  
 Jesse Moya, high school and undergraduate (Dartmouth University) student (2001 – 2002, 2004, 2006 – 7)  
 Cynthia Chang, pharmacology graduate student (2002)  
 Jeffrey Hartman, B.M.S. student (2002) pharmacology graduate student (2003)  
 Ben Szymanski, high school summer student (2002)  
 Angela Akpabio, SURE/minority program summer student (2002)  
 Andrew Jovanovski, high school and undergraduate (University of Michigan) summer student (2002, 2003, 2004, 2006)  
 Sondrayvonne Jennings-White, high school summer student (2002)  
 Heather Pulley, cancer biology graduate student (2002 – 2003)  
 Joshua Dilworth, pharmacology MD/PhD student (2003)  
 Trevor Hanly, high school summer student (2003)  
 Rosemarie Chirco, cancer biology graduate student (2003)  
 Jonathan Wojtkowiak, pharmacology graduate student (2004)  
 Jens Henrik Norum, visiting pharmacology student from University of Oslo (2004)  
 Wei Huang, pathology graduate student (2004)  
 Daniel LaLonde, high school and undergraduate (University of Michigan) summer student (2004, 2005, 2006, 2007)  
 Albert Chow, high school and undergraduate (University of Michigan) summer student (2004, 2005, 2006, 2007)  
 Komal Sane, pharmacology graduate student (2004)  
 Elizabeth Masko, cancer biology graduate student (2004)  
 Ryan Anderson, undergraduate (Wayne State University) student, IMSD (Initiative for Maximizing Student Diversity) program (2005 – 2008)  
 Nicole Najor, pharmacology graduate student (2006)  
 Hitchintan Kaur, pharmaceutical sciences graduate student (2007)  
 Eric Chow, undergraduate (University of Michigan) summer student (2008, 2009)  
 Lauren Kava, undergraduate (Northeastern University) summer student (2008)

Ivory Dean, cancer biology graduate student (2009)  
 Casey Droscha, undergraduate student (Central Michigan University) and Summer Fellow of the Karmanos Cancer Institute (2009)  
 Courtney Baracy, master's student (2009 – 2010)  
 Olivia Savalle, undergraduate (Wayne State University) student (2011 – 2012)  
 Anthony Mentz, undergraduate (Wayne State University) student (2011 – 2012)  
 Seema Shah, cancer biology graduate student (2011)  
 Ethan Brock, undergraduate student (2012)  
 Lauren Gauthier, undergraduate (Miami University, Ohio) student (2012)  
 Ryan Jackson, undergraduate (Wayne State University) student, IMSD (Initiative for Maximizing Student Diversity) program (2013 – 2017)  
 Thomas Ridella, undergraduate summer student (Notre Dame University) and Summer Fellow of the Karmanos Cancer Institute (2013, 2014)  
 Brooke Billings, undergraduate student, IMSD (Initiative for Maximizing Student Diversity) program (2015)  
 Markiesha Baines, undergraduate student, IMSD (Initiative for Maximizing Student Diversity) program (2015 – 2018)  
 Artem Berezovsky, cancer biology graduate student (2016)  
 Moises Rodriguez, undergraduate student, IMSD (Initiative for Maximizing Student Diversity) program (2016 – 2018)  
 Sasha King, undergraduate student, IMSD (Initiative for Maximizing Student Diversity) program (2018 – )  
 Favia Nixon, undergraduate student, IMSD (Initiative for Maximizing Student Diversity) program (2019 – )  
 Marjana Uddin, BCAP (biomedical career advancement program) high school student (2019)  
 Charlea Mossner, cancer biology M.S. graduate student (2019)  
 Syeda J. Islam, BCAP (biomedical career advancement program) high school student (2020)  
 Tanjina Saeed, BCAP (biomedical career advancement program) high school student (2020).

**Adviser for Basic Medical Sciences Essay (BMS 7999):**

Zachary Price (2000)  
 Jeffrey Hartman (2005)  
 Margaret Kilar (2006).

**Adviser for dissertation:**

Raymond Menard, pharmacology Ph.D. (1999 – 2003)  
 Joshua Dilworth, pharmacology Ph.D. (2003 – 2006)  
 Jonathan Wojtkowiak, pharmacology Ph.D. (2004 – 2008)  
 Komal Sane, pharmacology Ph.D. (2005 – 2010)  
 Hitchintan Kaur, pharmacology Ph.D. (2008 – 2012)  
 Seema Shah, cancer biology Ph.D. (2011 – 2016)  
 Ethan Brock, cancer biology Ph.D. (2014 – 2020).

**Co-adviser for dissertation:**

Michelle Milstein, pharmacology Ph.D. (2002 – 2007)  
 Julie Madden, Ph.D. in cancer biology (2011 – 2014).

**Adviser for M.S. thesis:**

Desma Cooley, pharmacology M.S. (2002 – 2004).

**Supervisor for postdoctoral research assistants:**

Vijay Saini, M.D. (1998 – 1999)

Gampala Harish Reddy, M.D. (2001).

**Supervisor for postdoctoral research associates:**

Huibin Yang, M.D. (2002 – 2005)

Quanwen Li, Ph.D. (2004 – 2008); Senior Research Scientist (2009 – 2013)

Chad Hancock, Ph.D. (2006 – 2008)

Janice M. Kraniak, Ph.D. (2013 – 2016); Research Assistant Professor (2016 – 2018).

**Co-supervisor for Research Scientist:**

Kyungmin Ji, Ph.D. (2019 – ).

**Thesis and Dissertation committee member:**

Ying Shao, M.S. in pharmaceutical sciences (1999)

Jiu Hong, Ph.D. in pathology (1999 – 2000)

Amy Bartrand, Ph.D. in cancer biology (2001 – 2004)

Stephanie Roshy, Ph.D. in cancer biology (2001 – 2005)

Raj Amin, Ph.D. in pharmaceutical sciences (2001 – 2003)

Mohamed A. Abdelmegeed, Ph.D. in molecular & cellular toxicology (2002 – 2005)

Frédéric Sigoillot, Ph.D. in biochemistry & molecular biology (2002 – 2005)

Chien-Chung Chen, Ph.D. in pharmacology (2002 – 2004)

Selina Glaros, Ph.D. candidate in cancer biology (2003 – 2006)

Beimeng Sun, Ph.D. in pharmacology (2003 – 2005)

Katherine Massey, Ph.D. in physiology (2004 – 2009)

Althea Elliott, Ph.D. in molecular & cellular toxicology (2004 – 8)

Jay Koepke, Ph.D. in pharmacology (2004 – 2006)

Christopher Jedeszko, Ph.D. in pharmacology (2004 – 9)

Deborah Leicht, Ph.D. in pathology (2005 – 7)

Anthony Cimini, Ph.D. candidate in pharmacology (2005 – 7)

Wei Huang, Ph.D. in pathology (2005 – 2009)

Keith Green, Ph.D. in chemistry (2005 – 2008)

Qing Zhong, Ph.D. in pharmacology (2006 – 2008)

Heather McClung, Ph.D. in pharmacology (2006 – 2011)

Bernadette Palazzolo, Ph.D. in cancer biology (2006 – 2011)

Irene Papanayotou, Ph.D. in pharmacology (2006 – 2011)

Margaret Prior, Ph.D. in pharmacology (2007 – 2010)

Mary Irwin, Ph.D. in pharmacology (2007 – 2010)

Kadija Abounit, Ph.D. in pharmacology (2007 – 2011)

Michael Price, Ph.D. in cancer biology (2008 – 2012)

Daniel Barkmeier, Ph.D. in molecular medicine and genetics and M.D./Ph.D. program (2008 – 2010)

Daochun Sun, Ph.D. in molecular medicine and genetics (2008 – 2012)  
 Kelly Haagenson, Ph.D. in cancer biology (2009 – 2013)  
 Jennifer Rothberg, Ph.D. in cancer biology (2009 – 2013)  
 Todd Faner, Ph.D. candidate in chemistry (2009)  
 Ivory Dean, Ph.D. in cancer biology (2010 – 2014)  
 Shermaine Mitchell, Ph.D. in cancer biology (2011 – 2014)  
 Sidra Ahsan, Ph.D. in cancer biology (2012 – 2015)  
 Wen Qu, Ph.D. Ph.D. in pharmacology (2013 – 2016)  
 Hao Bingqing, Ph.D. in biology (2013 – 2017)  
 Alexander Gasparski, Ph.D. in biology (2014 – 2018)  
 Sarah Dubaisi, Ph.D. in pharmacology (2015 – 2018)  
 Timothy Bryson, Ph.D. in physiology (2016 – 2019)  
 Ekta Shah, Ph.D. candidate in pharmacology (2018 – )  
 Monazza Shahab, Ph.D. candidate in pharmacology (2019 – )  
 Anindita Das, Ph.D. student in biology (2019 – ).

#### **External Examiner**

Jamie Grit, Ph.D. candidate in the Van Andel Institute Graduate School, 2020.

#### **Awards to trainees**

R.E. Menard, slot on Cancer Biology Training Grant, T32-CA09531 (11/01 – 11/03)  
 R.E. Menard, American Society for Pharmacology and Experimental Therapeutics Graduate Student Travel Award to Experimental Biology Meeting in San Diego, 2003  
 J.T. Dilworth, first place oral presentation, Wayne State University Graduate Student Research Day, 2004  
 J.W. Wojtkowiak, slot on Environmental Health Sciences Training Grant, T32-ES012163 (7/06 – 12/08)  
 K. Sane, American Society for Cell Biology Graduate Student Travel Award to annual meeting in Washington DC, 2007  
 J.W. Wojtkowiak, prize for poster presentation, Wayne State University Graduate Student Research Day, 2008  
 S. Shah, prize for poster presentation, 38th Annual Pharmacology Research Colloquium Toledo OH, 2011  
 R. Jackson, Outstanding Presentation Award at the ABRCMS (Annual Biomedical Research Conference for Minority Students) in Nashville TN, 2013  
 T. Ridella, prize for poster presentation, 3rd Annual Joint Summer Research Mini Symposium hosted by Wayne State University Office of Vice-President for Research, 2014  
 R. Jackson, first place award for oral presentation, 3rd Annual Joint Summer Research Mini Symposium hosted by Wayne State University Office of Vice-President for Research, 2014  
 E. Brock, slot on Cancer Biology Training Grant, T32-CA09531 (2015 – 2017)

R. Jackson, second place award for oral presentation, 4th Annual Joint Summer Research Mini Symposium hosted by Wayne State University Office of Vice-President for Research, 2015

R. Jackson, third place award for oral presentation, 5th Annual Joint Summer Research Mini Symposium hosted by Wayne State University Office of Vice-President for Research, 2016

E. Brock, NCI individual predoctoral fellowship F31 CA213807, "Sprouty4 is a negative regulator of ERK/MAPK signaling in breast cancer and plays a role in the transition from in situ to invasive disease", 9/1/17 – 8/31/20, \$122,886 total costs awarded

E. Brock, first place award for oral presentation at the WSU Cancer Biology Graduate Program's annual research symposium, 2018

J.M. Kraniak, Ph.D., Research Assistant Professor of Pharmacology, pharmaceutical company research award: "High throughput screening in 3-dimensional culture using NF1 plexiform neurofibroma cells", 2/1/08 – 10/31/08, \$27,449 total costs awarded.

### **Course or curriculum development**

Developed and delivered new mini-course: Signal Transduction Targets for Cancer Therapy, PHC7650F, 13 hours (Fall 2000, Winter 2003, Fall 2005)

Peer reviewer, Medical Pharmacology course, Wayne State University, 9 hours (2007 – 2008), 1 hour (2012), 1 hour (2013), 3 hours (2014)

Peer observer, Medical Psychiatry course, Wayne State University, 2 hours (2009)

Development of Medical Pharmacology Step1 Review material for Yr-II class, 4 hours (2009 – 2013)

Developed and co-delivered new mini-course: Novel Therapeutic Approaches Targeting the Tumor Microenvironment, PHC7650B, 12 hours (Winter 2010)

Development of Medical Pharmacology Step1 Review material for students on a delayed track, 2 hours (2012 – 2013).

### **GRANT SUPPORT**

#### **Active Grants**

NF Michigan/Walk for NF. P.I.: Raymond R. Mattingly. Philanthropic support to develop new therapeutic approaches for tumors that occur in NF1 patients. 1/1/17 – 12/31/20. \$83,500 total costs awarded.

NTAP (Neurofibromatosis Therapeutic Acceleration Program). P.I.: Raymond R. Mattingly. Title: Deconstruction and Reconstitution of NF1 Cutaneous Neurofibromas. 5/1/18 – 4/30/22. \$393,470 total costs awarded.

1 R01 ES029484. PI: A.J. Rosenspire (R.R. Mattingly is Co-I). Title: Understanding the connection between exposure to mercury, autoimmunity and tolerance in B cells. 9/1/2018 – 8/31/2023. \$2,742,834 total costs requested.

**Previously Funded Grants**

Howard Hughes Medical Institute, Doctoral Fellowship. P.I.: Raymond R. Mattingly. 1988 – 1993. \$121,500 total costs awarded.

National Research Service Award from the National Cancer Institute, F32-CA63793. P.I.: Raymond R. Mattingly. Sponsor: Dr Ian G. Macara. Title: Oncogenic signal transduction and the Ras-GAP SH3 domain. 1994 – 1997. \$80,400 total direct costs.

American Cancer Society Institutional Research Grant, IN-162. P.I.: Raymond R. Mattingly. Title: Regulation of the Ras-GRF exchange factor by phosphorylation. 7/98 – 7/99. \$20,000 total direct costs.

PhRMA Foundation, Research Starter Grant. P.I.: Raymond R. Mattingly. Title: Regulation of Ras through the Ras-GRF exchange factor. 1/1/99 – 12/31/00. \$25,000 total direct costs.

Parke-Davis and Pfizer Inc., Atorvastatin Research Award. P.I.: Raymond R. Mattingly. Title: Prenylation of Rho proteins in skeletal and vascular smooth muscle: A double-edged sword in the action of statins? 1/7/99 – 6/30/01. \$100,000 total costs awarded.

WSU Internal Medicine, Seed Grant. P.I.: Noreen F. Rossi (R.R. Mattingly, co-investigator). Title: Na,K-ATPase Stimulation by Angiotensin II. 1/1/00 – 12/31/00. \$25,000 total direct costs.

PhRMA Foundation, Faculty Development Award. P.I.: Raymond R. Mattingly. Title: Regulation of Ras through the Ras-GRF exchange factor. 7/1/00 – 3/31/01. \$30,000 annual direct costs originally awarded for 2 years, but further support terminated early due to overlap with R01 CA81150.

National Kidney Foundation of Michigan. P.I.: Douglas R. Yingst (R.R. Mattingly co-investigator). Title: Regulation of Na,K-ATPase by Angiotensin II. 7/1/00 – 6/30/01. \$29,659 total costs awarded.

Wayne State University. P.I.: Raymond R. Mattingly. Competitive Graduate Research Assistantship (Student: R.E. Menard). 9/1/00 – 8/31/01. \$21,500 total costs awarded.

CDMRP US Army Neurofibromatosis Research Program, New Investigator Award. P.I.: Raymond R. Mattingly. Title: Signal Transduction Targets for Pharmacological Intervention in Type 1 Neurofibromatosis. 10/1/00 – 9/30/03. \$285,300 total costs awarded.

NIH R01 CA81150. P.I.: Raymond R. Mattingly. Title: Regulation of Ras through the Ras-GRF exchange factor. 4/1/01 – 3/31/07. \$1,016,827 total costs awarded.

NIH P30 ES06639. P.I.: R.F. Novak, then M. Runge-Morris (R.R. Mattingly was co-investigator as Associate Leader of the Cell Signaling and Function Research Core). Title: Molecular and cellular toxicology with human applications. 4/1/01 – 3/31/10. \$11,803,559 total costs requested.

National Kidney Foundation of Michigan. P.I.: Douglas R. Yingst (R.R. Mattingly co-investigator). Title: Regulation of Na,K-ATPase by Angiotensin II, Role of Sodium and Calcium in Intact Proximal Tubules. 07/1/01 – 06/30/02. \$29,575 total direct costs awarded.

NIH P30 CA22453-22/23. P.I.: J.D. Crissman, then J.C. Ruckdeschel (R.R. Mattingly was co-investigator as Co-Leader of the Program in Molecular Biology and Human Genetics from 2003). Title: Cancer Center Support Grant. 12/1/00 – 3/31/05. \$3,460,570 total costs awarded.



NIH R01 ES011000. P.I.: Allen J. Rosenspire (R.R. Mattingly, co-investigator). Title: Disruption of lymphocyte signal transduction by Hg<sup>2+</sup>. 2/19/02 – 11/30/06. \$1,338,375 total costs awarded.

NIH Shared Instrumentation Grant, 1S10RR016771-01. P.I.: Christine Chow (R.R. Mattingly was 1 of 6 major users). Title: Purchase of a MALDI-TOF Mass Spectrometer. 4/1/02 – 3/31/03. \$259,800 total direct costs awarded.

NIH R01 DK60752. P.I.: Douglas R. Yingst (R.R. Mattingly co-investigator). Title: Mechanisms of Renal Na<sup>+</sup> Pump Stimulation by Angiotensin. 7/1/02 – 4/30/07. \$914,750 total costs awarded.

American Diabetes Association Research Award. P.I.: A. Kowluru (R.R. Mattingly co-investigator). Title: Novel regulation by Ras of IL 1-mediated Beta cell dysfunction and demise. 1/1/03 – 12/31/05. \$299,860 total costs awarded.

CDMRP US Army Neurofibromatosis Research Program, Idea Award. P.I.: Raymond R. Mattingly. Title: Therapeutic Approaches to the N-Ras Pathway in Type I Neurofibromatosis. 5/1/03 – 4/30/07. \$637,586 total costs awarded.

Wayne State University. P.I.: Raymond R. Mattingly. Competitive Graduate Research Assistantship (Student: J.T. Dilworth). 9/1/03 – 8/31/04. \$28,000 total costs awarded.

Ralph C. Wilson, Sr. and Ralph C. Wilson, Jr. Medical Research Foundation, Research Grant for Discovery in the Biomedical Sciences. P.I.: Raymond R. Mattingly. Title: Modeling the early stages of breast cancer: Assessing the roles of PAK1 in mammary epithelial hyperplasia through functional imaging. 2/1/04 – 1/31/06. \$200,000 total costs awarded.

NIH P30 CA22453-24/28. P.I.: J. Ruckdeschel, then G. Bepler (R.R. Mattingly was co-investigator as Co-Leader of the Program in Molecular Biology and Human Genetics). Title: Cancer Center Support Grant. 12/1/04 – 11/30/10. \$12,098,544 total costs awarded.

CDMRP US Army Neurofibromatosis Research Program, Concept Award. P.I.: Raymond R. Mattingly. Title: Does subcellular relocalization control neurofibromin function? 6/15/05 – 6/14/07. \$100,000 total costs awarded.

Susan G. Komen Foundation, Research Grant. PI: Raymond R. Mattingly. Title: Control of mammary epithelial hyperplasia and malignant progression by p21-activated kinase 1 (PAK1). 5/1/06 – 10/31/08. \$250,000 total costs awarded.

Karmanos Cancer Institute Strategic Research Initiative Grant. PI: Bonnie F. Sloane (R.R. Mattingly Co-I). Title: Working toward therapies that target the tumor and its microenvironment. 5/1/07 – 4/30/08. \$100,000 total direct costs awarded.

EHS Center/Autism Center of Excellence Pilot Grant. PI: Raymond R. Mattingly. Title: Aberrant control of dendritic morphogenesis by Rho proteins. 4/1/08 – 3/31/09. \$33,000 total direct costs awarded.

NIH 1R01 CA131990. P.I.: Raymond R. Mattingly; Bonnie F. Sloane (multi-PI). Title: Proteolytic Pathways in Progression of Pre-Malignant Breast Disease. 8/1/08 – 5/31/14. \$1,571,165 total costs awarded.

Wayne State University. P.I.: Raymond R. Mattingly. Competitive Graduate Research Assistantship (Student: K. Sane). 9/1/08 – 8/31/09. \$28,000 total costs awarded.

## Raymond R. Mattingly, Page 18

Karmanos Cancer Institute Strategic Research Initiative Grant. P.I.: Raymond R. Mattingly (N. Davis, Co-PI). Title: The Cancer Palmitoyl Proteome. 7/1/09 – 6/30/10. \$25,000 total direct costs awarded.

CDMRP US Army Neurofibromatosis Research Program, Exploration-Hypothesis Development Award, NF093146. P.I.: Raymond R. Mattingly. Title: Targeting insulin-like growth factor-1 receptor (IGF-1R) as a new approach to NF1 malignant tumors. 3/15/10 – 3/14/13. \$152,000 total costs awarded.

Wayne State University. P.I.: Raymond R. Mattingly. Competitive Graduate Research Assistantship (Student: H. Kaur). 9/1/10 – 8/31/11. \$28,000 total costs awarded.

Philanthropic Support from the Gilbert Family for Research on NF1 (Type 1 Neurofibromatosis). P.I.: Raymond R. Mattingly. 10/1/11 – 12/31/14. \$147,408 total costs awarded.

NIH P30 CA22453-29/33. P.I.: G. Bepler (R.R. Mattingly was co-investigator as Co-Leader of the Program in Molecular Biology and Human Genetics from 2003 – 2012). Title: Cancer Center Support Grant. 12/1/11 – 11/30/15. \$12,992,605 total costs awarded.

NIH T32-CA009531-26/30. P.I.: Larry H. Matherly (R.R. Mattingly was a no-cost Co-I as Deputy Director). Training Program in the Biology of Cancer. 09/1/12 – 08/31/17. \$1,407,780 total costs requested.

NTAP (Neurofibromatosis Therapeutic Acceleration Program). P.I.: Raymond R. Mattingly. Title: Plexiform Neurofibroma Model Systems for Preclinical Drug Screening. 5/1/13 – 4/30/16. \$330,000 total costs awarded.

WSU Office of the Vice-President for Research, Nano Incubator Program. P.I.'s: H. Sundararaghavan & R.R. Mattingly. Title: Using nanofibers to develop the first organotypic model of plexiform neurofibroma. 10/1/13 – 9/30/14. \$35,000 total direct costs.

Karmanos Cancer Institute Molecular Therapeutics Program, Short-term Funding Program. P.I.: Raymond R. Mattingly. Title: Potential Resistance to MEK Inhibitors in Type 1 Neurofibromatosis (NF1). 5/1/14 – 9/30/14. \$25,000 total direct costs awarded.

Karmanos Cancer Institute Molecular Therapeutics Program Grant. P.I.: Raymond R. Mattingly; co-P.I.: Julie L. Boerner. Title: Development of Sprouty4 as a Potential Biomarker to Indicate MEK Inhibitor Sensitivity to Reduce Recurrence in Aggressive vs. Indolent Breast Ductal Carcinoma *in Situ*. 3/1/15 – 6/30/16. \$23,330 total costs awarded.

NTAP (Neurofibromatosis Therapeutic Acceleration Program). P.I.: Raymond R. Mattingly. Title: Transition to confirmatory and secondary screening of plexiform neurofibroma models in 96-well format. 8/1/15 – 10/31/16. \$41,811 total costs awarded.

Wayne State University. P.I.: Raymond R. Mattingly. Competitive Graduate Research Assistantship (Student: S. Shah). 9/1/15 – 8/31/16. \$28,000 total costs awarded.

Wayne State University. P.I.: Raymond R. Mattingly. Grants Boost Award: Sprouty4 to Guide Potential Treatment Decisions for Aggressive Versus Indolent DCIS. 10/1/15 – 4/1/17. \$35,000 total costs awarded.

Michigan Corporate Relations Network [MCRN] Small Company Innovation Program/Technology and Commercialization Assistance [SCIP/TCA program]. P.I.: Raymond R.

Mattingly. Academic-Industrial Partnership with Life Magnetics, Inc.. 8/1/16 – 10/31/17. \$80,000 total costs awarded.

National Institutes of Health, National Cancer Institute, F31 CA213807. P.I.: Brock. (R.R. Mattingly mentor). Title: Sprouty4 is a negative regulator of ERK/MAPK signaling in breast cancer and plays a role in the transition from in situ to invasive disease. 9/1/17 – 8/31/20. \$122,886 total costs awarded.

National Institutes of Health, National Institute for Environmental Health Sciences, R56 ES027500. P.I.: Rosenspire (R.R. Mattingly Co-I). Title: Understanding the connection between exposure to mercury, auto-immunity and tolerance in B cells. 9/30/17 – 8/31/18. \$192,500 total costs awarded.

National Science Foundation to Life Magnetics, Inc.. Title: Highly Selective and Rapid Separation of RNA to Reduce Medical Diagnostic Costs. Sub-contract award, P.I.: Raymond R. Mattingly. 1/1/18 – 7/1/18. \$22,414 total costs awarded (sub-contract only)

CDMRP US Army Neurofibromatosis Research Program, New Investigator Award. P.I.: H. Sundararaghavan (R.R. Mattingly Co-I). Title: An Engineered Co-culture System for NF1 Neurofibromas. 5/1/16 – 4/30/20. \$665,726 total costs awarded.

Astellas Pharmaceuticals, Inc.. P.I.: Raymond R. Mattingly. The in vitro experiments for ASP6432 using NF1 related cells. 2/1/19 – 8/31/20. \$49,895 total costs awarded.

## BIBLIOGRAPHY [\*indicates co-author who is a student/trainee]

### Original observations in refereed journals

1. **R.R. Mattingly**, M.L. Dreher & M.R. Hanley. Down-regulation of phorbol diester binding to NG115-401L neuronal cells is dependent on structure, concentration and time. *FEBS Lett.*, 223:11-14 (1987)
2. R.M. Johnson, W.J. Wasilenko, **R.R. Mattingly**, M.J. Weber & J.C. Garrison. Fibroblasts transformed with *v-src* show enhanced formation of an inositol tetrakisphosphate. *Science*, 246:121-124 (1989)
3. **R.R. Mattingly**, L.R. Stephens, R.F. Irvine & J.C. Garrison. Effects of transformation with the *v-src* oncogene on inositol phosphate metabolism in Rat-1 fibroblasts: increased D-*myo*-inositol 1,4,5,6-tetrakisphosphate and synthesis from D-*myo*-inositol 1,3,4-trisphosphate. *J. Biol. Chem.*, 266: 15144-15153 (1991)
4. **R.R. Mattingly** & J.C. Garrison. Okadaic acid inhibits angiotensin II stimulation of Ins(1,4,5)P<sub>3</sub> and calcium signalling in rat hepatocytes. *FEBS Lett.*, 296:225-230 (1992)
5. **R.R. Mattingly**, W.J. Wasilenko, P.J. Woodring\* & J.C. Garrison. Selective amplification of endothelin-stimulated inositol 1,4,5-trisphosphate and calcium signalling by *v-src* transformation of Rat-1 fibroblasts. *J. Biol. Chem.*, 267:7470-7477 (1992)
6. **R.R. Mattingly**, A. Sorisky, M.R. Brann & I.G. Macara. Muscarinic receptors transform NIH-3T3 cells through a Ras-dependent signalling pathway inhibited by the Ras-GAP SH3 domain. *Mol. Cell. Biol.*, 14:7943-7952 (1994)

7. D.J. Wilson\*, K.A. Fortner\*, D.H. Lynch, **R.R. Mattingly**, I.G. Macara, J.A. Posada & R.C. Budd. Jun kinase, but not MAP kinase, activation is associated with Fas-mediated apoptosis in Human T cells. *Eur. J. Immunol.*, 26:989-994 (1996)
8. W.W. Liu\*, **R.R. Mattingly** & J.C. Garrison. Transformation of Rat-1 fibroblasts with the *v-src* oncogene increases the tyrosine phosphorylation state and activity of the  $\alpha$  subunit of Gq/G11. *Proc. Natl. Acad. Sci. USA.*, 93:8258-8263 (1996)
9. **R.R. Mattingly** & I.G. Macara. Phosphorylation-dependent activation of the Ras-GRF/CDC25<sup>Mm</sup> exchange factor by muscarinic receptors and G protein  $\beta\gamma$  subunits. *Nature*, 382:268-272 (1996)
10. **R.R. Mattingly**, V. Saini\* & I.G. Macara. Activation of the Ras-GRF/CDC25<sup>Mm</sup> exchange factor by lysophosphatidic acid. *Cell. Signal.*, 11:603-610 (1999)
11. **R.R. Mattingly**. Phosphorylation of Serine-916 of Ras-GRF1 contributes to the activation of exchange factor activity by muscarinic receptors. *J. Biol. Chem.* 274:37379-37384 (1999)
12. **R.R. Mattingly**, M.A. Milstein\* & B.L. Mirkin. Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. *Cell. Signal.* 13: 499-505 (2001)
13. **R.R. Mattingly**, A. Felczak\*, C.-C. Chen\*, M.J. McCabe Jr & A. Rosenspire. Low concentrations of inorganic mercury inhibit Ras activation during TCR mediated signal transduction. *Toxicol. Appl. Pharmacol.* 176: 162-168 (2001) [cover illustration]
14. S. Beqaj\*, S. Jakkaraju, **R.R. Mattingly**, D. Pan & L. Schuger. High RhoA activity maintains the undifferentiated mesenchymal phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis. *J. Cell Biol.* 156: 893-903 (2002)
15. V.G. Keshamouni\*, **R.R. Mattingly** & K.B. Reddy. Mechanism of 17- $\beta$ -estradiol-induced ERK1/2 activation in breast cancer cells: A role for HER2 and PKC- $\delta$ . *J. Biol. Chem.* 277: 22558-22565 (2002)
16. **R.R. Mattingly**, R.A. Gibbs, R.E. Menard\* & J.J. Reiners Jr.. Potent suppression of the proliferation of A10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase. *J. Pharmacol. Exp. Ther.* 303: 74 - 81 (2002)
17. H. Yang\*, D. Cooley\*, Q. Ge, R. Andrade & **R.R. Mattingly**. Phosphorylation of the Ras-GRF1 exchange factor at Serine-916/898 reveals activation of Ras signaling in the cerebral cortex. *J. Biol. Chem.* 278: 13278-13285 (2003)
18. R.E. Menard\* & **R.R. Mattingly**. Cell surface receptors activate p21-activated protein kinase I (PAK1) via multiple Ras and PI3-kinase-dependent pathways. *Cell. Signal.* 15: 1099-1109 (2003)
19. R.E. Menard\* & **R.R. Mattingly**. Gbetagamma subunits stimulate p21-activated kinase I (PAK1) through activation of PI3-kinase and Akt but act independently of Rac1/Cdc42. *FEBS Lett.* 556: 187-192 (2004)

20. D.P. Chopra, R.E. Menard\*, J. Januszewski\* & **R.R. Mattingly**. TNF-alpha mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. *Cancer Lett.* 203: 145-154 (2004)
21. D.R. Yingst, K.J. Massey\*, N.F. Rossi, M.J. Mohanty & **R.R. Mattingly**. Angiotensin II directly stimulates activity and alters phosphorylation of Na,K-ATPase in rat proximal tubule with a rapid time course. *Am. J. Physiol.* 287: F713-F721 (2004)
22. J.H. Norum\*, T. Methi, **R.R. Mattingly** & F.O. Levy. Endogenous expression and PKA-dependent phosphorylation of the guanine nucleotide exchange factor Ras-GRF1 in HEK293 cells. *FEBS J.* (formerly *Eur. J. Biochem.*) 272: 2304-2316 (2005)
23. R.E. Menard\*, A. Jovanovski\* & **R.R. Mattingly**. Active p21-activated protein kinase I (PAKI) rescues MCF10A breast epithelial cells from undergoing anoikis. *Neoplasia* 7: 638-645 (2005)
24. **R.R. Mattingly**, J.A. Kraniak, J.T. Dilworth\*, P. Mathieu, B. Bealmeare, J.E. Nowak, J.A. Benjamins, M.A. Tainsky & J.J. Reiners, Jr. The MEK inhibitor PD184352/CI-1040 selectively induces apoptosis in malignant schwannoma cell lines. *J. Pharmacol. Exp. Ther.* 316: 456-465 (2006)
25. S.E. Ziemba, **R.R. Mattingly**, M.J. McCabe Jr & A.J. Rosenspire. Inorganic mercury inhibits the activation of LAT in T cell receptor-mediated signal transduction. *Toxicol. Sci.* 89: 145-153 (2006)
26. H. Yang\* & **R.R. Mattingly**. The Ras-GRF1 exchange factor coordinates activation of H-Ras and Rac1 to control neuronal morphology. *Mol. Biol. Cell* 17: 2177-2189 (2006)
27. J.H. Norum\*, H. Dawood, **R.R. Mattingly**, D. Sandnes & F.O. Levy. Epac- and Rap-independent ERK1/2 phosphorylation mediated through Gs-coupled serotonin receptors in HEK293 cells. *FEBS Lett.* 581: 15-20 (2007)
28. M.K. Clark\*, S.A. Reigard\*, J. Wojtkowiak\*, R. Chirco\*, P. Mathieu, J.J. Reiners Jr, **R.R. Mattingly**, R.F. Borch & R.A. Gibbs. Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. *J. Med. Chem.* 50: 3274-3282 (2007)
29. M.J. McCabe Jr, M.D. Laiosa, L. Li, S.L. Menard, **R.R. Mattingly** & A.J. Rosenspire. Low and non-toxic inorganic mercury burdens attenuate BCR-mediated signal transduction. *Toxicol. Sci.*, 99: 512-521 (2007)
30. D.R. Yingst, T.M. Doci\*, K. Massey\*, N.F. Rossi, E. Rucker\* & **R.R. Mattingly**. Angiotensin II Stimulates Elution of Na,K-ATPase from a Digoxin-affinity Column by Increasing the Kinetic Response to Ligands that Trigger the Decay of E2-P. *Am. J. Physiol. Renal* 294: F990-F1000 (2008)
31. Q. Li\*, S. Roshy-Mullins\*, B.F. Sloane & **R.R. Mattingly**. p21-activated Kinase 1 Coordinates Aberrant Cell Survival and Pericellular Proteolysis in a Three-dimensional

- Culture Model for Pre-malignant Progression of Human Breast Cancer. *Neoplasia* 10: 314-328 (2008)
32. J.W. Wojtkowiak\*, F. Fouad\*, D.T. LaLonde\*, R.A. Gibbs, J.J. Reiners Jr, R.F. Borch & **R.R. Mattingly**. Induction of apoptosis in Neurofibromatosis Type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. *J. Pharmacol. Exp. Ther.* 326: 1-11 (2008) [cover illustration]
  33. J.T. Dilworth\*, J.W. Wojtkowiak\*, P. Mathieu, M.A. Tainsky, J.J. Reiners Jr, **R.R. Mattingly** & C.N. Hancock\*. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. *Cancer Biol. Ther.* 7: 1938-1946 (2008)
  34. Q. Li\* & **R.R. Mattingly**. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. *Neoplasia* 10: 1444-1458 (2008)
  35. D.R. Yingst, A. Araghi, T.M. Doci\*, **R.R. Mattingly** & W.H. Beierwaltes. Decreased renal perfusion rapidly increases plasma membrane Na-K-ATPase in rat cortex by an angiotensin II-dependent mechanism. *Am. J. Physiol. Renal* 297: F1324-F1329 (2009)
  36. Q. Li\*, A.B. Chow\* & **R.R. Mattingly**. Three-dimensional (3D) overlay culture models of human breast cancer reveal a critical sensitivity to MEK inhibitors. *J. Pharmacol. Exp. Ther.* 332: 821-828 (2010)
  37. K.M. Sane\*, M. Maynor\*, D.T. LaLonde\*, I.S. Dean\*, J.W. Wojtkowiak\*, F. Fouad\*, R.F. Borch, J.J. Reiners Jr., R.A. Gibbs & **R.R. Mattingly**. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. *J. Pharmacol. Exp. Ther.* 333: 23-33 (2010)
  38. J.M. Kraniak, D. Sun\*, **R.R. Mattingly**, J.J. Reiners Jr. & M.A. Tainsky. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. *Mol. Cell. Biochem.* 344: 267-276 (2010)
  39. J.W. Wojtkowiak\*, K.M. Sane\*, M. Kleinman\*, B.F. Sloane, J.J. Reiners Jr. & **R.R. Mattingly**. Aborted autophagy and non-apoptotic death induced by farnesyl transferase inhibitor and lovastatin. *J. Pharmacol. Exp. Ther.* 337: 65-74 (2011)
  40. L. Kava\*, N.F. Rossi, A.B. Chow\*, **R.R. Mattingly** & D.R. Yingst. Increased expression of Na,K-ATPase and a selective increase in phosphorylation at Ser-11 in the cortex of the 2-kidney, 1-clip hypertensive rat. *Am. J. Hypertens.* 25: 487-491 (2012)
  41. K.J. Massey\*, Q. Li\*, N.F. Rossi, **R.R. Mattingly** & D.R. Yingst. Angiotensin II-dependent phosphorylation at Ser-11/Ser-18 and Ser-938 shift the E2 conformations of rat kidney Na,K-ATPase. *Biochem J.* 443: 249-258 (2012)
  42. H. Kaur\*, S. Mao, Q. Li\*, M. Sameni, S.A. Krawetz, B.F. Sloane & **R.R. Mattingly**. RNA-seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. *PLOS One*, <http://dx.plos.org/10.1371/journal.pone.0050249> (2012)

43. A. Hammer, L. Rider, P. Oladimeji, L. Cook, Q. Li\*, **R.R. Mattingly** & M. Diakonova. Tyrosyl phosphorylated PAK1 regulates cell motility in response to prolactin through filamin A. *Mol. Endocrinol.* 27: 455-465 (2013)
44. H. Martin, R.S. Mali, P. Ma, A. Chatterjee, B. Ramdas, E. Sims, V. Munugalavadla, J. Ghosh, **R.R. Mattingly**, V. Visconte, R.V. Tiu, C.P. Vlaar, S. Dharmawardhane & R. Kapur. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. *J. Clin. Invest.* 123: 4449-4463 (2013)
45. J.M. Rothberg\*, K.M. Bailey, J.W. Wojtkowiak, Y. Bennun, M. Bogyo, E. Weber, K. Moin, G. Blum, **R.R. Mattingly**, R.J. Gillies & B.F. Sloane. Acid-Mediated Tumor Proteolysis: Contribution of Cysteine Cathepsins. *Neoplasia* 15: 1125-1137 (2013)
46. J.M. Madden\*, K.L. Mueller, A. Bollig-Fischer, P. Stemmer, **R.R. Mattingly** & J.L. Boerner. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. *Breast Cancer Res. Treat.* 147: 283-293 (2014)
47. K.O. Osuala\*, M. Sameni, S. Shah\*, N. Aggarwal\*, M.L. Simonait, O.E. Franco, Y. Hong, S.W. Hayward, F. Behbod, **R.R. Mattingly** & B.F. Sloane. IL-6 signaling between ductal carcinoma in situ cells and cancer-associated fibroblasts mediates tumor cell growth and migration. *BMC Cancer* 15: 584 DOI: 10.1186/s12885-015-1576-3 (2015)
48. K.J. Massey\*, Q. Li\*, N.F. Rossi, S.M. Keezer, **R.R. Mattingly** & D.R. Yingst. Phosphorylation of Rat Kidney Na, K-pump at Ser-938 Required for Rapid Angiotensin II-dependent Stimulation of Activity and Trafficking in Proximal Tubule Cells. *Am. J. Physiol.* 310: C227-C232 (2016)
49. M. Sameni, D. Cavallo-Medved, O.E. Franco, A. Chalasani, K. Ji\*, A. Anbalagan, X. Chen, **R.R. Mattingly**, S.W. Hayward, B.F. Sloane. Pathomimetic Avatars Reveal Divergent Roles of Microenvironment in Invasive Transition of Ductal Carcinoma in Situ. *Breast Cancer Res.* 19: 56 doi: 10.1186/s13058-017-0847-0 (2017)
50. J.M. Kraniak, A. Chalasani, M.R. Wallace, **R.R. Mattingly**. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. *Exp Neurol.* 2018 Jan;299(Pt B):289-298. PMID: 29055717
51. S. Shah\*, E.J. Brock\*, R.M. Jackson\*, K. Ji\*, J.L. Boerner, B.F. Sloane, **R.R. Mattingly**. Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. *Neoplasia* Sep;20(9):951-963. doi: 10.1016/j.neo.2018.07.002 (2018). PMID: 30144784.

#### Review articles

52. **R.R. Mattingly**. Signalling through small GTPases. *In Vitro Mol. Toxicol.*, 11:57-62 (1998)
53. J.T. Dilworth\*, J.M. Kraniak, J.W. Wojtkowiak\*, R.A. Gibbs, R.F. Borch, M.A. Tainsky, J.J. Reiners Jr & **R.R. Mattingly**. Molecular targets for emerging anti-tumor therapies for Neurofibromatosis Type 1. *Biochem. Pharmacol.* 72: 1485-1492 (2006)
54. J.W. Wojtkowiak\*, R.A. Gibbs & **R.R. Mattingly**. Working together: Farnesyl transferase inhibitors and statins block protein prenylation. *Mol. Cell. Pharmacol.* 1: 1-6 (2009)

55. M. Sameni, A. Anbalagan, M.B. Olive, K. Moin, **R.R. Mattingly** & B.F. Sloane. MAME Models for 4D Live-cell Imaging of Tumor:Microenvironment Interactions That Impact Malignant Progression. *Journal of Visualized Experiments* pii: 3661. Doi: 10.3791/3661 (2012)
56. H. Kaur\*, S. Mao, S. Shah\*, D.H. Gorski, S.A. Krawetz, B.F. Sloane & **R.R. Mattingly**. Next-generation sequencing: a revolutionary tool for the discovery of molecular markers in breast ductal carcinoma *in situ*. *Exp. Rev. Mol. Diagnos.* 13: 151-165 (2013)
57. **R.R. Mattingly**. Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. *ISRN Oncol.* Doi: 10.1155/2013/536529 (2013)
58. E.J. Brock\*, K. Ji\*, J.J. Reiners Jr. & **R.R. Mattingly**. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization. *Mini-Rev. Med. Chem.* 16(5): 358-369 (2016)
59. E.J. Brock\*, K. Ji\*, S. Shah\*, **R.R. Mattingly**, B.F. Sloane. In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ. *J Mammary Gland Biol Neoplasia.* 2018 Jul 28. doi: 10.1007/s10911-018-9405-3 (2018)
60. S. Shah\*, E.J. Brock\*, K. Ji\*, **R.R. Mattingly**. Ras and Rap1: A tale of two GTPases. *Semin Cancer Biol.* 54: 29-39. doi: 10.1016/j.semcancer.2018.03.005 (2019). PMID: 29621614
61. K. Ji\*, M. Sameni, K. Osuala\*, K. Moin, **R.R. Mattingly** & B.F. Sloane. Spatio-temporal Modeling and Live-cell Imaging of Proteolysis in the 4-D Microenvironment of Breast Cancer. *Cancer Metastasis Reviews* 38: 445-454 (2019). doi: 10.1007/s10555-019-09810-8.

#### Books and chapters

62. **R.R. Mattingly**. Mitogen-activated protein kinase signaling in drug-resistant neuroblastoma cells. In *Cancer Cell Signaling: Methods and Protocols*, D.M. Terrian, Ed., Humana Press, 218: 71-83 (2003)
63. K. Moin, M. Sameni, C. Jedeszko\*, Q. Li\*, M.B. Olive, **R.R. Mattingly**, & B.F. Sloane. Images of Cleavage: Tumor Proteases in Action. In: *The Cancer Degradome—Proteases and Cancer Biology*. D.R. Edwards, G.F. Hoyer-Hansen, F. Blansi & B.F. Sloane eds., Springer, New York, pp. 137-154 (2008)
64. K. Moin, M. Sameni, B.C. Victor\*, J.M. Rothberg\*, **R.R. Mattingly** & B.F. Sloane. 3D/4D functional imaging of tumor-associated proteolysis: Impact of microenvironment. *Meth. Enzymol.* 506: 175-194 (2012)
65. J.M. Kraniak, **R.R. Mattingly** & B.F. Sloane. Roles of pericellular proteases in tumor angiogenesis: therapeutic implications. Ch. 14 in *Extracellular Targeting of Cell Signaling in Cancer: Strategies Directed at MET and RON Receptor Tyrosine Kinase Pathways*. James W. Janetka (Editor), Roseann M. Benson (Editor), ISBN: 978-1-119-30018-2 (2018)
66. K.O. Osuala\*, K. Ji\*, **R.R. Mattingly** & B.F. Sloane. Breast Cancer: Proteolysis and Migration. Ch. 21 in *Breast Cancer Metastasis and Drug Resistance*. A. Ahmad (Editor), Springer Nature Switzerland AG. *Advances in Experimental Medicine and Biology* 1152 (2019). doi: 10.1007/978-3-030-20301-6\_21.



**PRESENTATIONS****Invited national/international meetings**

Johns Hopkins Center for Alternatives to Animal Testing, Baltimore MD: Symposium on Mechanisms of Toxicity, 1997

Juan March Institute for Study and Research, Madrid, Spain: Workshop on Exchange Factors, 2002

Cell Signaling World 2006 - Signal Transduction Pathways as Therapeutic Targets, Luxembourg

Sixth Annual Protein Kinase Targets – Drug Discovery and Design, Boston MA, 2008

National Technology Centers for Networks & Pathways: All Hands Meeting – Moving Proteomics from Static Maps to Quantitative Functional Models, NIH, Bethesda MD, 2009

17<sup>th</sup> Annual Molecular Medicine International Tri-Conference & 3<sup>rd</sup> Annual Cancer Molecular Markers Meeting, San Francisco CA, 2010

Evolution of Next-Generation Sequencing Conference, Providence RI, 2010

Symposium to Honor Prof. James C. Garrison, University of Virginia, 2011

Session chair at Functional Analysis and Screening Technologies Congress, Cambridge MA, 2013

Session chair at Physiologically-Relevant Cellular Models for Drug Discovery Meeting, San Diego CA, 2014

Keynote presentation on “Pharmacovigilance Education for Medical Students” and organizing committee member for 11<sup>th</sup> Annual Conference on Pharmacovigilance and Drug Safety, London 2018

World Pharma Week Conference on Patient-Derived Tumor Organoids, Boston MA, 2019

Topic presenter & on-hand expert, NF Hackathon2, Google Launchpad, San Francisco CA, 2019.

**Invited regional meetings**

Annual meeting of the Vermont Comprehensive Cancer Center, 1994

Session moderator, MichBio Drug Discovery & Development in Michigan Symposium, Ann Arbor MI, 2019.

**Invited seminars**

Department of Pharmacology, University of Virginia, 1993

Howard Hughes Medical Institute, Chevy Chase, Maryland 1993

Department of Pharmacology, University of Cambridge, 1996

Department of Pharmacology and Physiology, University of Rochester, 1997

Department of Pharmacology, Wayne State University, 1997

Department of Pharmacology, University of Iowa, 1997  
Children's Memorial Institute for Education and Research, Northwestern University, 1999  
Institute of Chemical Toxicology, Wayne State University, 1999  
Department of Pharmacology & Toxicology, West Virginia University, 1999  
Department of Pathology, Wayne State University, 1999  
Michigan Peptide Research Center, University of Michigan – Ann Arbor, 2000  
Department of Pharmaceutical Sciences, Wayne State University, 2000  
Department of Pharmacology, Case Western Reserve University, 2000  
Cell Signaling Program, University of Vermont, 2001  
ARA Summit Meeting, Pfizer, Inc., San Francisco, CA, 2002  
OSI Pharmaceuticals, Oxford, U.K., 2003  
Clinical Cancer Genetics Conference, Barbara Ann Karmanos Cancer Institute, 2004  
Cellular and Clinical Neurobiology Program, Wayne State University, 2005  
Department of Biochemistry and Molecular Pharmacology, West Virginia University, 2006  
Department of Physiology and Pharmacology, Northeastern Ohio College of Medicine, 2006  
Cancer & Cardiovascular Research Institute, Texas A&M University, 2007  
Department of Biology, University of Toledo, 2008  
Department of Pharmacology, University of Vermont, 2008  
Department of Physiology, Wayne State University, 2009  
Henry Ford Hospital, "Distinguished Researcher" Seminar Series, 2009  
Purdue University Cancer Center, 2010  
Program in Molecular Biology & Genetics, Karmanos Cancer Institute, 2010  
Department of Biochemistry, University of Iowa, 2010  
Department of Pharmacology, Wayne State University, 2010  
Department of Pharmacology, University of Pennsylvania, 2010  
Program in Proteases & Cancer, Karmanos Cancer Institute, 2011  
Josephine Ford Cancer Center (JFCC)/Henry Ford Health System, 2012  
Department of Pharmacology, University of Michigan – Ann Arbor, 2014  
Grand Rounds, Department of Pediatrics, Children's Hospital of Michigan, 2014  
Department of Immunology and Microbiology, Wayne State University, 2014  
Oakland University Honors College, Rochester MI, 2015  
Physical Sciences Oncology Center at Moffitt Cancer Center, 2015  
Molecular Therapeutics Program, Karmanos Cancer Institute, 2016.



**Health Sciences Committee**

November 11, 2021

Agenda Item: III. Closed Session

Responsible Person: Dr. Ron Mitchelson  
Interim Vice Chancellor, Health Sciences Division

Action Requested: Action

Notes: D. School of Dental Medicine Incentive Payments

- For any action items, we will include a DRAFT motion on the cover sheet so the board knows what is being requested of them.

## **Request to Board of Trustees for Approval of Faculty Practice Incentive Payments (Non-Salary and Deferred Compensation Plan in School of Dental Medicine)**

*The Board of Trustees is asked to approve Faculty Practice Incentive Payments to eligible faculty in the School of Dental Medicine (SoDM). UNC Policy Manual 300.2.14, Non-Salary and Deferred Compensation: and ECU Policy on Non-Salary and Deferred Compensation for Employees Exempt from the State Personnel Act authorize the Board of Trustees to approve non-salary compensation for EHRA employees.*

In accordance with The UNC Policy Manual 300.2.14, "Non-Salary and Deferred Compensation", this document delineates the SoDM Faculty Practice Incentive Payment criteria and the process for generating the proposed payments to faculty in the ECU School of Dental Medicine.

School of Dental Medicine faculty in Ross Hall are encouraged to develop a Faculty Practice (FP) to hone and maintain their skill set and to further meet the needs of the patient community. The services performed in the FP are exclusively provided by the faculty as opposed to students and residents under the supervision of faculty. These proposed incentives are designed to encourage activity that provides care to more complex patients in our communities as well as patients from the School of Dental Medicine student clinic whose treatment plans require certain procedures too complex for our students or residents to provide. In addition, these incentive payments are a critical tool in the recruiting package necessary to attract high quality faculty. Students and patients clearly benefit from instruction by faculty who are experienced and committed to caring for the more complex patients.

As the emerging Faculty Practice gains momentum, conventional wisdom is that we develop an incentive model to encourage faculty to increase clinical productivity in the FP. To incentivize the achievement of these clinical productivity targets, the School of Dental Medicine is developing a formal Incentive Payment Plan. Until this plan is developed and approved, we would like to pay 30% of collected net revenue to all faculty participating in Faculty Practice and thus, we seek the Board of Trustees' approval to make the specific payments proposed.

With the exception of five faculty, the incentives reflect an amount equal to 30% of collected revenue from the patient care each provider directly performed in the FP.

- The first exception is for Dr. Boushell who came to us in December of 2019 as the result of a search that began in October of 2018. We were able to attract Dr. Boushell by offering a 50% incentive the first year (FY20), 40% in his second (FY21), and 30% thereafter.

Due to Dr. Boushell not being able to build his faculty practice due to clinic closures as the result of COVID, the initial year one offering of 50% and the second year offering of 40% were extended an additional year – Year 1 is FY21 and Year 2 is FY22.

- The second exception is for Dr. Cui. She came to us in October of 2019 as the result of a search that began in September of 2018. We were able to attract Dr. Cui by offering a 50% incentive the first year, 40% in her second, and 30% thereafter.

Due to Dr. Cui not being able to build her faculty practice due to clinic closures as the result of COVID, the initial year one offering of 50% and the second year offering of 40% were extended an additional year – Year 1 is FY21 and Year 2 is FY22

- The third exception is for Dr. Schnoor a Board-Certified Endodontist. He came to us in May of 2020. We were able to attract Dr. Schnoor by offering a 40% incentive the first and second years (FY21 and FY 22), and 30% thereafter.
- The fourth exception is for Dr. Thakkar, an oral and maxillofacial surgeon. Dr. Thakkar came to us in September of 2020. We were able to attract Dr. Thakkar by offering a 50% incentive the first year, 40% in his second year, and 30% thereafter.
- The last exception is for Dr. Zhang, an oral and maxillofacial radiologist. Dr. Zhang came to us June of 2020. The compensation for radiologists differs slightly from the typical 30% as Dr. Zhang will be incentivized 40% for CBCT captures and interpretations from within the SoDM, 80% for CBCT captures and interpretations referred from outside the SoDM, and 30% for all other faculty practice contributions made by her.

All incentives will be paid from non-state clinical funds generated from the Faculty Practice.

<b>ECU School of Dental Medicine Incentive Information for BOT January 1, 2021 - June 30, 2021</b>	
<b>Faculty</b>	<b>Incentive Payment Sal Qtr 3 &amp; 4</b>
Dr. Maged Abdelaal	\$3,121.92
Dr. Loren Alves	\$7,661.57
Dr. Lee Boushell	\$3,715.46
Dr. Christopher Cotterill	\$1,207.02
Dr. Xioxi Cui	\$1,900.00
Dr. Hanan Elgendy	\$3,487.08
Dr. Andres Flores	\$1,746.70
Dr. Isabel Gay	\$3,790.38
Dr. Saulo Geraldeli	\$756.46
Dr. Alex Gillone	\$8,993.46
Dr. Amna Hasan	\$4,963.07
Dr. Iquebal Hasan	\$4,925.27
Dr. Daune Humphrey	\$1,076.48
Dr. Alex Kordis	\$10,694.55
Dr. David MacPherson	\$1,217.10
Dr. Acela Martinez-Luna	\$13,269.05
Dr. Van McCarlie	\$25,022.72
Dr. Mark Moss	\$927.74
Dr. Maggie Pafford	\$2,199.52
Dr. David Paquette	\$6,153.68
Dr. Zachary Schnoor	\$848.70
Dr. Mahmoud Serag	\$39,196.83
Dr. Moamen Sheba	\$5,458.34
Dr. Bushan Thakkar	\$32,377.45
Dr. Stevan Thompson	\$9,249.32
Dr. Nikki Tucker	\$13,352.81
Dr. Thomas Veraldi	\$10,086.93
Dr. Michael Webb	\$12,222.95
Dr. Wenjain Zhang	\$8,206.46
	<b>\$237,829.02</b>



**Health Sciences Committee**

November 11, 2021

Agenda Item: III. Closed Session

Responsible Person: Dr. Ron Mitchelson  
Interim Vice Chancellor, Health Sciences Division

Action Requested: Action

Notes: E. College of Allied Health Sciences Incentive Payments

- For any action items, we will include a DRAFT motion on the cover sheet so the board knows what is being requested of them.

Non-salary Compensation: CAHS 2021  
CAHS Temporary Variable Incentive Planned Payouts

Below is a summary of the faculty by department, their current institutional base salary, and the planned payout from participation in the temporary variable incentive program. The faculty members named below are eligible to receive performance-based research incentives under the College of Allied Health Temporary Variable Incentive Plan. As described in the Plan, the incentives are based on the amount of state appropriated salary for the faculty member that is recovered because of allocating effort to extramural grants and contacts and are paid from non-state sources of revenue.

**Participation Period: 8/16/2020 – 8/15/2021**

<i>Faculty</i>	<i>Rank</i>	<i>Dept</i>	<i>Institutional Base Salary</i>	<i>Incentive Payment</i>
Paul Vos	Professor	BIOS	\$121,511	\$4556.70
Qiang Wu	Associate Professor	BIOS	\$108,687	\$7,896.22
Kevin O'Brien	Professor	BIOS	\$129,540	\$6,477.00
Jamie Perry	Professor	CSDI	\$121,810	\$20,995.53
Ning Zhou	Associate Professor	CSDI	\$96,206	\$19,241.16
Paul Toriello	Professor	DARS	\$114,424	\$11,442.47
Akshat Kapoor	Assistant Professor	HSIM	\$72,000	\$3,375.00
Virginia Stage	Associate Professor	NUTR	\$93,527	\$14,029.38
Jane Trapp	Clinical Assoc Professor	PADP	\$99,493	\$7,462.00
Alan Gindoff	Clinical Professor	PADP	\$136,296	\$2,555.55





**Athletics & Advancement Committee  
November 11, 2021**

Agenda Item: IV. A. Naming Recommendation

Responsible Person: Chris Dyba  
Vice Chancellor for University Advancement

Action Requested: Approval

Notes:

**NAMING PROPOSAL TO EAST CAROLINA UNIVERSITY  
BOARD OF TRUSTEES**

Greg Abeyounis

Name of Originator

University Advancement

252-328-9573

abeyounisg@ecu.edu

Department/Division

Phone

Email

Proposed Name(s) to Honor: Larry & Emma Thaxton Ferguson (deceased) -gifted \$\$657,313  
for an Access Scholarship to benefit COE students. Nancy was an ECU alumna in Education.

This total represents 1/3rd of their estate for ECU

Address: City State Zip

Telephone: Home Business

Relationship to the University: Alumna - Emma Thanxton Ferguson.

Proposed Object for Naming: 1st floor student study room in Speight Building (COE)

Purpose for recommendation:

Honorary (Attach background materials as appropriate to justify the recommendation)

Gift (Attach background materials as appropriate to justify the recommendation and complete the section below)

Purpose of Gift:  Annual  Capital  Endowment

Date of Original Commitment: 10/2/2021

Amount of the Total Commitment: \_\_\_\_\_

Amount Paid: \$657,313.46

Current Pledge Balance: \_\_\_\_\_

Status of Payments: Paid In Full


Was the gift part of a campaign:  Yes  No Define: \_\_\_\_\_

Was the project pre-approved:  Yes  No

Directed to:  ECU Foundation  Educational Foundation  
 Medical Foundation  Other

If the Gift was more than \$25,000:

1. Attach a copy of the signed Letter of Intent.
2. Define in detail any special arrangements or expectations the donor may have resulting from this Gift.
3. If the Gift is other than cash or cash equivalent, explain the method of valuation, and the plan for liquidation.


  
Signature of Originator

10/11/21  
Date

PROPOSAL TO EAST CAROLINA UNIVERSITY BOARD OF TRUSTEES  
TO NAME A FACILITY OR ACTIVITY


ROUTING SHEET

**Office of Vice Chancellor for University Advancement:**

Received 10-12-21 / 10-12-21  
 Action Approved / 10-12-21  
 Date  
 Forwarded or returned Oct 12, 2021  
 Date

Comments \_\_\_\_\_

**Chancellor's Office:**

Received 10-14-21 / 10-14-21  
 Action Approved / 10-14-21  
 Date  
 Forwarded or returned \_\_\_\_\_  
 Date

Comments \_\_\_\_\_

**Athletics and Advancement Committee of the Board of Trustees:**

Received \_\_\_\_\_ / \_\_\_\_\_  
 Action \_\_\_\_\_ / \_\_\_\_\_  
 Date  
 Forwarded or returned \_\_\_\_\_  
 Chair's Signature \_\_\_\_\_ Date

Comments \_\_\_\_\_

**Board of Trustees:**

Received \_\_\_\_\_ / \_\_\_\_\_  
 Action \_\_\_\_\_ / \_\_\_\_\_  
 Date  
 Forwarded or returned \_\_\_\_\_  
 Chair's Signature \_\_\_\_\_ Date

Comments \_\_\_\_\_

Fund Title:

Fund Number:



## FUND AGREEMENT

### FOR THE LARRY AND EMMA THAXTON FERGUSON ACCESS SCHOLARSHIP ENDOWMENT

#### I. ESTABLISHMENT

- A. THIS AGREEMENT is made effective as of the date of the last signature affixed between Mikell Thaxton (Trustee) and the ECU Foundation, Inc. (Foundation).
- B. The Trustee and the Foundation agree to establish a **restricted endowment** in the Foundation known as the Larry and Emma Thaxton Ferguson Access Scholarship Endowment (Fund). The fund manager will be the President of the ECU Foundation or a comparable position should this position title no longer exist (Administrator).
- C. The Fund will be activated upon receipt of a gift or written commitment of at least \$125,000 which must be paid within five years. The endowment will be considered fully funded when the corpus reaches \$125,000.

#### II. STATEMENT OF INTENT

Emma Thaxton Ferguson was a 1965 Early Childhood Education Major at ECU. Emma grew up in McMinnville, TN and began her college studies at nearby Tennessee Tech, where she met the love of her life, Larry, a few years her senior. Shortly after Larry graduated from Tennessee Tech, they were married and his first job with DuPont brought them to North Carolina, and Emma to ECU, where she would earn her education degree, graduating Magna cum laude. Larry's career as a safety engineer took them to 12 different cities across the U.S. Emma taught elementary school along the way and earned her M.Ed. at the University of Southern Mississippi. Both Emma and Larry believed in the power of education, so it was always their plan to fund endowments for students with financial need perpetually. The hope is to give students who struggle to afford education a chance to attend ECU.

#### III. SOURCE OF FUNDS

The Fund shall be initially established with the following gifts and shall be consistent with the Foundation's Gift Acceptance Policy:

- A. Approximate Testamentary Gift of \$650,000 from the trust of Larry and Emma Ferguson (to be referred to as the estate of Larry and Emma Thaxton Ferguson).

Fund Title:

Fund Number:

#### IV. PURPOSE AND USE OF FUNDS

This Fund shall be used to provide scholarship support to students at ECU through the Access Scholarship program. This program was established to provide need-based scholarship support for full-time students. The amount and terms of each scholarship award and the recipient thereof shall be determined in accordance with College, University, and Foundation guidelines and procedures then in effect. The Administrator shall be responsible for administering the distributions from the Fund and applying such distributions in accordance with Foundation and University policies and procedures and the following preferences:

- A. Demonstrated financial need
- B. First preference is for a student in the College of Education
- C. Full-time students
- D. Other criteria as determined by the program administrator such as community service and extracurricular activities may be used to select recipients. Academic achievement should not be a determining factor.

This scholarship should not be used for athletics.

#### V. FUND ADMINISTRATION

This Fund shall be administered in accordance with the Foundation's policies and procedures and shall be consistent with the University's policies, as follows:

- A. The Fund shall be used only for a qualified charitable purpose consistent with the laws of the State of North Carolina and section 501(c) (3) of the Internal Revenue Code.
- B. The Foundation will hold and administer these proceeds and any subsequent additions to the Fund in accordance with the terms and conditions of this agreement and current endowment policies as regulated by the East Carolina University Foundation, Inc. Board of Directors (Foundation Board of Directors).
- C. With the consent of the Foundation, other parties may also make gifts to the Fund, but they may not change the purpose of the Fund.
- D. Fees: A one-time fee is charged to all new gifts to the Fund. An annual endowment management fee is also charged to the fund. Gifts made to the Fund via telefund or annual fund solicitations are subject to a one-time Annual Fund department fee. These fee amounts are determined annually by the Foundation Board of Directors and will be in accordance with the Foundation's Endowment Spending and Gift Fee Policy. All fees will be charged to the endowment's investment earnings fund and will not reduce the fund's corpus amount.
- E. All gifts to and accumulated earnings of the Fund will be invested in the Foundation's investment pool and will receive a prorated share of the net income or losses.
- F. The spending distribution is determined by the Foundation Board of Directors who votes annually to adopt a rate of spending distribution applicable to all endowment funds.
- G. In years when earned and accumulated investment earnings may be insufficient to meet the amount needed for the annual distribution or when multiyear commitments have been made, the Foundation Board of Directors may continue to make distributions, even if such distributions will reduce the total value of the endowment below the historical value of the corpus (the value of all gifts to the Fund). These spending distributions must

Fund Title:

Fund Number:


be in accordance with the Foundation's Endowment Spending and Gift Fee Policy, within what the Board has determined reasonable and prudent as noted within the North Carolina Uniform Prudent Management of Institutional Funds Act (UPMIFA), and consistent with the spending distributions from similar endowments within the Foundation.

- H. A supplemental fund may be established if the Trustee wishes to make annual gifts that will be used for the same purpose as the endowment. The Trustee may direct gifts to the supplemental fund to make annual awards while the endowment is building, to support annual awards in the event the endowment is underwater, or if the Trustee wishes to supplement the annual award from the endowment. The supporting fund is for annual awards, and like other annually funded awards, will be exempt from gift fees. Annually funded funds do not participate in investment earnings and are available to be spent at any time. Gifts made to the supplemental fund must clearly be stated as such or they will be deposited into the related endowed fund.
- I. If at some future time, it becomes impractical for the Foundation to achieve the designated purpose of the Fund, circumstances change, or it becomes unlawful or wasteful to expend the earnings from the Fund in the manner stated above, then, at the discretion of the Foundation Board of Directors, the Fund shall be used to further the objectives and purposes of East Carolina University, bearing in mind the desires of the Trustee as expressed in this agreement. Should the academic area move to another school/college, have a name change, or other placement issue related to this Fund that may require a movement of the funding within or between Foundations at ECU, the Foundation Board of Directors shall review and approve the changes, again, bearing in mind the desires of the Trustee as expressed in this fund agreement.

IN WITNESS WHEREOF, these parties execute this Agreement.

By:   
 Mikell Thaxton, Trustee and Nephew of Donors  
 Larry and Emma Thaxton Ferguson, Donors

Date: 9/22/21

DocuSigned by:  
 By:   
 Christopher M. Dyba  
 Vice Chancellor of University Advancement &  
 President of the ECU Foundation

Date: 9/24/2021 | 10:15 AM EDT